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ABSTRACT 
 
Alcohol dependence damages the brain through a multiplicity of factors 
including thiamine deficiency, liver disease, head injuries, and repeated 
episodes of alcohol withdrawal.  Alcohol withdrawal is a potential opportunity 
for reducing damage as it is an intensive time of contact between doctors and 
patients.  Pre-clinical models of alcohol dependence have demonstrated 
activation of microglia, resident tissue macrophages, and expression of 
cytokines and other inflammatory mediators both in the brain and peripheral 
blood during alcohol withdrawal.  These changes were associated with 
neuronal death, and learning deficits.  Similar processes may occur in man as 
increased microglial numbers, increased chemokine expression and raised 
circulating pro-inflammatory cytokines have been reported in alcohol 
dependence.   
 
The aim of the thesis was to characterise the peripheral cytokine profile during 
alcohol detoxification, to investigate whether there are relationships between 
peripheral cytokines and clinical features of alcohol withdrawal, to investigate 
neuroinflammation in alcohol dependence by using [11C]PBR28 Positron 
Emission Tomography to assess microglial activation in recently abstinent 
alcohol dependent patients in vivo and to investigate how these processes 
relate to elevated cortisol and elevated cerebral glutamate reported in alcohol 
withdrawal respectively. 
 
The longitudinal study undertaken in 51 alcohol dependent patients during 
detoxification demonstrated that both pro- and anti-inflammatory cytokines, 
and chemokines, decreased significantly during detoxification while T cell 
cytokines increase.  IL-6 was positively associated with withdrawal severity 
and depressive symptoms during withdrawal.  The chemokine CCL-2 was 
positively associated with performance on cognitive tasks.  Serum cortisol 
was in the high normal range and decreased during detoxification.  The 
salivary Cortisol Awakening Response (CAR) was also in the normal range at 
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all time points.  Both serum cortisol and the CAR were positively correlated 
with IL-6 concentrations suggesting hyperfunction of the HPA axis during 
alcohol detoxification may relate in part to inflammatory stimulation.   
 
The PET study comparing alcohol dependent men in early abstinence and 
healthy controls was undertaken using the ligand, [11C]PBR28 that binds to 
the Translocator Protein 18 kDa (TSPO) richly expressed in microglia.  
Alcohol dependent patients had lower TSPO binding in the hippocampi than 
healthy controls.  TSPO binding in the hippocampus was also positively 
correlated with performance on tests of verbal memory.  This suggests that 
hippocampal microglial loss or dysfunction may be related to memory 
problems in alcohol dependence. Given that benzodiazepines are used to 
treat alcohol withdrawal, an in vitro binding study was conducted to 
investigate whether benzodiazepines would significantly block [11C]PBR28 
binding and found that benzodiazepines do not block a significant proportion 
of TSPO at all but the highest clinical doses.  The relationship between brain 
glutamate, as measured with Magnetic Resonance Spectroscopy, and 
microglial activation was investigated.  Alcohol dependent patients had 
significantly lower glutamate + glutamine (Glx) concentrations in the occipital 
cortex with no difference in glutamate concentrations in the anterior cingulate 
cortex (ACC).  
 
In summary, there are changes in both peripheral and brain inflammatory 
processes in early abstinence from alcohol dependence that are related to 
clinical symptoms.  Peripheral pro-inflammatory cytokines are raised early in 
detoxification relative to late detoxification and are related to withdrawal and 
affective symptoms.  Surprisingly, evidence of decreased microglial function in 
the hippocampus was found and this related to poorer cognitive function, 
suggesting a positive role for immune cells in the brain in alcohol 
dependence.  Inflammatory processes were related to HPA axis function 
during detoxification but not to changes in brain glutamate concentrations.  In 
conclusion, characterisation of inflammation through multiple approaches in 
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this series of studies demonstrates the likely importance of such processes 
and provides novel approaches for treatment to reduce brain damage due to 
alcoholism.  
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ACC Anterior cingulate cortex 
ACTH Adreno-corticotropic hormone 
ADPs Alcohol-dependent patients 
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ARBD Alcohol-related brain damage 
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AUQ Alcohol Urge Questionnaire 
BBB Blood brain barrier 
BDI Beck Depression Inventory 
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CBG Cortisol binding globulin 
CCL Chemokine with adjacent cysteine residues near amino terminal 
CCL-2  Monocyte Chemoattractant Protein 1 
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CCL-4 Macrophage Inflammatory Protein 1-Beta (MIP-1β) 
CCL-5 Regulated On Activation, Normal T cell Secreted (RANTES) 
CCL-11 Eosinophil chemotactic protein (Eotaxin) 
[Cho] Choline concentration 
CIWA-Ar Clinical Institute Assessment of Withdrawal from Alcohol –revised 
CNS Central nervous system 
[Cr] Creatine concentration 
CRP C-reactive protein 
CRH Corticotrophin 
CSF Cerebrospinal fluid 
CXCL Chemokine in which cysteine residues are separated by a single amino acid 
CXCL-8 Interleukin 8 
CXCL-9 Monokine induced by gamma interferon 
CXCL-10 Interferon gamma-induced Protein 10 
DLPFC Dorsolateral prefrontal cortex 
DSM-IV Diagnostic and Statistical Manual, Fourth Edition 
ELISA Enzyme-Linked Immunosorbent Assay 
FAS Phonemic verbal fluency test, using the letters ‘F’, ‘A’ and ‘S’ 
FSS Fatigue Severity Scale  
GGT Gamma-glutamyl transferase 
GFP Green fluorescent protein 
[Glu] Glutamate concentration 
[Gln] Glutamine concentration 
[Glx] Glutamate + glutamine concentration 
GM-CSF Granulocyte macrophage colony stimulating factor 
HABs High affinity binders 
HCs Healthy controls 
HDs Heavy drinkers 
HPA axis Hypothalamo-pituitary-adrenal axis 
HPLC High performance liquid chromatography 
ICD-10 International Classification of Diseases, 10th Edition 
IFN-α  Interferon alpha 
IFN-γ  Interferon gamma 
IL-1β Interleukin 1 Beta 
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IL-1RA Interleukin 1 receptor antagonist 
IL-2 Interleukin 2 
IL-2R Interleukin 2 receptor 
IL-4 Interleukin 4 
IL-5 Interleukin 5 
IL-6 Interleukin 6 
IL-7 Interleukin 7 
IL-12 Interleukin 12 
IL-13 Interleukin 13 
IL-15 Interleukin 15 
IL-17 Interleukin 17 
LABs Low affinity binders 
LOD Limit of detection 
LPS Lipopolysaccharide 
MABs Mixed affinity binders 
MAR Missing at random 
MCAR Missing completely at random 
MCI Mild cognitive impairment 
MCV Mean corpuscular volume 
MEGAPRESS Mescher-Garwood point resolved spectroscopy 
[mI] Myoinositol concentration 
MINI-6 Mini-International Neuropsychiatric Interview, Version 6 
MLE Maximum likelihood estimation 
MMSE Mini-mental state examination 
MPRAGE Magnetisation Prepared Rapid Gradient 
MRI Magnetic resonance imaging 
MRS Magnetic resonance spectroscopy 
MS Multiple Sclerosis 
[NAA] N-acetyl aspartate concentrations 
NHS National Health Service 
OCC Occipital cortex 
OCDS Obsessive Compulsive Drinking Scale 
PBR Peripheral benzodiazepine receptor 
PET Positron emission tomography 
POC Parieto-occipital cortex 
PRESS Point resolved spectroscopy 
PVE Partial volume effect 
ROCF Rey-Osterrieth Complex Figure 
ROI Region of interest 
SADQ Severity of Alcohol Dependence Questionnaire 
SSAI Spielberger State Anxiety Inventory 
STAI  Spielberger Trait Anxiety Inventory 
TAC Time activity curve 
TE Echo time 
TNF-α Tumour Necrosis Factor alpha 
TR Repetition time 
TSPO Translocator Protein 18 kDa 
WMS Weschler Memory Scale – paragraph version 
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CHAPTER 1 
INTRODUCTION 
1.1  Overview 
The aim of my thesis is to characterise peripheral inflammation and 
neuroinflammation during alcohol withdrawal and early abstinence, and to 
understand how these responses relate to clinical measures and objective 
neurochemical and neuroendocrine derangements during this period.  My 
hypothesis in broad terms is that both peripheral inflammation and 
neuroinflammation occur in man during alcohol withdrawal and early 
abstinence and that these are related to both withdrawal severity and 
cognitive impairment during this period.  I also hypothesise that these 
inflammatory processes correspond to hypothalamo-pituitary-adrenal axis 
derangements and increased brain glutamate during withdrawal.  
 
This is motivated by pre-clinical evidence that suggests a cerebral immune 
response – so-called ‘neuroinflammation’ – occurs in the setting of chronic 
alcohol intake and withdrawal, and that this may relate to brain damage.  
Clinical observations in alcohol-dependent patients regarding systemic 
cytokines, which are known to reach the brain and influence cerebral 
immunity, provides further support for the idea that both peripheral 
inflammation and neuroinflammation may contribute to brain damage 
occurring during withdrawal and early abstinence.  This has considerable 
clinical implications. 
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In recently abstinent alcohol-dependent patients, I have (1) characterised 
peripheral inflammation by measuring circulating cytokine activity and  (2) 
neuroinflammation, captured through microglial activation with [11C]PBR28 
(Translocator Protein 18kDa (TSPO)) Positron Emission Tomography (PET).  
I have explored the association between (3) cytokines and hypothalamo-
pituitary-adrenal axis dysfunction by measuring the cortisol awakening 
response and serum cortisol.  I also explored the relationship between (4) 
[11C]PBR28 and brain glutamate as measured by Magnetic Resonance 
Spectroscopy (MRS).   
 
The remainder of this introduction sets out the background to each of these 
approaches and the preclinical and clinical observations that support the 
hypothesis that inflammatory processes are important in alcohol withdrawal 
and early abstinence.  Key concepts in peripheral inflammation such as the 
function of circulating cytokines and their influence on brain function will be 
explored.  Neuroinflammation will be defined and critiqued and microglial 
activation and its role as a marker of neuroinflammation in clinical research 
explained.  Abnormalities in hypothalamo-pituitary-adrenal axis function and in 
brain glutamate transmission during withdrawal and early abstinence, means 
of investigating these, and the ways in which inflammatory processes may be 
hypothesised to relate to them will be described.  Finally, the aims and 
hypotheses will be laid out in detail.   
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1.1.1  Alcohol-related brain damage is an increasing problem 
Alcohol damages the brain.  Neurological syndromes representing extreme 
forms of alcohol-related neurodegeneration are well-recognised, occurring in 
the context of co-morbid nutritional deficiencies, electrolyte shifts, or other 
end-organ damage: Wernicke-Korsakoff syndrome (WKS), Marchiafava-
Bignami disease, central pontine myelinolysis, cerebellar degeneration, and 
hepatic encephalopathy.  Alcohol-related brain damage (ARBD) is a diffuse 
presentation of cognitive impairment in multiple domains that has been 
recognised more recently.  Although synonymous with alcohol-associated 
dementia (DSM-IV) ARBD is the preferred term (Jauhar and Smith, 2009) 
because the disorder is not progressive with abstinence.  Rather, in the 
context of abstinence, 25% remain severely affected, 25% improve minimally, 
25% improve moderately and 25% recover completely (Royal College of 
Psychiatrists, 2014).  In this respect, ARBD is more similar to traumatic brain 
injury than it is to other forms of dementia (Thomson et al., 2012).   
 
1.1.2  ARBD involves multiple domains of function but is non-progressive 
ARBD is defined as impairment in multiple cognitive domains occurring within 
three years of prolonged heavy drinking (Oslin et al., 1998).  The diagnosis is 
supported by improvement with abstinence, ataxia, other alcohol-related end 
organ damage and cerebellar atrophy on Magnetic Resonance Imaging and is 
cast in doubt by anomia, or clinical or neuroimaging evidence of 
cerebrovascular disease (Oslin et al., 1998).  ARBD predominantly affects 
people between the ages of 40 and 60 years old (Royal College of 
Psychiatrists, 2014).  A high proportion of patients are likely to go 
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unrecognised because of a lack of knowledge of the condition and the stigma 
against patients with addictions (Wilson, 2011).  Unlike patients with other 
dementia syndromes, patients with ARBD are more likely to show agitation, 
disinhibition, delusional experiences and aggression (Ferran, 1996).  This 
presents challenges for patient management that are exacerbated by the 
paucity of expertise in the area in mainstream adult or older adult psychiatry 
services (Wilson, 2011) (Royal College of Psychiatrists, 2014) (Thomson et 
al., 2012).  Alcohol is also a factor in the development of other forms of 
dementia: heavy drinking is associated with a 4.6 times increased risk of 
developing dementia (Saunders et al., 1991). 
 
1.1.3  There are cognitive deficits in alcohol dependence even in those 
without frank ARBD 
ARBD represents a severe degree of a continuum of cognitive impairment.  
Even apparently healthy alcohol-dependent patients (ADPs) exhibit 
impairment across multiple domains of cognitive function (Davies et al., 
2005)(reviewed in (Stavro et al., 2013)).  Deficits in episodic memory (Fama 
et al., 2004) (Davies et al., 2005) (Stavro et al., 2013), spatial and verbal 
memory and executive function have been described consistently (Stavro et 
al., 2013).  Episodic memory deficits have been reported to exceed those 
explained by poor executive function alone (Pitel et al., 2007).  Longitudinal 
studies (Bartels et al., 2007), and cross-sectional studies of patients who are 
more than one year abstinent (reviewed in (Stavro et al., 2013) suggest that 
recovery may occur but that deficits persist for some months of abstinence.  
Recovery of cognitive function is dependent on continued abstinence (Pitel et 
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al., 2009) (Johnson-Greene et al., 1997).  However, long-term remission from 
alcohol dependence occurs in less than 50% of patients (Drugs, 2013) and 
relapse occurs early in abstinence for a similar proportion of patients 
(Hayashida et al., 1989).   
 
1.1.4  Subclinical cognitive impairment may impact motivation and relapse 
There is no consensus in the literature regarding the relationship between 
cognitive impairment and prognosis in healthy ADPs.  Although cognitive 
deficits may predispose to the development of addiction, evidence from a 
longitudinal study in adolescence, supports the worsening of cognition with 
continued substance use (Tapert and Brown, 1999).  Early reports suggested 
that poor cognitive function had an adverse effect on prognosis: patients with 
poorer performance on cognitive tasks were more likely to leave residential 
rehabilitation and had more problems in general functioning (Bowden et al., 
2001).  A regression analysis of a cohort with severe dependence found an 
association between poor cognitive test performance and relapse at 6 months 
(Allsop et al., 2000).  Later reports, however, have failed to show significant 
relationships between verbal and spatial memory and relapse (Bartels et al., 
2007) (Pitel et al., 2009).  Associations between aspects of executive function 
and relapse are found in some studies (Blume et al., 2005) (Bartels et al., 
2007) but not others (Pitel et al., 2009).  The link between cognitive function 
and outcome may be mediated by the impact of poor cognition on subjective 
factors such as motivation to change (Le Berre et al., 2012), self-efficacy 
(Bates et al., 2006) and compulsion to use (Rupp et al., 2012), and 
behavioural measures such as treatment compliance.   
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1.2  Pathogenesis of alcohol-related brain damage is complex 
1.2.1  Thiamine deficiency has been emphasised 
The pathogenesis of alcohol-related brain damage is multi-factorial, including 
direct effects of alcohol, alcohol withdrawal, nutritional deficiencies, head 
injury, hepatic encephalopathy, and electrolyte shifts (reviewed in (Zahr et al., 
2011)).  Clinically, thiamine deficiency has been emphasised, as Wernicke-
Korsakoff syndrome is a well-recognised consequence of alcohol dependence 
(Pilling et al., 2011) (Royal College of Psychiatrists, 2014).  There is also 
evidence that both cognitive deficits and regional brain volume deficits seen in 
ADPs with clinical Wernicke-Korsakoff syndrome occur to a lesser extent in 
those without clinical Wernicke-Korsakoff syndrome (Pitel et al., 
2011)(reviewed in (Zahr et al., 2011)).  National guidelines recommend using 
parenteral thiamine on admission for detoxification, to reverse thiamine 
deficiency (Pilling et al., 2011).  Despite this, alcohol-related brain damage 
continues to be a problem (Wilson, 2011).  Animal studies where the relative 
contributions of poor nutrition and alcohol dose can be controlled suggest that 
alcohol itself is neurotoxic (Zahr et al., 2009) and alcohol promotes thiamine 
deficiency-associated neurotoxicity (Ke et al., 2009). 
 
1.2.2  Episodes of detoxification contribute to alcohol-related brain damage 
This thesis will focus on alcohol withdrawal and early abstinence, as episodes 
of detoxification are also relevant to the pathogenesis of alcohol-related brain 
damage.  They are of special interest to the clinical researcher, as they 
coincide with clinical contact, offering an opportunity for preventative 
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intervention.  Alcohol withdrawal is the product of adaptive changes in 
receptor expression in response to chronic alcohol intake.  These include 
down-regulation and changes in receptor subtype expression in γ-
aminobutyric acid A (GABA-A) receptors such that the brain is less sensitive 
to GABA-ergic inhibition, and upregulation and changes in receptor subtype 
expression in glutamatergic N-methyl-D-aspartate receptors such that the 
brain is more sensitive to excitatory glutamatergic transmission.  (reviewed in 
(Clapp et al., 2008)).    
 
Repeated episodes of detoxification are associated both with increased 
severity of withdrawal symptoms and an increased risk of seizures (reviewed 
in (Duka et al., 2004)), and an equivalent process is described in animal 
models (Stephens, 2001).  The phenomenon is analogous to ‘kindling’ in the 
generation of epilepsy from repeated electric stimulation.  Pre-clinical studies 
of alcohol withdrawal have proposed a possible mechanism, as repeated 
episodes of withdrawal are associated with progressive increases in extra-
cellular glutamate and increased neuronal death.  Animal behavioural studies 
have described deficits in forms of learning such as aversive conditioning 
following multiple episodes of withdrawal (Stephens, 2001).  Similarly, a 
relationship has also been demonstrated between multiple detoxifications and 
progressive impairment in frontal lobe test performance, though this is 
mediated partly by other factors e.g. length of drinking history (Duka, 2003).  
There is also impairment in emotional processing, particularly a sensitivity to 
fear, in clinical populations (Townshend, 2003).  
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1.3  Neuroinflammation may contribute to alcohol-related brain damage 
1.3.1  Inflammation in the central nervous system is tightly regulated 
The role of the immune system in the central nervous system is of increasing 
interest in the pathogenesis of both acute brain damage from stroke or blunt 
trauma, and chronic neurodegenerative conditions.  Previously, the brain was 
thought to be ‘immune privileged’, or lacking a specific immune response 
(Galea, 2007).  Changes in the morphology of astrocytes, the support cells of 
the central nervous system (CNS), and in microglia, the resident CNS 
macrophages, around sites of tissue injury, were seen as a passive 
‘bystander effect’.  It is now recognised, however, that the CNS immune 
response is highly regulated rather than absent.  Adjustments include down-
regulation of microglia by neurons, an antibody-predominant response, and 
inhibition of T cell invasion by CNS expression of molecules that trigger T cell 
death (Galea, 2007). Therefore the predominant immune response – so-
called ‘neuroinflammation’ (O'Callaghan et al., 2008) – involves astrocytes 
and microglia, and local expression of inflammatory mediators such as 
cytokines and prostaglandins, while invasion of peripheral immune cells is 
absent or late.   
 
The immune response is associated with changes in the appearance of 
microglia and astrocytes, a process called ‘activation’.  In the case of 
microglia, there is a progressive change from the highly ramified morphology, 
where ramifications are retracted, and in full activation an amoeboid shape is 
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taken and migration and proliferation may occur.  Activation can be detected 
via histology, although immunohistochemistry has revealed that 
morphologically activated microglia are associated with different functions 
(Perry et al., 2010).  It is the  ‘M1’ microglial activation – the type of activation 
induced in vitro by interferon-γ, or in vivo by neuronal damage – that is 
associated with production of pro-inflammatory cytokines, prostaglandins and 
reactive oxygen species.  Levesque, among others, have proposed that this 
leads to a vicious circle where microglial products cause further neuronal 
damage, which in turn further activates microglia (Levesque et al., 2010). 
 
1.3.2  Pre-clinical models of alcohol dependence demonstrate 
neuroinflammation 
Pre-clinical models of alcohol dependence, especially those with repeated 
cycles of withdrawal, show widespread microglial activation.  Activation has 
been demonstrated to peak within two days of alcohol withdrawal but persist 
for up to three weeks (Obernier et al., 2002).  Cerebral expression of pro-
inflammatory cytokines and chemokines such as IL-1β, TNF-α and CCL-2 
persist for ten days following alcohol withdrawal, outlasting detectable 
expression in the liver and blood (Qin et al., 2008).  Other inflammatory 
mediators such as iNOS are reported and are associated with neuronal death.   
Most importantly from a translational perspective, both inflammatory 
mediators and cell death can be suppressed by pre-treatment with simple 
non-steroidal anti-inflammatory drugs (Pascual et al., 2007) 
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1.3.3  Alcohol contributes to neuroinflammation via direct and indirect 
mechanisms 
There are several mechanisms – direct and indirect – whereby alcohol 
dependence in thought to induce neuroinflammation.  In vitro studies from a 
single laboratory have demonstrated astroglial and microglial activation in 
response to alcohol via toll-like receptor 4 (TLR4), a receptor that responds to 
bacterial proteins and damage-associated proteins.  Knock-out of the TLR4 
gene has also been reported to diminish both alcohol-related microglial 
activation and neuronal death (Alfonso-Loeches et al., 2010).  Subsequent to 
the discovery of TLR4 stimulation by alcohol, induction of down-stream intra-
cellular inflammatory signaling proteins and transcription factors such as 
HMBG1 and NFKB by alcohol have been described (Crews et al., 2013).   
Alcohol withdrawal may also precipitate neuroinflammation.  As outlined 
above, microglial activation has been observed to peak on day 2 of 
withdrawal, the timing making it unlikely direct TLR4 stimulation is responsible 
(Nixon et al., 2008).  Elevated extra-cellular glutamate measured by 
microdialysis has been recorded in brain areas such as the hippocampus 
where microglial activation during withdrawal is also prominent (Ward et al., 
2009), raising the possibility that elevated glutamate may precipitate microglial 
activation. Microglia have also been shown to be sensitive to glutamate 
elevations in other contexts (Vinet et al., 2012) (Palazuelos et al., 2009) 
(Lambertsen et al., 2009).   
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Systemic inflammatory effects also contribute to neuroinflammation in alcohol 
dependence.  Small bowel bacterial overgrowth has been described in alcohol 
dependence with increased bacterial translocation, with increased portal and 
circulating concentrations of lipopolysaccharide and peptidoglycan.  Although 
it had been thought that bacterial translocation stopped very soon after 
cessation of alcohol, recent evidence (Leclercq et al., 2014) suggests that 
circulating peptidoglycan concentrations remain increased throughout 
withdrawal, and into early abstinence.  These bacterial proteins are important 
because they stimulate Kupffer cells (hepatic macrophages) to produce pro-
inflammatory cytokines and chemokines, with systemic and cerebral 
consequences.  Thus the study described in Chapter 2 concerns systemic 
cytokines and their relationship to clinical symptoms and cognitive function 
during alcohol detoxification. 
 
1.4  Cytokines and alcohol dependence 
1.4.1  Cytokines are chemical messengers of the immune system 
Cytokines are soluble regulatory peptides (<30kDa) (Dinarello, 2007) that co-
ordinate the innate and adaptive immune response.  They are similar to 
hormones, in that they may be produced by one cell to act on another via cell 
surface receptors, sometimes at a distance.  They differ, however, in that 
most cells of the body can produce cytokines, that they are expressed in 
response to specific stimuli, rather than in regular circadian cycles, and that 
they have a physiological effect at much smaller – picomolar – concentrations 
(Dinarello, 2007).  
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Cytokines are classified according to action (see Table 1.1).  Innate immune 
cytokines are involved with the initial, non-specific response to infection.  
Historically, they have been divided into pro-inflammatory and anti-
inflammatory cytokines.  Pro-inflammatory cytokines such as IL-1, TNF-α and 
IL-6 augment the immune response by inducing expression of acute phase 
proteins such as C reactive protein (CRP), producing fever and activating T 
and B lymphocytes (Kronfol and Remick, 2000).  Anti-inflammatory cytokines 
such as IL-10 and IL-1 receptor antagonist, IL-1RA, a soluble IL-1 receptor, 
suppress inflammation.  Cytokines associated with adaptive, specific 
immunity, relate to lymphocyte function.  CD4+ or T helper (Th) lymphocyte 
polarisation leading to a pathogen-specific immune response is stimulated by 
specific cytokines with IL-12 inducing Th1 polarisation and IL-4, Th2 
polarisation.  Polarisation in turn is associated with specific cytokines with Th1 
cells IL-2, TNF-α and IFN-γ and Th2 cells producing IL-4, IL-6, and IL-13.  
Soluble IL-2 receptors (IL-2R) are a general marker of the adaptive response 
and concentrations are correlated with the degree of T cell activation (Maes, 
2011). Finally, chemokines are small cytokines that induce the chemotaxis of 
white blood cells, arrest their movement and co-ordinate their extravasation 
from blood to inflamed tissue (Ransohoff, 2009).  
1.4.2  Cytokines access the central nervous system and affect brain function 
Circulating pro-inflammatory cytokines IL-1β, TNF-α and IL-6 can affect the 
brain as they are able to penetrate it directly via vagal afferents (Dantzer et 
al., 2008) and several humoral routes: specific blood brain barrier transporters 
(Banks et al., 1989) (Banks et al., 1994); diffusion in BBB-deficient areas 
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(Capuron and Miller, 2011) and induction of endothelial prostaglandin 
expression stimulating activation of perivascular macrophages and 
parenchymal microglia to produce cytokines.  Cerebral pro-inflammatory 
cytokines stimulate neurons in the hypothalamus and limbic regions, giving 
rise to fever, HPA axis activation and the constellation of behaviours known 
as ‘sickness behaviour’: decreased motor activity, social interaction, and 
response to reward (Dantzer and Kelley, 2007).  Conversely, anti-
inflammatory cytokines inhibit this response (Bluthe et al., 1999). 
 
Table 1.1: Classification of cytokines 
Cytokine class  
 Cytokines associated with innate immunity 
Pro-inflammatory cytokines IL-1β, TNF-α, IL-6, GM-CSF 
Anti-inflammatory cytokines IL-10, IL1-RA 
Type 1 interferon  IFN-α 
Cytokines related to T cell activation  
Non-specific T cell cytokines IL-2, IL-7, IL-15, IL-2R 
Th-1 associated cytokines IL-12, IFN-γ 
Th-2 associated cytokines IL-4, IL-5, IL-13 
Th-17 associated cytokines IL-17 
Chemokines  
Chemokines with a CXC motif* CXCL-8 (IL-8), CXCL-9 (MIG), CXCL-10 (IP-
10) 
Chemokines with a CC motif CCL-2 (MCP-1), CCL-3 (MIP-1α), CCL-4 
(MIP-1β), CCL-5 (RANTES), CCL-11 
(Eotaxin) 
Legend:  Chemokines are additionally classified according to molecular structure.  In CXC 
chemokines, the two amino-terminal cysteine residues are separated by a single amino acid, 
whereas in CC chemokines, these are adjacent.  
 
It is not known how or whether chemokines access the central nervous 
system, but strong positive correlations have been described between serum 
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CCL-2 and cerebrospinal fluid CCL-2 (Westin et al., 2012).  In clinical 
populations, increased peripheral pro-inflammatory cytokines and chemokines 
are associated with neuropsychiatric disorders such as delirium (Rudolph et 
al., 2008) (Terrando et al., 2010) (Cibelli et al., 2010), dementia (Holmes et 
al., 2009) (Zuliani et al., 2007) and depression (Dowlati et al., 2010) (Liu et al., 
2012).  Increased pro-inflammatory cytokines are associated with poorer 
prognosis in dementia (Holmes et al., 2009) and treatment response in 
depression (Yoshimura et al., 2009). 
 
1.4.3  There are increased circulating cytokine levels in alcohol-dependent 
patients 
Increased circulating cytokine and chemokine concentrations in association 
with heavy alcohol use, dependence and withdrawal have been described by 
several studies (see Table 1.2).  Epidemiological studies show that there is a 
J-shaped relationship between alcohol intake, and both IL-6 and C-reactive 
protein (CRP) (Volpato et al., 2004) (Pai et al., 2006) (Marques-Vidal et al., 
2012).  There is a direct, dose-dependent relationship between serum CXCL-
8 (IL-8) concentration and alcohol consumption (Gonzalez-Quintela et al., 
2007).  Studies of peripheral cytokine concentrations in alcohol-dependent 
patient populations predominantly focus on recently abstinent populations 
(see Table 1.2).  An increase in IL-6 has been reported in the first few days of 
abstinence (Latvala et al., 2005) (Gonzalez-Quintela et al., 1999) (Gonzalez-
Quintela et al., 2000) (Nicolaou et al., 2004) (Garcia-Valdecasas-Campelo et 
al., 2007) (Vidali et al., 2008) (Leclercq et al., 2012) but returns to control 
levels within the first week (Khoruts et al., 1991) (Gonzalez-Quintela et al., 
! 28 
2000) (Chatzipanagiotou et al., 2010) (Gonzalez-Reimers et al., 2012) 
(Leclercq et al., 2012).  TNF-α is raised in early abstinence in most, but not all 
studies (Khoruts et al., 1991) (Kiefer et al., 2002) (Nicolaou et al., 2004) 
(Latvala et al., 2005) (Garcia-Valdecasas-Campelo et al., 2007) (Gonzalez-
Quintela et al., 2008) (Vidali et al., 2008) (Leclercq et al., 2012).  This may 
reflect specific pathology in alcohol dependence, relating to an autoimmune 
reaction to peroxidised lipids present in a sub-set of patients (Vidali et al., 
2008), or to stage of liver disease (Vidali et al., 2008) (Gonzalez-Quintela et 
al., 2008).   
 
The anti-inflammatory cytokine IL-10 is increased early in withdrawal 
according to some, but not all reports (Gonzalez-Quintela et al., 1999) 
(Gonzalez-Quintela et al., 2000) (Nicolaou et al., 2004) (Garcia-Valdecasas-
Campelo et al., 2007) (Leclercq et al., 2012) and like IL-6, falls to control 
levels by the end of one week (Gonzalez-Quintela et al., 2000) (Leclercq et 
al., 2012).  This is unsurprising given that pro- and anti-inflammatory 
cytokines are often co-expressed in order to modulate the immune response.  
Cytokines relating to T cell activation and chemokines have been measured in 
relatively few studies during early abstinence and there have been 
inconsistent findings for IL-2, IL-12, IFN-γ, IL-13, and CXCL-8 (IL-8) 
(Gonzalez-Quintela et al., 1999) (Nicolaou et al., 2004) (Garcia-Valdecasas-
Campelo et al., 2007) (Vidali et al., 2008) (Laso et al., 1998) (Gonzalez-
Reimers et al., 2012).  No increases in IL-4 and IL-5 have been reported 
(Gonzalez-Reimers et al., 2012). 
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In summary, a wide range of cytokines associated with both innate and 
adaptive immunity are elevated in the peripheral blood of alcohol-dependent 
patients during the first few days of abstinence, although not invariably.  
Although the elevations reported are two to three times the mean of the 
control population (Gonzalez-Quintela et al., 2000) (Kiefer et al., 2002) 
(Latvala et al., 2005), similar to patient populations with depression 
(Krishnadas and Cavanagh, 2012), it is important to note that these are far 
smaller differences than would be seen in acute sepsis, where ten- to one 
hundred- fold increases are common. 
1.4.4 Multiple cytokines can be measured simultaneously using Multiplex 
platforms 
Circulating cytokines can be measured in the serum using immunoassays.  
Until recently, enzyme-linked immunosorbent assays (ELISAs) have been 
used to measure individual cytokines.  This method, however, uses a 
relatively large amount of serum to measure a single cytokine (Vignali, 2000).  
Multiplex systems have been developed in order to provide information 
regarding co-expressed cytokines and therefore, cytokine networks, and 
enable simultaneous measurement of multiple cytokines using the same 
volume of body fluid as would be used for a single ELISA experiment, and 
have a similar sensitivity to ELISA (de Jager et al., 2003).   
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Table 1.2: studies of peripheral blood cytokine concentrations in alcohol-dependent patient (ADP) populations 
Study  Population Cytokines Tissue/body fluid Assay Results (relative to controls) 
Khoruts 1991 Healthy ADPs 7-14 days abstinent (n=21) 
Controls (n = 20) 
Abstinent ADPs with cirrhosis(n=20) 
Alcoholic hepatitis patients (n=8) 
TNF-α 
IL-1 
IFN-γ 
IL-6 
Serum ELISA  
Bioassay 
Healthy ADPs: all ↔ 
Cirrhosis: all ↑  
Alcoholic hepatitis: all ↑ 
Laso 1998 Healthy alcoholics<24 hrs abstinent (n = 14) 
Controls (n = 10) 
ADPs with cirrhosis <24 hrs abstinent (n = 6) 
ADPs with cirrhosis >1 yr abstinent (n = 6) 
IL-4 
IL-12 
IFN-γ 
Serum ELISA Healthy ADPs 
All ↔ 
ADPs with cirrhosis: 
IL-12 ↑ in recently abstinent group 
Gonzalez-
Quintela 1999 
Healthy ADPs <72 hours abstinent (n=65) 
Controls (n=40) 
IL-4 
IL-5 
IL-6 
IL-8 
IL-10 
IL-12 
IL-13 
IFN-γ 
Serum ELISA IL-4 below limit of detection 
IL-5 below limit of detection 
IFN-γ detectable in 6% of alcoholics (0% of controls) 
IL-6 ↑ 
IL-8 ↑ 
IL-10 ↑ 
IL-12 ↑ 
IL-13 ↑ 
Laso 1999 Healthy ADPs <24 hrs abstinent (n = 10) 
Controls (n = 10) 
ADPs with cirrhosis <24 hrs abstinent (n = 10) 
ADPs with cirrhosis >1 yr abstinent (n = 10) 
IL-2 
IL-4 
IFN-γ 
Whole blood Flow cytometry 
Chemiluminescent 
antibody 
Healthy ADPs: 
IL-2 ↑ 
IFN-γ ↑ 
IL-4 ↔ 
ADPs with cirrhosis <24hrs abstinent: 
IL-2 ↑ but < healthy alcoholics 
IFN-γ ↑ but < healthy alcoholics 
IL-4 ↔ 
ADPs with cirrhosis >1yr abstinent: 
IL-2 ↔ 
IFN-γ ↔ 
IL-4 ↑ 
 
Gonzalez-
Quintela 2000 
Healthy ADPs (n=29) measured on day 1 (24-48 
hours abstinent) and mean day 6 (2-15) of 
detoxification 
Controls (n=5) pre and post 60g alcohol 
IL-6 
IL-8 
IL-10 
IL-12 
Serum EIA IL-6 ↑ 
IL-10 ↑ 
Both decreased during withdrawal 
IL-8 ↑ in controls after acute alcohol intake 
Kiefer 2002 Healthy ADPs 15-25 hours abstinent (n= 30) TNF-α Serum RIA TNF-α ↑ 
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Study  Population Cytokines Tissue/body fluid Assay Results (relative to controls) 
Controls (n=30)  
Nicolaou 2004 Healthy ADPs 24 ± 12 hours abstinent (n= 43) 
Controls (n= 20) 
TNF-α 
IL-6 
IL-8 
IL-10 
IL-12 
Serum ELISA TNF-α ↔ 
IL-6 ↑ 
IL-8 ↔  
IL-10 ↔ 
IL-12 ↔ 
Latvala 2005  Healthy ADPs 2 ± 2 days abstinent (n=54) 
ADPs with alcoholic liver disease (fatty liver, hepatitis, 
fibrosis or cirrhosis) (n=32) 
TNF-α 
IL-6 
IL-8 
IL-10 
IL-2 
Serum ELISA Healthy ADPs: 
TNF-α ↑ 
IL-6 ↑ 
IL-8 ↑  
IL-10 ↔ 
IL-2 ↔ 
ADPs with cirrhosis: 
TNF-α ↑ 
IL-6 ↑ 
IL-8 ↑  
IL-10 ↑ 
IL-2 ↑ 
Garcia-
Valdecasas-
Campelo  2007 
Healthy ADPs admitted for alcohol withdrawal ie v 
early abstinence (n=12) 
Controls (n=12) 
ADPs with cirrhosis in v early abstinence (n=10) 
TNF-α 
IL-1β 
IL-6 
IL-8 
IL-10 
Serum Chemiluminescent 
assay 
ELISA 
Healthy ADPs: 
IL-8 ↑; others ↔ 
Alcoholics with cirrhosis: 
IL-8 ↑; others ↔ 
 
Gonzalez-
Quintela 2008 
Healthy ADPs admitted to hospital for treatment of 
withdrawal ie recently abstinent (n=35) 
Alcoholics with acute liver damage admitted to 
hospital (n = 44) 
Alcoholics with advanced liver disease (n = 30) 
Healthy controls (n = 460) 
TNF-α Serum Chemiluminescent 
immunoassay 
TNF-α ↑ 
TNF-α ↑ associated with AST >2x ULN and advanced 
liver disease 
Vidali 2008 Healthy ADPs < 4 days abstinent (n=29) 
Controls (n =34) 
Alcoholics with liver disease < 4 days abstinent (n = 
30) 
TNF-α 
IL-2 
IL-6 
IL-8 
Serum ELISA TNF-α and IL-2 ↑ in those with antibodies to 
peroxidised lipids 
Elevation of TNF-α + antibodies predictive of advanced 
ALD 
Gonzalez-
Riemers 2012 
ADPs without cirrhosis admitted to hospital 10-15 
days abstinent (n=31) 
TNF-α 
IL-6 
Serum Chemiluminescent 
immunoassay 
TNF-α ↑ 
IL-6 ↔ 
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Study  Population Cytokines Tissue/body fluid Assay Results (relative to controls) 
ADPs with cirrhosis 10-15 days abstinent (n=16) 
Controls (n = 18) 
IFN-γ 
IL-10 
IL-13 
IL-4 
ELISA IFN-γ ↑ 
IL-10 ↑ 
IL-13 ↑ 
IL-4 ↓ 
Le Clerq 2012 Healthy ADPs (n = 52) measured on day 1-2 (T1) and 
day 18-19(T2) of detoxification 
Controls (n = 16) 
TNF-α 
IL-6 
IL-10 
Plasma Multiplex  TNF-α ↑ 
IL-6 ↑ 
IL-10 ↑ 
All decreased from T1 to T2 
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1.5  Circulating cytokines and Hypothalamo-Pituitary-Adrenal (HPA) axis 
abnormalities during alcohol withdrawal 
1.5.1  A brief introduction to the hypothalamo-pituitary-adrenal (HPA) axis 
Derangement of hypothalamo-pituitary-adrenal (HPA) axis function is 
consistently reported in alcohol withdrawal.  Chapter 3 investigates the 
relationship between cytokines and cortisol during alcohol detoxification.  The 
HPA axis is an endocrine system that contributes to the body’s response to 
physiological or psychological stress via effects on glucose availability and the 
immune system.  Corticotrophin Releasing Hormone (CRH) is released from 
paraventricular nucleus of the hypothalamus into the hypophyseal portal 
system in response to stressors.  CRH stimulates release of adrenocortico-
stimulating hormone (ACTH) into the systemic circulation, which in turn 
stimulates adrenal production of cortisol.  Cortisol binds to glucocorticoid 
receptors with relatively weak affinity, resulting in stimulation at high doses 
only.  This inhibits further HPA axis activation.  
  
1.5.2  Alcohol dependence is related to abnormally high morning cortisol 
levels 
Both actively drinking alcohol-dependent patients (Mendelson et al., 1971) 
(Stokes, 1973) (Adinoff et al., 2003) and patients in alcohol withdrawal have 
been reported to have higher morning cortisol levels than control samples 
(Errico et al., 2002) (Keedwell et al., 2001) (Adinoff et al., 1991) (Leggio et al., 
2008) (Kruger et al., 2006).  Morning cortisol levels (a single blood sample 
around 9am) are used clinically to detect gross HPA derangements, as in 
Cushing’s syndrome or Addison’s disease.  ADPs in withdrawal have higher 
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cortisol than while they are still drinking, suggesting that withdrawal 
represents an acute-on-chronic stressor (Adinoff et al., 2003).  
 
A morning cortisol increase of between 2 to 5 fold in ADPs relative to those in 
a matched control sample has been reported (Adinoff et al., 1991) (Keedwell 
et al., 2001).  Whilst such levels are higher than those in a control population, 
or in the same patients after a longer abstinence duration, they still fall within 
clinical laboratory normal ranges for cortisol, which are set for diagnosing 
primary adrenal or pituitary pathology (Kruger et al., 2006) (Leggio et al., 
2008).  This implies that alcohol dependence is associated with a more subtle 
derangement of HPA axis function than primary endocrine disease in the 
majority of cases, though in rare cases, alcohol-related pseudoCushing’s 
syndrome has been reported (Besemer et al., 2011).   
 
A loss of circadian variation in those patients with moderate to severe 
withdrawal symptoms has been reported (Adinoff et al., 1991) (Mukai et al., 
1998), though the circadian rhythm appears preserved in those with mild 
symptoms or those who are receiving medication for detoxification (Keedwell 
et al., 2001) (Adinoff et al., 1991) (Mukai et al., 1998).  ACTH and cortisol 
levels have been found to decrease after two to six weeks of abstinence 
(Errico et al., 2002).  Counterintuitively, once withdrawal symptoms have 
resolved, lower levels of cortisol are associated with an elevated risk of 
relapse (Kiefer et al., 2006).  
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1.5.3  Blunted cortisol responses to challenge are found in alcohol 
dependence  
The observation that cortisol levels are higher in ADPs prompted further 
investigation of the function of the HPA axis employing challenge studies, 
using synthetic hormones such as dexamethasone and corticotrophin-
releasing hormone.  Suppression tests have revealed no consistent 
abnormality although a recent review found that studies in early abstinence 
reported a greater proportion of patients with non-suppression than in later 
abstinence (Besemer et al., 2011).  Stimulation tests using CRH have 
consistently described a lower increase in cortisol – that is a hyporesponsive 
HPA axis (Merry and Marks, 1972) (Coiro and Vescovi, 1999) (Adinoff et al., 
2005) (Bailly et al., 1989) – in ADP men.  In contrast, a single study in women 
found no abnormality (Adinoff et al., 2010).   
 
HPA axis hyporesponsiveness has also been found in ADPs using 
psychological stress as a probe (Lovallo et al., 2000) (Errico et al., 2002) 
(Junghanns et al., 2005) (Fox et al., 2012).  The Cortisol Awakening 
Response!– the physiological rise in cortisol of between 35% – 70% (Wust et 
al., 2000b) (Clow et al., 2010) occurring within the first thirty minutes of 
waking – has been used as a more easily administered challenge which is 
feasible in large studies; individuals collect saliva samples themselves during 
the first half hour to hour after waking using specially prepared dental swabs.  
It is unaffected by smoking, gender or length of sleep (Wust et al., 2000b).  
The single study of the Cortisol Awakening Response in ADPs found blunted 
responses in recently abstinent ADPs relative to those who had been 
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abstinent for some months (Junghanns et al., 2007) suggesting 
hyporesponsiveness to physiological, as well as psychological stressors in 
early abstinence. 
  
1.5.4 There are specific relationships between HPA axis function and cytokine 
expression 
It is important to characterise the relationship between the HPA axis and 
cytokines in alcohol withdrawal, as under physiological conditions the HPA 
axis is activated by peripheral inflammatory stimuli, and provides a major 
negative feedback loop (Rhen and Cidlowski, 2005).  The main anti-
inflammatory action of cortisol is inhibition of inflammatory transcription 
pathways such as Nuclear Factor Κβ (NFΚβ).  Increase in cortisol is thus 
associated with suppression of pro-inflammatory cytokines such as IL-6, Th-1 
cytokines such as IL-12, and an increase in anti-inflammatory cytokines such 
as IL-10 (van der Poll et al., 1996), as illustrated in Figure 1.1.  Stimulated 
ACTH production may also suppress inflammation: ACTH was inversely 
correlated with TNF-α after CRH challenge (Schuld et al., 2003). 
 
Under homeostatic conditions, pro-inflammatory and Th-1 cytokines are 
suppressed by ACTH and cortisol.  Under chronic inflammatory states, 
glucocorticoid receptor (GR) function is impaired, and the inflammatory 
stimulation of the HPA axis is not limited by negative feedback via cortisol 
(Pace and Miller, 2009) (Zunszain et al., 2011).  Thus, suppression of certain 
cytokines by ACTH and cortisol does not occur.  Additionally, cytokines may 
contribute to poor GR function by inhibiting glucocorticoid receptor 
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translocation, affecting interactions with other proteins, and reducing binding 
of the glucocorticoid receptor (Pace et al., 2007).   
 
Figure 1.1: Relationship between HPA axis function and cytokines 
 
Legend:  Peripheral pro-inflammatory cytokines, IL-1β, TNF-α and IL-6, stimulate the HPA 
axis resulting in cortisol production.  Both cortisol and ACTH are associated with suppression 
of pro-inflammatory cytokines and cortisol is associated with increased anti-inflammatory IL-
10.    
 
Dexamethasone non-suppression in alcohol-dependent patients in early 
abstinence (Besemer et al., 2011) suggests that GR function is impaired in 
this population.  Studies measuring cortisol and immune measures 
concurrently in surgical patients with alcohol abuse or dependence, however, 
found raised anti-inflammatory cytokines (Sander et al., 2005) and decreased 
Th-1 associated lymphocytes (Spies et al., 2004), which is inconsistent with 
glucocorticoid resistance.  The latter abnormality was reversed by HPA axis 
inhibition (Spies et al., 2006), providing further support for GR sensitivity 
rather than resistance.  These findings may have been affected by the acute 
inflammatory milieu of surgery and a more heterogenous patient population 
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(abuse and dependence).  Against this background, Chapter 3 investigates 
the relationship in a naturalistic clinical sample of alcohol-dependent patients 
undergoing planned detoxification.   
 
1.6  Microglial activation in alcohol-dependent patients during early 
abstinence 
Chapter 5 describes an imaging experiment using [11C]PBR28 Positron 
Emission Tomography to characterise activated microglia in alcohol-
dependent patients.  Microglia are the resident tissue macrophages of the 
central nervous system (CNS), comprising 10% of CNS cells.  There are four 
distinct populations of microglia classified according to their anatomical 
location – parenchymal, perivascular, meningeal and choroid plexus microglia 
– and these have differing immune functions (Ransohoff and Cardona, 2010).  
They have small cell bodies with multiple thin branching ramifications.  This 
morphology enables microglia to detect and respond dynamically to minute 
changes in their environment, even while in a morphological state previously 
known as ‘resting’, but now more accurately called ‘surveillant’ (Nimmerjahn 
et al., 2005) (Ransohoff and Cardona, 2010).  In response to injury their 
ramifications extend to the site of injury within seconds and fuse with the 
ramifications of other microglia to form a wall between healthy and injured 
tissue (Davalos et al., 2005).   
 
With more significant injury, microglia proliferate and change from a highly 
branched to a more amoeboid, macrophage-like structure.  This change is 
termed ‘activation’.  As described above, several functional states of activation 
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are recognized, and two specifically named: an ‘M1’ neurotoxic phenotype 
that produces pro-inflammatory cytokines, reactive oxygen species (Chao et 
al., 1992), and excitotoxins (Piani et al., 1992); and a neurotrophic ‘M2’ 
phenotype which secretes anti-inflammatory cytokines, nerve growth factors 
and clears debris via phagocytosis (Morgan et al., 2004).  It is hypothesised 
that further functional types of activated microglia exist (Perry et al., 2010) and 
that the type of activation may be contingent both upon the microenvironment 
(Morgan et al., 2004), neuronal regulation (Nakajima et al., 2007), and 
systemic inflammation (Wright et al., 2014).  Either overactivity of the M1 
phenotype or suppression of the M2 phenotype could be associated with 
exacerbation of an acute or chronic neural insult. 
1.6.1  Microglial activation relates to the extent of damage in a variety of 
conditions 
Clinical imaging studies have found relationships between microglial 
activation and structural measures of damage or clinical measures of 
cognitive decline in a variety of neurodegenerative diseases.  An inverse 
relationship between Mini-Mental State Examination (MMSE) score and 
binding of [11C]PK11195, a radiotracer with affinity for a protein highly 
expressed in activated microglia (see below),  has been found in mild 
cognitive impairment (Edison et al., 2008).  In Multiple Sclerosis (MS), studies 
using [11C]PK11195 have found a positive correlation with atrophy in areas 
unaffected by acute lesions (Versijpt et al., 2005), and that high [11C]PK11195 
binding was associated with greater disability in progressive MS (Giannetti et 
al., 2014).  Similarly, in an acute insult such as stroke, microglial activation 
around the lesion was associated with a worse clinical outcome (Thiel and 
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Heiss, 2011).  However, microglial activation in projection areas was 
associated with better outcome, perhaps representing disparate functional 
activation in different brain areas (Thiel and Heiss, 2011).   
1.6.2  Microglial activation is associated with alcohol withdrawal pre-clinically 
Pre-clinical studies have demonstrated microglial activation or proliferation 
during alcohol withdrawal (Nixon et al., 2008), (Marshall et al. 2013).  
Particularly, microglial activation has been reported in the hippocampus in 
areas where glutamate was increased (Ward et al., 2009).  Microglial 
proliferation is detectable for up to three weeks after withdrawal (Obernier et 
al., 2002), (Marshall et al. 2013).  There is debate over the functional 
phenotype of activated microglia during alcohol withdrawal.  Pascual and 
colleagues described increased inducible nitric oxide synthetase and cyclo-
oxygenase in pre-clinical models, which would be consistent with an 
inflammatory milieu involving M1 microglial activation (Pascual et al., 2007).  
Further, another pre-clinical study found initial inflammatory microglial 
activation in the hippocampus and parietal cortex, with expression of TNF-α 
and IL-1β during the first four days of withdrawal, associated with cognitive 
decline, followed by proliferation of trophic microglia around fourteen days 
post withdrawal, associated with cognitive recovery (Zhao et al., 2013).  In 
contrast, a more recently published paper found that microglial activation 
during alcohol withdrawal was not full activation, occurred after neuronal 
death, and was associated with increased expression of IL-10 (anti-
inflammatory), rather than TNF-α (inflammatory) (Marshall et al. 2013).  
Hence there is uncertainty about whether microglia may exacerbate damage 
or be protective.  Although the most recent findings were published 
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subsequent to the design of my study, the pleotrophic nature of microglia and 
the uncertainty regarding their role in other conditions led me to investigate 
the relationship between microglial activation and cognitive function as a 
proxy of acute damage following detoxification. 
 
Human tissue post-mortem studies in alcohol-dependent patients have shown 
increased microglial numbers, increased inflammatory chemokine CCL-2 
expression, and increased expression of inflammatory receptors and 
transcription factors.  It has been suggested that inflammatory processes may 
be related to alcohol-related brain damage (Zahr et al., 2011).  It has also 
been suggested that inflammatory pathways are involved in plasticity of 
striatal-frontal circuits related to compulsive behaviour in addiction (Crews et 
al., 2011).   
1.6.3  Microglial activation can be detected in humans in vivo using Positron 
Emission Tomography (PET) 
Activated microglia can be imaged in vivo in humans using PET.  This brain 
imaging technique involves the intravenous injection of a ‘radiotracer’ or 
‘radioligand’, which is a chemical labelled with a radioisotope, in such small 
amounts (‘tracer’ amounts) that it is able to bind to the protein of interest 
without perturbing the biological system concerned.  The isotope decays, 
emitting a positron, the antimatter equivalent of an electron.  The positron 
travels – usually a distance <1mm – until it encounters an electron, which it 
annihilates.  When this occurs, two gamma photons are emitted, travelling in 
opposite directions.  A ring of detectors containing scintillation material, in the 
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scanner itself, detect gamma photons.  Those that reach them simultaneously 
are detected as representative of a single annihilation and the scanner uses 
information from simultaneous pairs of gamma photons incident on detectors 
opposite one another to locate and quantify the amount of radioactivity in a 
given area of brain.   
 
This information is gathered for separate periods of time during the scan in a 
‘time-activity curve’ plotting radioactivity over time for each brain voxel.  
Arterial blood is obtained from the radial artery continuously at first and then 
at intervals later in the scan, to measure both radioactivity and metabolite 
concentrations in the plasma.  This information is used to generate a 
metabolite-corrected input function, the time activity curve of the radioactivity 
curve in the blood.  These measurements are used to estimate a model of 
tracer pharmacokinetics, which captures the movement of the tracer from 
plasma, to tissue, to bound and back.  Information about the tracer 
pharmacokinetics and binding in the brain is used in model selection, as are 
mathematical best fit criteria such as the Akaike Information Criteria (Akaike, 
1974). 
 
1.6.4 The PET target representing microglial activation is the Translocator 
Protein (18kDa)  
PET radioligands that bind the Translocator Protein (18kDa) (TSPO) are used 
to detect microglial activation.  The TSPO is a mitochondrial membrane 
protein found in a heteromer with a voltage-dependent anion channel and an 
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adenine nucleotide transporter (McEnery et al., 1992).  It has multiple 
functions, including translocation of cholesterol during steroid synthesis, 
calcium homeostasis, and cell death regulation (Papadopoulos et al., 2006).  
It is highly expressed in steroid-producing tissues (Papadopoulos et al., 2006) 
and is conserved across species.  TSPO is expressed in cerebral connective 
tissue: arteriolar smooth muscle, perivascular macrophages, the choroid 
plexus, ependyma, meninges, and the olfactory bulb and pituitary (Turkheimer 
et al., 2007).  Expression in brain parenchyma under normal conditions has 
long been thought to be low.  Recently however, expression has been 
reported in healthy human endothelium, choroid, human glia and microglia 
(Cosenza-Nashat et al., 2009), with higher binding in the hippocampus than in 
other brain regions (Gulyas et al., 2009), in neural progenitors in vitro (Varga 
et al., 2009), and in mature granule cell neurons in the hippocampus and 
Purkinje cells in the cerebellum of transgenic Translocator Protein 18kDa-
Green Fluorescent Protein (TSPO-GFP) mice (Wang et al., 2012). 
 
Microglia in a ramified state, express TSPO, but at relatively low levels (Banati 
et al., 2004).  When microglia become activated, their expression of TSPO is 
increased at least twofold (Banati et al., 2000).  This increase appears to 
relate to activation in addition to proliferation (Ito et al., 2010).  On a sub-
cellular level the increase in signal is associated with an increase in the 
number of mitochondria, mitochondrial elongation, and arrangement in ring 
aggregates (Banati et al., 2004).   Although microglia and astrocytes increase 
expression of TSPO when activated, the distribution of the TSPO-PET signal 
(most commonly of [11C]PK11195) in in vivo studies of a variety of brain 
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pathologies corresponds to microglia rather than astrocytes (for a review, see 
(Venneti et al., 2006)).  Although very early increase in [11C]PK11195 binding 
following a neurotoxic lesion reflects a mixed glial/microglial response, the 
profile of the signal in terms of time course, peak and persistence of the signal 
is consistent with ongoing microglial activation rather than a mixed signal 
(Venneti et al., 2006).  
 
PET imaging with ligands for the TSPO has already been used to characterise 
microglial activation in neurodegenerative conditions, hepatic encephalopathy, 
stroke and traumatic brain injury (Edison et al., 2008), (Thiel and Heiss, 
2011), (Ramlackhansingh et al., 2011).  [11C]PK11195 is the tracer most 
frequently used to study differences in TSPO binding (Cagnin et al., 2007).  
There are, however, some methodological issues with [11C]PK11195 PET.  
Despite high affinity to the TSPO in vitro, it has a low specific-to-nonspecific 
binding ratio in vivo (Banati et al., 2000) and is difficult to quantify in plasma 
(Cleij, 2003), (Kropholler et al., 2005).  Newer tracers have a superior signal-
to-noise ratio (Van Camp et al., 2010), but suffer from other limitations.  A 
single nucleotide alanine to threonine polymorphism affects the affinity of new 
generation ligands for the TSPO (Owen et al. 2011).  Those who are 
homozygous for the alanine nucleotide are ‘high affinity binders’ (HABs) in 
that TSPO radioligands bind to their binding site on the TSPO with a high 
affinity.  Those who are homozygous for the threonine nucleotide are ‘low 
affinity binders’ (LABs) in that TSPO radioligands bind to their binding site with 
low affinity.  No specific [11C]PBR28 PET signal is detectable in the brain in 
LABs.  For this reason they were previously known as ‘non-binders’ (Imaizumi 
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et al., 2007), (Imaizumi et al., 2008).  Heterozygotes, or ‘mixed affinity binders’ 
(MABs) have mixed TSPO, comprising 50% TSPO with the high affinity sites 
and 50% with the low affinity sites.  It is therefore necessary to screen for the 
TSPO polymorphism prior to scanning, to exclude LABs.  Knowledge of 
genotype is also important in interpreting scanning data, as specific binding in 
MABs measured by PET in vivo, is around half that of HABs (Kreisl et al. 
2012). 
 
Alcohol-dependent patients are usually treated with benzodiazepines during 
alcohol withdrawal.  This complicates TSPO PET as certain benzodiazepines, 
including diazepam, bind to the TSPO.  In fact, the TSPO was originally 
characterised as a ligand for benzodiazepines in the peripheral organs, which 
explains its the name it was first given, the Peripheral Benzodiazepine 
Receptor (Papadopoulos et al., 2006).   
 
Previous in vitro radioligand binding studies in human brain had been 
published only for certain benzodiazepines, and under conditions that did not 
approximate the in vivo environment in terms of pH or temperature (Rao and 
Butterworth, 1997).  Further, the effect on benzodiazepine affinity of the 
genetic polymorphism that affects radioligand binding is unknown.  For this 
reason, I performed radioligand competition assays with commonly prescribed 
benzodiazepines including diazepam, chlordiazepoxide, and their metabolites, 
which are described in Chapter 4. 
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1.6.5 The affinity of benzodiazepines for the TSPO can be established using 
radioligand binding assays 
Competition assays use a fixed concentration of a radioactive tracer or ‘hot’ 
ligand, for example, [3H]PK11195 or [3H]PBR28, of known affinity for a 
receptor.  This is incubated with homogenised tissue containing the receptor 
of interest, in this case, brain, and varying concentrations of the ‘cold’ ligand, 
the benzodiazepine of interest.  Each concentration of benzodiazepine is 
incubated at body temperature with the tissue and radioligand in physiological 
buffer until equilibrium is reached.  The process is stopped by harvesting of 
the tissue, with the ‘cold’ ligand and radioligand labelling the receptors of 
interest, onto discs of filter paper. These are then placed in a vial of 
scintillation fluid and the amount of radioactivity is measured by a beta-
counter.  The affinity, or inhibition constant, of the cold ligand can then be 
calculated using the Cheung-Prosoff equation, as follows: 
!! = !!!" 1+ !!!  
where Ki is the affinity of the cold ligand, IC50 is the concentration at which the 
cold ligand displaces 50% of the hot ligand, L is the concentration of the hot 
ligand, and KD is the affinity of the hot ligand.  This competition study was 
therefore necessary to determine whether the TSPO-PET study could be 
undertaken in patients taking, or having recently taken, benzodiazepines.  
 
1.7  The relationship between brain glutamate and microglial activation 
The increase in extracellular glutamate is a key neurobiological derangement 
during alcohol withdrawal and has been related to neuronal death.  Chapter 6 
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describes Magnetic Resonance Spectroscopy undertaken to establish the 
relationship between TSPO expression, as a proxy of microglial activation, 
and MRS brain glutamate concentrations.  Microglial activation in response to 
increased glutamate provides a plausible mechanism for the increase in 
microglial activation during alcohol withdrawal, as set out below, in contrast to 
the multiple mechanisms of microglial activation identified during chronic 
alcohol drinking.  
 
Glutamate is the primary excitatory neurotransmitter in the central nervous 
system.  It participates in cellular metabolism via conversion to a-
ketoglutarate, a substrate of the Krebs cycle, and is also the precursor of γ-
hydroxy-amino-butyrate (GABA) the predominant inhibitory neurotransmitter 
and glutathione, a compound involved in conjugating toxic metabolites 
(Erecinska and Silver, 1990) (Bak et al., 2006).  Glutamate does not cross the 
blood brain barrier, so it is synthesised de novo from glucose in the brain 
(Hertz et al., 1999). 
 
Glutamate acts at an array of ionotropic and metabotropic receptors (these 
and its regulation are extensively reviewed in (Clapp et al., 2008)).  There are 
three types of ionotropic receptors: N-methyl-D-aspartate (NMDA), AMPA and 
kainate, which are situated post-synaptically.  Binding of glutamate to these 
receptors causes influx of positively charged ions the post-synaptic neuron 
and evokes a rapid neuronal response.  Metabotropic glutamate receptors are 
situated pre-synaptically and on glial and microglial cells, and modulate 
glutamate release.  Glutamate transmission via NMDA receptors is crucial in 
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memory function as it is involved in the process of long-term potentiation that 
underpins synaptic plasticity.  It is highly regulated as excess calcium influx 
via NMDA receptors can result in NMDA-mediated excitotoxicity.  Synaptic 
glutamate is rapidly taken up by astrocytic transporters and converted into 
glutamine, which is not a neurotransmitter, so can be safely released and 
taken up by neurons, for conversion into glutamate (Hertz et al., 1999) (see 
Figure 1.2). 
 
Figure 1.2: The relationship between glutamate and glutamine, and other 
metabolic pathways in the brain 
 
 
Acute alcohol intake inhibits ionotropic glutamate receptors, particularly 
NMDA receptors (Lovinger et al., 1989) (Hoffman, 2003).  Chronic alcohol 
intake is associated with an up-regulation of NMDA receptors in both pre-
clinical models (Floyd et al., 2003) (Snell et al., 1996) and post mortem 
alcoholic brain samples (Freund and Anderson, 1996).  In vitro studies have 
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reported that neurons exposed to alcohol have more NMDA receptors 
clustered around synapses.  NMDA receptors also become more sensitive to 
glutamate, so more calcium ions enter the cell for a given glutamate 
concentration, which is attributed to a change in subunit composition (for a 
review see (Nagy, 2008)).   
 
Not only is the alcohol-dependent brain therefore more primed to respond to 
glutamate, but it is also exposed to more extracellular glutamate during 
alcohol withdrawal.  Concentrations of extracellular glutamate as measured by 
microdialysis in animals (De Witte et al., 2003) and in cerebrospinal fluid 
(CSF) and plasma in man, are reported to be increased during alcohol 
withdrawal (Tsai et al., 1998) (Brousse et al., 2012) while GABA 
concentrations are lower in man (Tsai et al., 1998) (Brousse et al., 2012).  
Subsequent cycles of withdrawal in animal models are associated with 
progressive increases in glutamate and other excitatory amino acids 
(Dahchour and De Witte, 2003).  Pre-clinical studies have demonstrated an 
association between increased NMDA transmission and cell death in the 
hippocampus during alcohol withdrawal (Mayer et al., 2002).  In humans, CSF 
concentrations of excitatory neurotransmitters correlate with oxidative stress 
markers, which implies glutamate has a role in withdrawal-related damage 
(Tsai et al., 1998).  Withdrawal seizures can be prevented in pre-clinical 
models by NMDA antagonists, which suggests they may also relate to excess 
excitatory neurotransmission (Stepanyan et al., 2008).  Traditionally, 
benzodiazepines which potentiate GABA-A transmission have been used to 
treat symptoms of alcohol withdrawal (Pilling et al., 2011) (Lingford-Hughes et 
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al., 2012b), though NMDA antagonists such as MK801 and memantine have 
been shown to prevent alcohol withdrawal-related seizures in rodents 
(Stepanyan et al., 2008).  In humans, medications that inhibit glutamatergic 
transmission, such as memantine, have had comparable effects to diazepam 
in the treatment of alcohol withdrawal (Krupitsky et al., 2007).   
 
Magnetic resonance spectroscopy (MRS) has been used to measure brain 
glutamate in alcohol-dependent patients.  MRS is a form of Magnetic 
Resonance Imaging (MRI) used to detect concentrations of brain metabolites. 
Human brain MRS most commonly detects hydrogen atoms, which are 
abundant, using a standard head coil.   
 
MRS is based on the principle that when the brain is placed within a magnetic 
field, atomic nuclei within the tissue will predominantly spin around an axis 
aligned with the direction of the magnetic field.  Pulsed radiofrequency waves 
knock the nuclei off their axes, causing them to flip to a perpendicular axis 
and then relax towards the aligned axis.  This oscillation occurs at a particular 
frequency, or ‘resonance’.  The magnetic field produced causes an electric 
current in the head coil, which is acquired by the scanner.  The specific 
frequency is influenced by the surrounding electron clouds, which vary 
according to molecular make-up.  These cause a local magnetic field that 
‘shields’ the nuclei from the external magnetic field to a small extent.  Thus 
hydrogen nuclei within different compounds resonate at different frequencies.   
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The difference in resonance confers information about molecular structure 
and is measured in parts per million (ppm).  Some metabolites, such as 
glutamate, yield multiple peaks as hydrogen nuclei exist in three different 
environments in the molecule.  The x axis scale of the MRS spectrum 
generated by the scan is of ppm.  The y axis represents the amplitude of the 
oscillation, and is proportional to the total concentration of the metabolite. 
 
Pre-processing is necessary to deal with some of the challenges inherent in 
MRS.  First, ‘shimming’ is performed by altering the electrical currents in the 
head coil, in order to render the magnetic field as homogenous as possible, 
thus maximising the signal-to-noise ratio.  Second, water suppression pulses 
are performed, as the concentration of water in the brain is several thousand 
fold the concentration of the metabolites of interest.   
 
MRS detects total glutamate ([Glu]) and glutamine ([Gln]) concentrations in 
the voxel of interest, and so cannot distinguish between metabolic and 
synaptic pools.  It has been proposed that glutamine could represent a marker 
of glutamatergic neurotransmission, as it is produced from synaptic glutamate 
taken into astrocytes (Yuksel and Ongur, 2010) (Theberge et al., 2002).  [Glx] 
is a composite measurement of glutamate and glutamine concentration that is 
calculated when their separate spectra cannot be resolved.  It has been 
proposed that [Glx] represents the total glutamate store available for 
metabolic and synaptic purposes (Yuksel and Ongur, 2010). 
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In cross-sectional studies comparing controls with ADPs (summarised in 
Table 1.3), most published after the beginning of my study, there have been 
no consistent findings, which may reflect differences in the region selected, 
magnet strength and duration of abstinence.  For instance, both increased 
and decreased [Glu] has been reported in the anterior cingulate cortex (ACC) 
(Lee et al., 2007) (Thoma et al., 2011) with no differences in [Glu] in frontal 
white matter (Ende et al., 2013), dorsolateral prefrontal cortex, and occipital 
cortex (Mon et al., 2012) in ADPs compared with healthy controls.  
Acamprosate, a derivative of taurine, an amino acid that had been 
demonstrated to reduce extracellular glutamate levels during repeated 
withdrawal cycles pre-clinically, was associated with a decrease in [Glu] 
during early abstinence (Umhau et al., 2010). 
 
[Glu] and [Glx] relate to important clinical variables in ADPs.  An inverse 
correlation reported between [Glu] and cognitive function in depressed 
patients provides additional weight to the argument that [Glu] is related to 
damage  (Ende et al., 2013).  However in binge drinking patients, lower [Glu] 
was related to a history of blackouts suggesting that in the acute setting 
higher [Glu] compensates for the amnestic effect of alcohol (Silveri et al., 
2014).  Increased [Glx] has been reported in the occipital cortex of those 
ADPs who smoked in one study, relative to ADPs who did not smoke, and 
controls (Mason et al., 2006), but no different to healthy controls in the 
nucleus accumbens and ACC in another (Bauer et al., 2013).  A positive 
correlation has also been found between craving and [Glx] (Bauer et al., 
2013).  Given the integral role of glutamate in the neurobiology of alcohol 
! 53 
withdrawal, and its relationship with clinical variables, it was important to 
investigate the relationship between microglial activation and glutamate in 
man.  The pre-clinical association between the two (Ward et al., 2009) 
strengthened the rationale for this study.    
 
Table 1.3:  MRS studies of glutamate, glutamine, [Glx] in alcohol 
dependence 
Study Population Voxels Findings 
Bauer 2013 29 ADPs 10 days 
abstinent 
31 HCs 
NAcc 
ACC 
↑[Glu] in NAcc 
↔[Glu] in ACC 
↔ [Glx], [NAA], [Cho], [Cr] in both 
Glx in ACC related to craving 
Ende 2013 23 actively drinking 
HDs 
9 HCs 
 
Frontal white 
matter 
↑[Cho] 
↔[Glu] 
↔[NAA] 
↔[Cr] 
Inverse correlation between [Glu] 
and cognitive function 
Yeo 2013 213 HDs abstinent 
for 24 hrs 
66 HCs 
ACC ↑[Glx], [NAA], [Cr], [Cho] 
Hermann 2012 47 ADPs  
2 scans: day 1 an 
day 14 of abstinence 
57 HCs 
ACC ↑[Glu] on day 1 
[Glu] decreased to control levels 
by day 14 
↓[NAA] on day 1 
Mon 2012 20 ADPs abstinent 
for 1 week 
36 ADPs abstinent 
for 5 weeks 
16 HCs 
1 week 
5 weeks 
ACC 
POC 
DLPFC 
At 1 week: 
ACC:↓[Glu], [NAA], [Cho], [Cr] 
↔[GABA+], [mI] 
POC, DLPFC: no differences 
Normalisation by 5 weeks 
abstinence 
Inverse correlation between [mI] 
and cognitive function 
Thoma 2011 7 ADPs actively 
drinking 
ACC ↑[Gln] 
↓[Glu] 
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Legend:  ACC = anterior cingulate cortex; ADPs = alcohol-dependent patients; [Cho] = 
choline concentration; [Cr] = creatine concentrations; DLPFC = dorsolateral prefrontal cortex; 
[GABA+] = Gamma amino butyric acid concentration; [Gln] = glutamine concentration;  [Glu] = 
glutamate concentration; [mI] = myoinositol concentration; [NAA] = N-acetyl aspartate; NAcc 
= nucleus accumbens; POC = parieto-occipital cortex; HDs = heavy drinkers; HCs = healthy 
controls; OCC = occipital cortex  
 
1.8  Aims and hypotheses 
The aim of my thesis was, first, to ascertain whether there was evidence of 
peripheral inflammation and neuroinflammation during alcohol withdrawal and 
early abstinence.  Second, I aimed to investigate the relationship between 
these immune processes and the neurochemical and neuroendocrine 
derangements that characterise the withdrawal-early abstinence period.  
Third, I aimed to explore whether there was a relationship between 
inflammatory processes and clinical features of withdrawal and early 
abstinence, in particular impaired cognitive function.  Thus I aimed not only to 
establish evidence for the presence of peripheral inflammation and 
6 ADPs 1 year 
abstinent 
17 HCs 
↔ [NAA], [mI], [Cho], [Cr] 
No difference between actively 
drinking and abstinent groups 
Umhau 2010 2 scans during first 
month of abstinence 
15 ADPs on 
acamprosate 
18 ADPs on placebo 
ACC [Glu]↓ in acamprosate group  
[Glu]↑ in placebo group  
(after treatment) 
Lee 2007 13 ADPs abstinent 
15 d (14 – 28) 
18 HCs 
ACC 
Insula 
↓[Cho], [Cr] in ACC 
↑[Glu]: [Cr] in ACC 
Glu:Cr directly correlated with 
short term memory 
Mason 2006 2 scans during first 
month of abstinence 
16 ADPs 
8 HCs 
OCC Smoking v.s. non-smoking ADPs: 
↑[Glx] in smoking ADPs 
↓[GABA+] in smoking ADPs 
ADPs vs HCs: 
↔[Glx], [NAA], [Cho], [Cr] 
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neuroinflammation, but also the possible clinical relevance of these processes 
and the way in which they related to the neurobiology of alcohol withdrawal 
and early abstinence. 
 
Concerning peripheral inflammation, I hypothesised that circulating pro-
inflammatory cytokines and chemokines would be raised in early 
detoxification relative to late detoxification, that there would be a positive 
relationship between cytokine concentrations and withdrawal severity and an 
inverse relationship between cytokines and cognitive function.  I hypothesised 
that hypothalamo-pituitary-adrenal axis function would be deranged, as 
described previously, and that this derangement would correlate with pro-
inflammatory cytokine concentrations.  
 
I hypothesised that there would be a widespread increase in [11C]PBR28 VT, 
signalling microglial activation in the brain during early abstinence from 
alcohol, particularly in the hippocampus where it had been described pre-
clinically.  Further, I hypothesised that there would be an inverse relationship 
between [11C]PBR28 VT and performance on cognitive tests.  Based on pre-
clinical evidence describing co-occurring microglial activation and increased 
extracellular glutamate during withdrawal, I hypothesised that brain glutamate 
as detected would be increased and that there would be a positive 
relationship between glutamate and  [11C]PBR28 VT.  
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CHAPTER 2 
PERIPHERAL CYTOKINE PROFILE IN ALCOHOL DETOXIFICATION: 
RELATIONSHIP TO CLINICAL SYMPTOMS 
2.1  Introduction 
2.1.1  Circulating cytokines and chemokines are increased during alcohol 
detoxification. 
The peripheral blood cytokines TNF-α, IL-1β and IL-6 are raised in early 
abstinence in alcohol dependence, as described in Chapter 1 Section 4 
(Gonzalez-Quintela et al., 1999), (Gonzalez-Quintela et al., 2000), (Kiefer et 
al., 2002), (Nicolaou et al., 2004), (Latvala et al., 2005), (Garcia-Valdecasas-
Campelo et al., 2007), (Gonzalez-Quintela et al., 2008), (Gonzalez-Reimers et 
al., 2012), (Leclercq et al., 2012).  In addition, IL-6 and the chemokine CXCL-
8 (IL-8) are positively correlated with alcohol consumption in population 
studies (Volpato et al., 2004) (Gonzalez-Quintela et al., 2007).  Pro-
inflammatory cytokine levels of two to three times greater than control values 
have been reported, elevations of similar magnitude to those found in other 
chronic inflammatory conditions such as rheumatoid arthritis (Gottenberg et 
al., 2012) and depression (Krishnadas and Cavanagh, 2012).  Circulating 
cytokines are well-recognised to be of clinical relevance to alcoholic liver 
disease (Thurman, 1998); and raised cytokines related to innate and T cell 
function, TNF-α and IL-2, are associated with more advanced stages (Vidali 
et al., 2008), (Gonzalez-Quintela et al., 2008), (Laso et al., 1998).  This 
chapter sets out the evidence that circulating cytokines may also be of 
! 57 
relevance to the brain in alcohol dependence and describes an experiment 
that aims to characterise the relationship between circulating cytokines, 
alcohol withdrawal and cognitive function in early abstinence. 
 
2.1.2 Cytokines communicate with the brain and may influence 
neurotransmission 
Circulating cytokines may be of relevance to pathological processes in the 
brain because pro-inflammatory cytokines, TNF-α, IL-1β and IL-6 
communicate with the brain via the vagus nerve, passive diffusion in blood-
brain barrier (BBB) deficient regions, specific BBB transporters and 
stimulation of perivascular macrophages, leading to cerebral cytokine 
expression and microglial activation (Dunn, 2006).  Cytokines bind to specific 
receptors present on neurons and glia and influence neurotransmission and 
neuroendocrine function in numerous ways (Dunn et al., 2005) (Dunn, 2006).  
Of interest in alcohol dependence is the relationship between NMDA receptor 
function and IL-6, which is protective in some in vitro models of excitotoxicity 
when applied acutely (Yamada and Hatanaka, 1994) (Ali et al., 2000) but in 
others, increases damage when applied chronically (Qiu et al., 1998).   
 
Furthermore, the hypothalamo-pituitary-adrenal (HPA) axis, the function of 
which is altered during alcohol withdrawal, is potently stimulated by peripheral 
pro-inflammatory cytokines, particularly IL-1β and TNF-α (reviewed in 
(Haddad et al., 2002).  There are also behavioural, emotional and cognitive 
changes associated with increased expression of circulating pro-inflammatory 
cytokines (reviewed in (Dantzer and Kelley, 2007)).  For example, ‘sickness 
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behaviour’ characterised by disrupted sleep, fatigue, irritability and low mood 
in response to an infection, is thought to occur via cytokine-related modulation 
of the HPA axis, and altered processing in midbrain and limbic structures 
(Harrison et al., 2009a), (Harrison et al., 2009b).  Of relevance to this study is 
that a recent pre-clinical study found similar behavioural alterations during 
alcohol withdrawal to those observed following injection of lipopolysaccharide 
(LPS), a bacterial protein used to induce sickness behaviour (Richey et al., 
2012). 
 
As well as clinical evidence of peripheral cytokine elevation in alcohol 
withdrawal, there is pre-clinical evidence of elevated cytokines in the brain 
during withdrawal.  Cerebral expression of cytokines TNF-α, IL-1β and CCL-2 
(Qin et al., 2008) (Zhao et al., 2013), or their messenger RNA, an indirect 
measure of protein expression, has been reported during alcohol withdrawal 
(Whitman et al., 2013).  Microglial activation associated with increased 
extracellular glutamate concentrations during withdrawal has also been 
described (Ward et al., 2009).  Pre-clinical evidence suggests that peripheral 
inflammation may exacerbate withdrawal severity.  Repeated peripheral 
injection of lipopolysaccharide, or injection of pro-inflammatory cytokines TNF-
α or IL-1β, or the chemokine CCL-2, sensitised animals to withdrawal-related 
anxiety in a similar fashion to psychological stress (Breese et al., 2008), 
perhaps in part via modulation of the HPA axis (Knapp et al. 2008 2008).  
Longitudinal studies found elevated IL-6 (Chatzipanagiotou et al., 2010), TNF-
α, and IL-10 (Gonzalez-Quintela et al., 2000) (Leclercq et al., 2012) early in 
withdrawal, when withdrawal symptoms were most intense, but reduced one 
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week later.  IL-12 and CXCL-8 have been measured in a single longitudinal 
study, which showed no changes (Gonzalez-Quintela et al., 2000).  
 
2.1.3  Circulating cytokines: a link with depression and cognitive impairment in 
alcohol dependence? 
In addition to their potential relationship to alcohol withdrawal severity, 
cytokines may be related to common complications of alcohol dependence, 
that is, depression and cognitive impairment.  Increased circulating cytokines 
have been described in depression.  In particular, raised peripheral blood 
TNF-α, IL-1β, IL-6, and IL-2R have been found consistently (for recent meta-
analyses, see (Dowlati et al., 2010), and (Liu et al., 2012)) and have clinical 
relevance, as higher IL-6 may predict poor treatment response (Yoshimura et 
al., 2009).  A single study investigated the relationship between depression 
and cytokines in an alcohol-dependent population found an inverse 
association between depressive symptoms and the anti-inflammatory cytokine 
IL-10 after one week of abstinence, but no associations with pro-inflammatory 
cytokines TNF-α and IL-6 (Leclercq et al., 2012).  This analysis, however, did 
not take into account alcohol withdrawal severity, which could influence 
depressive symptoms. !
Inflammatory signals including cytokines, prostaglandins and inducible nitric 
oxide, may also be involved in cognitive impairment in alcohol dependence.  
Pre-clinical binge alcohol models have shed light on three aspects.  First, 
microglial activation has been associated with perseverative behaviour 
following alcohol administration (Obernier et al., 2002).  Second, 
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prostaglandin expression is associated with neuronal death following alcohol 
administration (Pascual et al., 2007).  Third, indomethacin pre-treatment 
prevents neuronal death caused by alcohol (Pascual et al., 2007).  Peripheral 
cytokines are associated with cognitive impairment in a variety of other 
disorders.  In Alzheimer’s disease, higher serum TNF-α concentrations were 
associated with cognitive deterioration (Holmes et al., 2009).  Higher IL-6 
concentrations are associated with worse cognitive function in healthy older 
adults (Mooijaart et al., 2013), in heart failure (Athilingam et al., 2013) and in 
depression (Elderkin-Thompson et al., 2012).  Finally, increased serum and 
CSF concentrations of CCL-2, a pro-inflammatory chemokine, have been 
associated with Alzheimer’s Disease (Sun et al., 2003) (Westin et al., 2012). 
 
In summary, pre-clinical evidence suggests that alterations in peripheral 
cytokine levels may be involved in the pathogenesis of alcohol withdrawal, 
and observational clinical studies suggest that peripheral cytokines are raised 
during alcohol withdrawal.  There is also pre-clinical and clinical evidence to 
suggest that peripheral pro-inflammatory cytokines may be important in 
depression and cognitive impairment, two common complications of alcohol 
dependence.  In particular, pro-inflammatory cytokines TNF-α, IL-1β and IL-6, 
T cell cytokine IL-2R, and chemokines CCL-2 and CXCL-8, are of interest.  
Although increased concentrations of a number of serum cytokines in alcohol 
dependence have been described, relatively few have been measured, so a 
broader knowledge of the cytokine milieu is lacking.   
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2.2  Aims and Hypotheses 
Against this backdrop, the aims of this study were:  
1. To identify changes in circulating cytokines and chemokines occurring 
in a naturalistic patient sample during alcohol detoxification, 
2. To elucidate the relationship between cytokines and clinical symptoms 
in the sample. 
Based on previous evidence, I hypothesised that both pro-inflammatory (TNF-
α, IL-1β, IL6) and anti-inflammatory cytokines (IL-10, IL-1RA) would decrease 
during detoxification, and that pro-inflammatory cytokines would be related to 
severity of withdrawal.  Further, I hypothesised that cytokines and chemokines 
previously identified in association with depression – TNF-α, IL-6, IL-10 and 
IL-2R – and cognitive impairment – TNF-α, IL-6, and CCL-2 – in non-alcohol-
dependent populations, would be associated with a simple measure of 
depression and performance on brief cognitive tests in an alcohol-dependent 
population.  In the absence of existing evidence, exploratory analyses were 
undertaken to characterise the time course of remaining cytokine and 
chemokine levels during detoxification, and their relationships with one 
another.  !
2.3  Methods 
2.3.1  Participants and recruitment 
59 participants were recruited on admission to a dedicated addiction 
psychiatric in-patient unit for elective detoxification from alcohol between July 
2011 and February 2012.  Assessment of capacity to consent to research was 
performed prior to taking consent.  Informed consent was taken during the 
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admission clerking or later on the day of admission, when participants were 
judged no longer incapacitated by intoxication   All patients met criteria for 
alcohol dependence according to ICD-10 criteria, as judged by the admitting 
psychiatrist.  Exclusion criteria included inability to follow the procedures of 
the study, recent participation in a clinical trial and recent significant blood 
loss.  Patients who developed pneumonia were excluded, as the associated 
increase in circulating cytokines would be likely to overwhelm any change 
relating to alcohol withdrawal (McInnes, personal communication), but minor 
soft tissue infections were allowed.  Five participants withdrew consent before 
the first data collection point.  Three further patients were diagnosed with 
pneumonia during their stay and their data are excluded from analysis. 
 
Clinical information regarding participants’ physical and psychiatric co-
morbidity was obtained from patient interview, information from GP records, 
and blood tests.  Current co-morbidity was diagnosed clinically and with 
information from blood tests and medical notes.  For example, alcoholic 
hepatitis was considered to be present if the patient had right upper quadrant 
pain, elevated liver function tests, and elevated bilirubin, but no previous 
diagnosis of cirrhosis.  Previous co-morbidity was obtained from GP records, 
as acute hospital or specialist out-patient records were not routinely available 
in mental health trusts.  Caine criteria for risk of Wernicke-Korsakoff syndrome 
(Caine et al., 1997) were derived from patient interview and medical notes.   
 
Patients were visited three times: in early detoxification (day 2-3 of 
admission), mid-detoxification (day 4-6) and late (day 7-10) detoxification.  All 
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visits occurred between 8am and 10am in the morning.  Visits were 
necessarily brief so as not to interfere with administration of medications and 
the programme of psychosocial interventions on the ward.  The revised 
Clinical Assessment of Withdrawal from Alcohol (CIWA-Ar) (Sullivan et al., 
1989) was administered.  Visual analogue scales for depression, anxiety and 
craving, anchored by statements such as ‘not at all depressed’, ‘moderately 
depressed’ and ‘the most depressed ever’, were completed.  Patients 
completed paper and pencil cognitive tests during the final visit.  Trail Making 
Tests A and B (Reitan, 1958), and phonemic verbal fluency were chosen as 
tests of frontal lobe function, and the Weschler Memory Scale paragraph test 
(Weschler, 1987) was chosen as a test of verbal memory.  These were 
chosen as they were easy and quick to administer, and are known to be 
sensitive to cognitive impairment secondary to alcohol dependence in 
‘healthy’ alcohol-dependent patients (Davies et al., 2005).   
 
2.3.2  Blood measures and analysis 
Blood was taken for cytokine concentration, high sensitivity C reactive protein 
(CRP) as a general measure of systemic inflammation and gamma glutamyl 
transferase as a marker of hepatic oxidative stress between 8am and 10am 
and transported on ice.  Blood samples were centrifuged (1300G, 10 min) and 
serum stored in sterile microcentrifuge tubes at –80ºC within 90 minutes of 
collection.   
 
Samples for cytokine analysis were analysed by collaborators at the 
University of Glasgow using Luminex Multiplex Human 25-plex plates 
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(Luminex, Austin, USA) performed in duplicate.  Each well in the Luminex 
plate contained a specified number of populations of micropores, small 
spheres stained with red and orange fluorescence in different proportions, 
such that different populations have different spectroscopic signatures 
(Vignali, 2000).  In each population of micropores a separate assay for a 
single cytokine occurs, similar to an ELISA.  Each micropore carries capture 
antibodies for a single cytokine.  A green fluorescence-labelled detection 
antibody is incubated with the body fluid of interest in the well containing the 
micropores.  The Luminex machine reads the red and orange fluorescence 
from the micropores in order to distinguish different populations of micropores 
and the amount of green fluorescence attached to each.  By measuring the 
green fluorescence against the amount detected using internal standards, it is 
possible for the machine to quantify the amount of each cytokine present in 
the fluid.  High sensitivity CRP (0.3 – 500mg/dl) and gamma glutamyl 
transferase were analysed by clinical biochemistry services at the 
Hammersmith Hospital. 
 
Patients were asked to collect salivary cortisol samples on waking, and at 15 
minute intervals for the following 45 minutes, at the same three stages of 
detoxification.  These samples were analysed using a standard ELISA assay 
(DRG Salivary Cortisol ELISA, DRG Instruments GmBH, Germany), 
performed in duplicate.  In addition, serum cortisol and cortisol binding 
globulin was analysed by Hammersmith Hospital biochemistry services.  This 
will be discussed in Chapter 3. 
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2.3.3  Statistical analysis 
51 participants were included in the analysis.  Data were inspected graphically 
via Q-Q plots to identify distribution and outliers and D’Agostino-Pearson 
omnibus normality tests implemented in GraphPad Prism Version 6 were 
performed, with information from both used to make decisions about 
normality.  Those data with a log-normal distribution were log-transformed to 
aid comparison of means and standard deviations, and for statistical 
procedures assuming a normal distribution.   
 
There were a number of cytokines where several data points were below the 
limit of detection (LOD) of the assay, as shown by Table 2.1.  Where this 
affected more than 25% of the sample (TNF-α, IL-1β, IFN-γ, IL-2, IL-4, IL-7, 
IL-15, IL-17, CXCL-9, GM-CSF), the cytokines were excluded from further 
analysis.  TNF- α and IL-1 β are known to be difficult to detect.  For this 
reason, IL-1RA, which antagonises the action of IL-1β and as such is 
regulated as a counter-balance, was used as a surrogate marker for IL-1β as 
it has been previously (Maes, 2011).  For those cytokines with less than 25% 
values below the LOD, values were estimated using maximum likelihood 
estimation (MLE), implemented in Matlab (Mathworks, 2008).  MLE is an 
accepted method that produces less biased estimates in data with a known 
distribution than simpler methods such as LOD/2 (Helsel, 2010).  Given that 
cytokines are known to follow a normal or log-normal distribution, this was the 
most appropriate choice. 
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The other form of missing data in the study resulted from missed visits or 
unrecorded information in the medical notes, withdrawal of consent, or self-
discharge (summarised in Table 2.2).  Two patients missed their first visit, four 
their second, and four their final visit.  I assumed that this missing data could 
be considered Missing At Random (MAR) and Missing Completely at Random 
(MCAR), as ‘missingness’ was likely to be explained either by clinical factors 
known to the research team, such as poor liver function necessitating 
admission to the acute hospital, or by completely random factors, such as the 
morning group meeting starting early (Donders et al., 2006).  This form of 
missing data was handled where possible using statistical models that 
accommodated missing values, such as mixed models implemented in SPSS 
20.0, or in the case of the multivariate analysis of variance, via a complete 
case analysis. 
 
Mixed statistical models were implemented in SPSS 20.0 to examine changes 
in cytokine concentrations over time, and explore how cytokines relate to 
withdrawal symptoms, depression, and craving.  Mixed statistical models are 
able to handle incomplete datasets, adjust for differences in variance across 
time points using different covariance structures, and can be used to examine 
relationships between two sets of repeated measures variables. The 
covariance structure for the models was chosen to optimise model fit 
according to the Akaike Information Criteria (Akaike, 1974) and Likelihood 
Ratio statistic and model fit examined graphically.  In the case of mixed 
models used to examine the effects of cytokine titres on clinical symptoms, 
the number of independent variables examined in each model was restricted 
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to a maximum of five, using the rule of thumb that ten participants are 
required per variable examined (Field, 2012).  A Bonferroni correction for 
multiple comparisons was performed to set a significance level for the main 
comparisons relating to cytokine changes over time; significance for 
exploratory hypotheses was set at p<0.05.  Exploratory analysis of the 
relationships between different circulating cytokines was undertaken using 
bivariate parametric correlations at each time point.  These are displayed 
below via graphical correlation ‘heatmaps’ using Excel (Microsoft). 
 
Multivariate analysis of variance (MANOVA) was used to ascertain the 
relationship between cytokines and performance on cognitive tests.  Since 
performance on different cognitive tests is consistently reported to be highly 
correlated, a multivariate analysis was used to ascertain whether there was a 
relationship between cytokine levels and ‘cognitive function’, a linear 
composite of performance on the following tests: Trails A score, Trails B 
score, FAS score, and both immediate and delayed Weschler Memory Scale 
paragraph version.  A median split of the cytokine concentrations was used to 
generate ‘high’ and ‘low’ concentration groups for comparison, as this was 
necessary in order to perform a multivariate analysis.  A complete case 
analysis was performed as MANOVA excludes missing values and SPSS 
does not support a MANOVA using multiply imputed data.  Levene’s equality 
of variances and Box’s test were checked to ensure model assumptions were 
met.  Post-hoc univariate ANOVAs were employed to investigate particular 
relationships between cytokines and verbal memory and frontal lobe function, 
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where a significant relationship between a cytokine and ‘cognitive function’ 
had been found, using a Sidak correction for multiple comparisons. 
 
Table 2.1: Proportion of cytokines above the assay limit of detection 
Cytokine % of samples with detectable values 
Pro- and anti-inflammatory cytokines  
IL-1β 48 
TNF-α 32 
IL-6 96 
GM-CSF 25 
IL-10 80 
IL1-RA 93 
Type 1 interferon   
IFN-α 100 
Cytokines related to T cell activation  
IL-2 14 
IL-7 14 
IL-15 43 
IL-2R 100 
Th1 cytokines  
IL-12 100 
IFN-γ 8 
Th2 cytokines  
IL-4 41 
IL-5 75 
IL-13 100 
Th17 cytokines  
IL-17 
 
10 
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Cytokine % of samples with detectable values 
Chemokines  
CXCL-8 (IL-8) 92 
CXCL-9 (MIG) 62 
CXCL-10 (IP-10) 100 
CCL-2 (MCP-1) 100 
CCL-3 (MIP-1α)  100 
CCL-4 (MIP-1β) 100 
CCL-5 (RANTES) 100 
CCL-11 (Eotaxin) 100 
 
Table 2.2: Summary of data missing completely at random/missing at 
random 
Variables Number missing % missing 
Caine criteria 7 13.7% 
Trails A&B 6  11.8% 
Weschler Memory Scale, FAS 5 9.8% 
Bloods and psychological measures (time 
point 3) 
4 7.8% 
Bloods (time point 1 and time point 2) 3 5.9% 
Recent alcohol use 1 2.0% 
 
2.4  Results 
2.4.1  Clinical characteristics 
Patient demographics are presented in Table 2.3.  The mean alcohol intake 
per day over the previous month was 33 UK standard alcohol units (259 
grams) per day.  Patients had undergone a median of two detoxifications 
previously with the majority (54%) having a history of previous alcohol 
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withdrawal seizures.  The median number of Caine criteria was 1 (range 0 – 
4).  Co-morbid nicotine dependence was present in a large proportion (68%) 
of patients and cannabis, cocaine and heroin dependence in a sizable 
minority (11%).   
Table 2.3: Clinical characterisation: Demographic features and 
substance misuse 
Demographic details   
Age  47 ± 12 
Gender 33 M : 18 F (65% M) 
Years of drinking  33 ± 13 
Mean alcohol intake/day in month prior to admission (Standard 
Alcohol Units) 
33 ± 15 
Mean alcohol intake/day in month prior to admission (g) 259 ± 105 
Number of previous detoxifications  2 (range 0 – 13) 
History of alcohol withdrawal seizures  28 (54%) 
Caine criteria  1 (range 0 – 4) 
Co-morbid drug use   
Nicotine 35 (68%) 
Cannabis  11 (20%) 
Cocaine 6 (11%) 
Opiates 6 (11%) 
 
Physical co-morbidity is described in Table 2.4.  The most common physical 
co-morbidity was concurrent gastrointestinal inflammation (25%).  A 
significant minority suffered from symptomatic alcoholic liver disease: 
alcoholic hepatitis (18%) or decompensated cirrhosis (10%).  Clinical blood 
tests on admission (Table 2.5) showed that with the exception of liver 
enzymes, blood parameters were in the normal range on admission. 
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Table 2.4: Clinical characterisation: physical co-morbidity 
Current physical co-morbidity   
Liver   
Cirrhosis 7 (14%) 
Decompensated cirrhosis 5 (10%) 
Chronic viral hepatitis  4 (8%) 
Alcoholic hepatitis  9(18%) 
Gastrointestinal tract  
GI inflammation 13 (25%) 
Chronic pancreatitis  2 (4%) 
Other systemic sources of inflammation  
Soft tissue infections 4 (8%) 
COPD 4 (8%) 
Connective tissue disease 2 (4%) 
Diabetes mellitus 2 (4%) 
Atherosclerosis 3 (6%) 
Psoriasis 1 (2%) 
 
Table 2.5: Routine clinical blood results on admission 
Blood marker Mean ±  SD Geometric 
mean 
Normal range 
White cell count 6.5 ± 2.2 6.2 3 – 10 
Platelets 162 ± 81 140 150 – 400 
Albumin 43 ± 5 43  34 – 50 
Bilirubin 15 ± 15 11 0 – 20 
Alanine transferase 64 ± 47 50 10 – 35 
Alkaline phosphatase 118 ± 57 107 35 – 105 
Gamma glutamyl transferase 625 ± 846 258 6 – 42 
This table shows those blood values that were related to inflammation or to liver function, 
taken from routine clinical blood tests on admission.  CRP, MCV and INR were not routinely 
recorded so are not included.   
 
2.4.1  Changes in pro-inflammatory and anti-inflammatory cytokines during 
detoxification 
Cytokine and chemokine values and statistical test results are presented in 
Tables 2.6 and 2.7.  There was a significant association with time point for IL-
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6 (p = 0.003) and IL-10 concentrations (p = 0.000) (see Figure 2.1).  Post-hoc 
Bonferroni corrected pair-wise comparisons found that IL-6 decreased in a 
progressive way with significant differences between each time point 
(early>middle: p = 0.015; middle>late: p = 0.003), while IL-10 significantly 
decreased early in withdrawal only (early>middle: p = 0.000).  IL-1RA did not 
change significantly.  Neither TNF-α nor IL-1β were detectable in the majority 
of samples.  
Figure 2.1: IL-6 and IL-10 decrease significantly during detoxification 
 
Legend: Stars denote Bonferroni-corrected significant post-hoc pairwise comparisons: * p 
<0.05; ** p <0.01 
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2.4.2  Changes in T cell cytokines during detoxification. 
The T cell regulatory cytokine IL-12(p35/p40) changed significantly during 
detoxification (p = 0.000).  Post-hoc pair-wise comparisons indicated that 
there was a significant increase between early and mid-detoxification  (p = 
0.000).  IL-2R, IL-5 and IL-13 did not change significantly.  IL-2 and IL-4 were 
not detectable in a majority of samples. 
Figure 2.2: IL-12 increases significantly during detoxification 
 
Legend: Stars denote Bonferroni-corrected significant post-hoc pairwise comparisons: * p 
<0.05; ** p <0.01 
2.4.3  Changes in chemokines during detoxification 
Both CXCL-8 and CCL-2 changed significantly during detoxification (CXCL-8: 
p = 0.001; CCL-2: p = 0.003).  Post-hoc pair-wise comparisons indicated that 
CCL-2 was lower at the later time point relative to the early time point (p = 
0.001), CXCL-8 decreased progressively (early>middle: p = 0.032; 
middle>late: p = 0.011; early>late: p = 0.000).  CXCL-10 changed significantly 
during detoxification (p = 0.003).  The change characterized by post-hoc 
testing was a significant increase occurring between early and mid 
detoxification (early<mid: p = 0.003).  CCL-3, CCL-4, CCL-5 and CCL-11 did 
not change significantly during detoxification. 
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Figure 2.3: CXCL-8 and CCL-2, while CXCL-10 increases during 
detoxification 
 
 
Legend: Stars denote Bonferroni-corrected significant post-hoc pairwise comparisons: * p 
<0.05; ** p <0.01 
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2.4.4  Changes in CRP and GGT during detoxification 
High sensitivity C-reactive protein (hsCRP) changed significantly during 
detoxification (p = 0.000).  Post-hoc analysis revealed that hsCRP increased 
between the early and middle time point (p = 0.000) but then decreased 
between the middle and late time point (p = 0.009) though at the late time 
point it was still higher than the early time point (p = 0.011).  Gamma glutamyl 
transferase decreased significantly (p = 0.000) and progressively 
(early>middle: p = 0.001; middle>late: p = 0.003).    
 
Table 2.6: Descriptive statistics (mean, SD, and geometric mean for log-
transformed cytokines) 
Cytokine Early 
detoxification 
Mid detoxification Late detoxification 
Pro- and anti-inflammatory cytokines 
Log IL-6 
IL-6 
1.57 ± 1.267 
4.81 
1.40 ± 1.057 
4.06 
1.17 ± 1.252 
3.98 
Log IL-10 
IL-10 
0.33 ± 0.932 
1.39 
0.06 ± 0.898 
1.06 
0.20 ± 0.965 
1.21 
Log IL-1RA 
IL-1RA 
3.64 ± 1.409 
38.22 
3.73 ± 1.534 
42.05 
3.86 ± 1.399 
42.36 
Type 1 interferon 
Log(IFN-α) 
IFN- α 
3.43 ± 0.429 
31.0 
3.39 ± 0.498 
29.6 
3.34 ± 0.673 
29.6 
Cytokines related to T cell activation 
IL-2R 137 ± 63.37 
 
155 ± 127.1 159 ± 144.0 
Log IL-5 
IL-5 
0.97 ± 0.608 
2.62 
0.98 ± 0.617 
2.65 
1.00 ± 0.588 
2.66 
Log IL-12 
IL-12 
4.97 ± 0.343 
144 
5.05 ± 0.382 
157 
5.07 ± 0.352 
153 
Log IL-13 
IL-13 
1.78 ± 0.423 
5.92 
1.78 ± 0.447 
5.95 
1.83 ± 0.430 
6.04 
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Cytokine Early 
detoxification 
Mid detoxification Late detoxification 
Chemokines 
Log CXCL-8 (IL-8) 
CXCL-8 
3.30 ± 1.161 
27.00 
3.09 ± 1.511 
21.95 
2.75 ± 1.488 
21.12 
Log CXCL-10 (IP-10) 
CXCL-10 
3.30 ± 0.689 
27.0 
3.48 ± 0.747 
32.4 
3.40 ± 0.674 
29.7 
CCL-2 (MCP-1) 733 ± 315.9 
 
646 ± 240.6 570 ± 222.0 
Log CCL-3 (MIP-1α) 
CCL-3 
3.34 ± 0.557 
28.2 
3.34 ± 0.627 
28.5 
3.29 ± 0.640 
27.8 
Log CCL-4 (MIP-1β) 
CCL-5 
4.19 ± 0.560 
66.0 
4.12 ± 0.649 
61.4 
4.21 ± 0.604 
64.94 
Log CCL-5 (RANTES) 
CCL-5 
8.36 ± 0.446 
4274 
8.36 ± 0.274 
4283 
8.40 ± 0.307 
4336 
CCL-11 (Eotaxin) 61.7 ± 30.32 
 
56.3 ± 25.40 56.0 ± 27.18 
Acute phase proteins  
Log(CRP) 
CRP 
1.05 ± 1.189 
2.85 
1.77 ± 1.051 
5.88 
1.45 ± 1.078 
4.14 
Oxidative stress markers 
Log(GGT) 
GGT 
5.44 ± 1.466 
230 
5.38 ± 1.365 
216 
5.31 ± 1.191 
216 
Legend: Mean and standard deviations (cytokines in ng/ml and log-transformed cytokines) 
and geometric mean (ng/ml) provided for cytokines that were log-transformed for analysis. !  
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Table 2.7: Variation in cytokines and CRP during detoxification 
 Df F statistic p 
Pro- and anti-inflammatory cytokines    
Log IL-6 2, 90.114 6.106 0.003** 
Log IL-10 2, 90.714 8.679 0.000*** 
Log IL-1RA 2, 92.656  0.908 0.407 
Type 1 interferon    
Log(IFN-α) 2, 86.998 1.028 0.362 
Cytokines related to T cell activation    
IL2R 2, 89.339 0.675 0.512 
Log IL-5 2, 92.016 0.269 0.765 
Log IL-12 2, 93.031 12.703 0.000*** 
Log IL-13 2, 90.603 2.297 0.106 
Chemokines    
Log CXCL-8 (IL-8) 2, 90.776 7.209 0.001** 
Log CXCL-10 (IP-10) 2, 91.089 6.204 0.003** 
CCL-2 (MCP-1) 2, 87.078 6.388 0.003** 
Log CCL-3 (MIP-1α) 2, 89.87 3.346 0.040* 
Log CCL-4 (MIP-1β) 2, 91.223 1.721 0.185 
Log CCL-5 (RANTES) 2, 86.973 0.872 0.422 
CCL-11 (Eotaxin) 2, 89.083 1.869 0.160 
Acute phase proteins     
Log(CRP) 2, 88.177 17.916 0.000*** 
Legend: **p <0.01; *** p <0.001. 
 
2.4.5  Relationship between cytokines at each time point during detoxification 
Correlations between cytokines at each time point are graphically displayed in 
Figures 2.4a – c as ‘heatmaps’.  Of interest is that the cytokines and 
chemokines that changed during detoxification are not correlated with many 
other cytokines or chemokines, that is, they did not appear to function as a 
network at all time points.  IL-6 is strongly inversely associated with CCL-5 at 
all time points but is correlated with Th-2 related cytokines at the mid and late 
detoxification time points only.  IL-10 is correlated with the T cell regulatory 
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cytokine IL-2R throughout detoxification, but is associated with the 
chemokines CCL-2, 3, and 4 only at the mid and late time points.  IL-12 is 
associated with the anti-inflammatory IL-1RA and the chemokines CCL-5 and 
CXCL-10 at all time points.  CCL-2 is associated with CCL-11 at the early and 
late time points, but not the mid time point, and with IL-10 during mid and late 
detoxification.  CXCL-8 is inversely related to CCL-5 throughout detoxification.  
In contrast, the cytokines and chemokines that did not change significantly 
during detoxification are highly correlated with many other cytokines  and 
chemokines, and the pattern of correlations is similar at different time points.  
For example, IL-2R, is positively correlated with six to eight cytokines during 
detoxification.   
2.4.6  Changes in clinical symptoms during detoxification 
Mean CIWA-Ar score during early detoxification was 10 (with a standard 
deviation of 7), corresponding to severity meriting pharmacological treatment.  
At mid-detoxification it reduced significantly in severity (for log(CIWA): p = 
0.001), to 6 (± 4), and remained 6 (± 5) during late detoxification (post-hoc: 
early>middle: p = 0.032; early>late: p = 0.001).  Depression also reduced 
significantly during detoxification (log(Depression): p = 0.04) from 42 (± 31), a 
measurement approaching ‘quite depressed’, to 34 (± 31) then to 30 (± 30) 
corresponding to ‘a little depressed’.  Craving decreased significantly from a 
mean of 37 (± 34) early in detoxification, to 25 (± 29) mid detoxification, then 
17 (± 25) in late detoxification (for log(Craving) p = 0.002).   
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Figure 2.4a: Heatmap of bivariate correlations between cytokines in 
early detoxification 
 
Figure 2.4b: Heatmap of bivariate correlations between cytokines in mid 
detoxification 
 
Figure 2.4c: Heatmap of bivariate correlations between cytokines in late 
detoxification 
 
Legend: The heatmaps show positive (red) and negative correlations (blue) where the 
intensity of the colour is related to the value of Pearson’s r.  A key is displayed next to Figure 
4a.  * denotes p < 0.05.  ** denotes p < 0.01. 
Colour key: 
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Figure 2.5: Withdrawal symptoms, depression and craving decrease 
during detoxification 
 
Legend: Stars refer to Bonferroni-corrected significant post-hoc pair-wise comparisons: * p 
<0.05; ** p < 0.01 
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2.4.5  Relationship between cytokines and clinical symptoms during alcohol 
detoxification 
There was a significant positive association of IL-6 concentrations with 
withdrawal severity across all time points (log(IL-6) F(1, 92.323) 7.060, p = 
0.009).  When recent alcohol use, previous detoxifications and time point 
were controlled for, the positive association remained significant (F (1, 
91.626) = 4.851, p = 0.030).  The effect size was 0.125 (95% confidence 
intervals 0.012 – 0.237) implying a 12.5% change in withdrawal severity for 
each percentage change in IL-6. 
 
There was also a significant positive association between IL-6 concentrations 
and depression (effect size 0.356, 95% C.I. 0.125 - 0.587, F (1, 98.318) 
3.063, p = 0.003).  This association persisted when antidepressant treatment 
and withdrawal severity were taken into account, with an adjusted effect size 
of 0.245 (95% C.I. 0.014 – 0.476, F (1, 104.581) 4.435, p = 0.038).  
Withdrawal severity was also significantly positively associated with 
depression (effect size 0.582, 95% C.I. 0.271 – 0.893, F (1. 110,75) 13.756, p 
= 0.000), but IL-2R and antidepressant treatment were not (p > 0.05).!
 
2.4.6  Relationship between cytokines and chemokines, and cognition 
Performance on cognitive tasks in this population fell below reported 
population norms, though a statistical comparison was not possible given that 
we did not have a control group.  The mean score for phonemic verbal fluency 
was 8.33 ± 3.45, below the age-related norm of 40 ± 10.7 – adjusted for 0-8 
years of education (Tombaugh et al., 1999).  Similarly, the mean number of 
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minutes to complete Trail Making Task A was 59 ± 37 seconds and Task B 
was 155 ± 90 seconds while reported means and ranges for a similar normal 
age group are 31 seconds (range 18-56 seconds) and 64 seconds (range 32 
– 92 seconds) respectively (Tombaugh, 2004).  Mean performance on 
immediate recall in the Weschler Memory Scale paragraph test was 6 ±2.3 
and on delayed recall was 4 ± 2.7.  Published age-matched norms are 13 ±
3.3 and 9 ± 3.9 respectively (Abikoff et al., 1987).    
 
CCL-2 was found to be associated positively with ‘cognitive function’, a linear 
composite of performance on the following tests: Trails A score, Trails B 
score, FAS score, Weschler Memory Scale paragraph score (immediate) and 
Weschler Memory Scale paragraph (delayed) (Pillai’s trace; V = 0.331 F(5, 
37) = 3.655; p = 0.009).  The association persisted when age and recent 
alcohol dose (alcohol units/day) had been taken into account (Pillai’s trace; V 
= 0.388; F (4, 35) = 5.536; p = 0.001).  Post-hoc univariate ANOVAs showed 
that CCL-2 concentration was positively associated with performance on 
Trails A (F(1, 38) = 14.839; p = 0.000), Trails B (F(1, 38) = 9.522; p = 0.004) 
and the delayed Weschler Memory Scale (F (1, 38) = 6.935; p = 0.012).  Post-
hoc contrasts showed that high CCL-2 was associated with better cognitive 
function in the following tasks (p<0.05): completing the Trail Making Tasks 
(log(Trails A time)) was 0.479 (0.177 – 0.852) longer in the low CCL-2 group 
than the high CCL-2 group; for log(Trails B time) the difference was 
0.515(0.177 – 0.852).  Similarly, patients remembered 1.725 (95% C.I. 0.399 - 
3.05) fewer phrases in the delayed Weschler Memory Task in the low CCL-2 
group relative to the high CCL-2 group.  IL-6 and CXCL-8 concentrations were 
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not associated with cognitive function.  Recent alcohol use was associated 
with poorer cognitive function in the multivariate analysis (V = 0.282; F(4, 38) 
= 3.434; p = 0.018).   Post-hoc univariate analyses indicated that recent 
alcohol use had a significant effect on delayed verbal memory (F (1, 38) = 
10.134; p = 0.003). There was no overall effect of age on cognitive function in 
the multivariate analysis. 
 
2.5  Discussion 
This study is the first to measure twenty-five circulating cytokines and 
chemokines at three time points during alcohol detoxification in a large 
naturalistic cohort of alcohol-dependent in-patients, generating a highly 
comprehensive profile of cytokine expression.  The findings from this cohort 
replicated the findings from studies measuring only a handful of cytokines: 
that the concentrations of IL-6 and IL-10 decrease significantly during 
detoxification.  I have demonstrated an association between IL-6 and IL-10 
and hepatic oxidative stress, suggesting a hepatic origin for these cytokines.  I 
have demonstrated for the first time that the Th-1 cytokine IL-12 and the 
chemokine CXCL-10 increase during detoxification, while the inflammatory 
chemokines CXCL-8 and CCL-2 decrease.  While cytokines and chemokines 
which did not change were highly positively correlated with one another, those 
which did change were correlated with few other cytokines and chemokines.  
Of note, IL-6 was related to both withdrawal severity and depression during 
detoxification and this association persisted even when other factors that 
would influence these symptoms, for example withdrawal severity in the case 
of depression, were accounted for.  I found an association between the 
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inflammatory chemokine, CCL-2, and better cognitive function, though the 
difference in cognitive task performance between those participants with high 
CCL-2 and those with low CCL-2 was small.   
 
The characteristics of the sample were broadly representative of patients in 
UK alcohol inpatient treatment services.  Their mean age was 47, reflecting a 
typical age when individuals come into contact with health services for 
treatment of alcohol dependence (Pilling et al., 2011). There were some 
differences with the sample having a higher proportion of women than 
epidemiological studies of alcohol dependence (Drummond, 2005) (Proudfoot 
et al., 2002), a higher median number of detoxifications than in previous 
studies of cognition in alcohol dependence (Duka et al., 2003) and the 
majority (54%) had a history of withdrawal seizures.  This likely reflects the 
clinical context of the study since in-patient detoxification is indicated for those 
with complications of withdrawal and end-organ damage. This explains the 
high prevalence of seizures, greater number of detoxifications – which make 
complications more likely – and proportion of women, who are more 
vulnerable to physical complications of alcohol dependence (Nolen-
Hoeksema, 2004).  The median score for Caine criteria of 1 suggested that 
most patients had missed meals but did not have clinical evidence of 
Wernicke-Korsakoff syndrome or other neurological complications of 
malnutrition.  Co-morbid nicotine dependence and use of other illicit drugs 
were present in a greater proportion of participants than in the general 
population, but reflects rates of co-morbidity in substance misuse services.  
The physical co-morbidity reflected physical complications of chronic alcohol, 
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cigarette or drug intake.  Although liver enzymes were increased, albumin and 
bilirubin were within normal limits, suggesting preserved synthetic and 
metabolic function.  White cell counts were within normal limits suggesting no 
sepsis.   
 
The decrease in IL-6 and IL-10 during detoxification is consistent with 
previous reports, which found differences in these cytokines between the day 
of admission for detoxification and a week later (Gonzalez-Quintela et al., 
2000) (Leclercq et al., 2012).  This study refines and extends earlier reports 
by establishing that IL-10 decreases early, and IL-6 continues to decrease 
progressively.  Other cytokines TNF-α and IL-1β were not detectable in our 
sample; such difficulty in detection in peripheral serum has previously been 
described (Maes, 2011).  In our sample, IL-1RA, used as a surrogate marker 
for IL-1β, did not change during detoxification.  In addition to replicating 
previous findings that many cytokines decrease during detoxification, I have 
demonstrated for the first time that both the T cell regulatory cytokine IL-
12(p40/p35), and chemokines change during detoxification.  This is in contrast 
with a previous report, which found no change in CXCL-8 and IL-12 during 
detoxification (Gonzalez-Quintela et al., 2000).  In contrast, CXCL-8 
decreased and IL-12 increased significantly in our sample.  The discrepancy 
may relate to the fact that in the previous study the second measurement took 
place over a wider range – from day 2 to day 15 – that may have obscured 
changes.  
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Chemokines other than CXCL-8 have not been studied previously in 
detoxification.  While CCL-2 decreased, suggesting that its function in this 
context related to that of IL-6 and CXCL-8, CXCL-10 increased.  CXCL-10 
was first characterised as an IFN-γ induced chemokine, and has chemotactic 
effect on Th-1 T cells (Luster et al., 1985) (Eriksson et al., 2013).  Taken 
together with the parallel increase in IL-12, this change indicates an increase 
in Th-1 function.  In total, decrease in macrophage-associated cytokines, early 
suppression of Th-1 cytokines and no change in Th-2 cytokines are broadly 
consistent with the changes that would be expected in the context of 
increased sympathetic activity at the early, but not later time points.  A 
possible implication is that this signature relates to alcohol withdrawal itself, 
as sympathetic hyperactivity is a feature of early withdrawal (reviewed in 
(Kahkonen, 2004)). 
 
Of interest is that the cytokines that decreased during detoxification – IL-6, IL-
10, CXCL-8 and CCL-2 – were not consistently strongly correlated with one 
another during detoxification.  This suggests that they do not operate as part 
of a consistent cytokine network under these circumstances.  It is probable 
that mediators that I did not measure, for example noradrenaline, and those 
that I was unable to detect, such as TNF-α, influenced their expression.  This 
requires further investigation.  IL-12 and CXCL-10 were positively correlated 
throughout detoxification suggesting that they form a single cytokine network 
that would be consistent with the Th-1 related function for both mediators.  
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This is the first study to report a relationship between IL-6 and withdrawal 
symptoms during alcohol detoxification.  The finding remained significant 
when variance related to alcohol dose before detoxification, previous 
detoxifications and time point in detoxification was taken into account.  The 
relationship between alcohol withdrawal and circulating cytokines is likely to 
be complex, because alcohol affects all components of the so-called ‘gut-liver-
brain axis’ (Wang et al., 2010) (see Figure 2.6).  Chronic alcohol consumption 
is associated with small bowel bacterial overgrowth and increased bacterial 
translocation with increased lipopolysaccharide (LPS) in the portal vein 
(Leclercq et al., 2012).  LPS stimulates activation of Kupffer cells, hepatic 
macrophages, which produce cytokines such as IL-1β, TNF-α and IL-6, and 
chemokines such as CCL-2 and CXCL-10 (Wang et al., 2010).  IL-1β, TNF-a 
and IL-6 access the brain via vagal afferents and via the stimulation of 
inflammatory signalling in cerebral endothelial cells, which in turn stimulate 
perivascular macrophages (Dantzer et al., 2008). 
 
Even though circulating cytokines may not have come from the brain directly, 
the brain influences circulating cytokine production by the liver and spleen.  
Alcohol withdrawal is associated with increased cerebral expression of IL-1β, 
TNF-α and CCL-2 (Zhao et al., 2013) (Qin et al., 2008) with similar, though 
shorter-lived, cytokine and chemokine expression in the liver (Qin et al., 
2008).  Central nervous system pro-inflammatory cytokine expression is 
reported to give rise to Kupffer cell activation, macrophage recruitment and 
expression of CCL-2 and CXCL-10 (Campbell et al., 2005), (Campbell et al., 
2008).   
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Sympathetic hyperactivity is a hallmark of early alcohol withdrawal (reviewed 
in (Glue and Nutt, 1990) and (Kahkonen, 2004)).  The effect of sympathetic 
activity on cytokine expression is complex, as adrenergic receptors on 
immune cells differ according to subset; but suppression of Th-1 associated 
cytokine expression such as IL-12 and increase in expression of IL-6, IL-10 
and CXCL-8 has been described (reviewed in (Elenkov et al., 2000)).  
Although hepatic production of cytokines may also relate to increased 
bacterial translocation early in detoxification (Leclercq et al., 2012), the 
relationship between IL-6 and withdrawal symptoms across all time points 
suggest that the brain may be the predominating driver of hepatic cytokine 
and chemokine expression in this instance.  In particular, increased bowel 
permeability and increased systemic LPS is not present at later time points in 
detoxification (Leclercq et al., 2012). 
 
This study demonstrates for the first time that IL-6 concentrations are 
associated with depression in an alcohol-dependent population throughout 
detoxification.  The association remained when withdrawal symptom severity 
was accounted for.  This is consistent with studies in depressed populations 
(Dowlati et al., 2010) suggesting that IL-6 plays a key role in depression.  No 
association between IL-10 and depression was found in our sample, although 
an inverse association between IL-10 in late detoxification, but not in early 
detoxification, has been reported previously (Leclercq et al., 2012).  However, 
Leclercq and colleagues performed bivariate correlations at each separate 
time point and did not take withdrawal severity into account.  Unlike studies in 
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depression, the current study found no association between IL-2R and 
depression suggesting that changes in adaptive immunity in depressed 
populations (Maes, 2011) are different from those with co-morbid alcohol 
dependence, at least during detoxification. 
 
Figure 2.6: Relationship between alcohol dependence and circulating 
cytokines 
!
Legend: This figure illustrates the relationships between peripheral inflammation and cerebral 
microglial activation and cytokine expression.  Both peripheral inflammatory drive from portal 
LPS and cerebral stimulation of hepatic Kupffer cell activation and cytokine expression are 
likely to contribute to increased circulating cytokines in the setting of alcohol detoxification. 
iNOS = inducible nitric oxide synthetase; LPS = lipopolysaccharide; SNS = sympathetic 
nervous system; TLR4 = Toll-like receptor 4. 
 
Finally, I found an association between only one of the cytokines and 
chemokines, CCL-2, hypothesised to be associated with cognitive function.  
Performance on tasks of verbal memory and frontal lobe function was not as 
proficient at the end of detoxification compared with published population 
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norms (Abikoff, et al. 1987) (Tombaugh, 1999) (Tombaugh, 2004).  It was not 
possible to compare their performance with healthy controls directly as this 
study lacked a control group.  Further, the differences were small and of 
probable limited clinical relevance.  There are previous reports of increased 
peripheral CCL-2 in mild cognitive impairment (MCI) compared to healthy 
control participants (Galimberti et al., 2006), (Westin et al., 2012).  In the 
context of MCI, higher CSF CCL-2 levels at baseline did not relate to cognitive 
performance based on the Mini-Mental State Examination at baseline, but 
were associated with a greater cognitive deterioration over the next five years 
(Westin et al., 2012).  The disparity between these findings and mine may 
relate to differences in cognitive tests used – for example the Mini-Mental 
State Examination does not emphasise frontal lobe function – or differences in 
disease processes. 
 
Previously, increased CCL-2 expression has been described in post-mortem 
brain samples from alcohol-dependent patients (He and Crews, 2008).  CCL-2 
is a chemokine, which is produced by microglia and perivascular 
macrophages in the brain under conditions of chronic cerebral inflammation, 
such as experimental autoimmune encephalitis, attracting circulating 
monocytes to the brain (reviewed in (Ransohoff, 2009)).  Increased CCL-2 
expression, both in liver and brain, has also been noted in conditions of 
chronic hepatic inflammation such as primary bile duct ligation, and has been 
associated with microglial activation in this context (D'Mello et al., 2013).  
Although not an expected association, my finding is support by pre-clinical 
literature suggesting that increase in CCL-2 may be adaptive: CCL-2 or CCR-
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2 knock-out mice exhibit lower alcohol intake in a free-choice alcohol 
administration paradigm and longer loss of righting reflex during alcohol 
dosing at a given concentration relative to C57B/6 wild-type mice, which could 
be consistent with lower tolerance to the intoxicating effects of alcohol 
(Blednov et al., 2005).  
 
Factors related to cognitive impairment in alcohol dependence, such as 
history of head injury, previous detoxifications, and thiamine deficiency, were 
not accounted for in the multivariate analysis.  Very few patients had a history 
of clinically significant head injury, so this was excluded from analysis.  
Variation in Caine criteria and previous detoxifications were omitted because 
the sample size prohibited inclusion of many independent variables, and 
cytokines were prioritised as the focus of the study.  Further work in a larger 
sample should be done to explore the relationship between CCL-2 and other 
clinical variables related to cognitive function in this population. 
2.5.1  Limitations 
Many cytokines were not detectable in a majority of sample, which could 
reflect insufficient sensitivity of the Luminex technique compared to ELISA.  
Previous studies (Gonzalez-Quintela et al., 2000), (Leclercq et al., 2012) that 
have reported increased TNF-α in early abstinence, and TNF-α and IL-1β 
stimulate IL-6 production, so a concomitant increase would be expected.   
Further investigation of the dynamics of cytokines related to innate and 
adaptive immunity elucidated by this study is warranted, using more sensitive 
methods.   
 
! 92 
This study lacked a control group, which means that it is unclear whether 
cytokines were in the normal range in this sample.  After consideration, a 
control group was not recruited because the focus of the study was the 
longitudinal course of cytokines during alcohol detoxification, and whether 
cytokine concentrations were predictive of clinical symptoms within this 
patient population.  Cytokines in healthy populations are also subject to 
fluctuations, which may render a single cross-sectional measure 
uninformative. In addition, given the aim of determining the impact of alcohol 
detoxification on cytokine levels, a number of ‘control’ groups might have 
been required e.g. those with hepatic disease, other physical diseases, or 
depression. Recruiting such a range of populations was outside the remit of 
the study, but should be collated in order to characterise causes and 
consequences of cytokines and chemokines in alcohol detoxification.  
 
2.6  Conclusion 
In summary, I have demonstrated that IL-6, IL-10, CXCL-8, and CCL-2 
decreased significantly during alcohol detoxification, while IL-12, CXCL-10 
and CRP increased.  IL-6 was related to withdrawal severity and depression.  
CCL-2 was related to improved cognitive function, though the differences 
were small and of uncertain clinical significance.  Circulating cytokines are 
likely to be of largely hepatic origin.  The time course of the cytokines and 
chemokines, and relationship to clinical symptoms of withdrawal across time 
points, suggest that they represent a peripheral signature of the neurobiology 
of alcohol withdrawal.  Sympathetic hyperactivity during early withdrawal is 
likely to contribute to the increase in cytokines associated with innate 
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immunity – IL-6, IL-10 – relative to later time points together with the 
suppression of Th-1 related cytokines.  Cerebral cytokine expression may 
influence peripheral expression of chemokines such as CCL-2.  This further 
supports a view that the peripheral cytokines during alcohol detoxification 
reflect cerebral processes during alcohol withdrawal and associated with 
depression and cognitive impairment.  
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CHAPTER 3 
THE HYPOTHALAMO-PITUITARY ADRENAL AXIS DURING DETOXIFICATION 
AND ITS RELATIONSHIP TO CYTOKINES 
 
3.1  Introduction  
The previous chapter described changes in cytokines during detoxification 
and their relationship to clinical features.  As pro-inflammatory cytokines 
stimulate the hypothalamo-pituitary-adrenal (HPA) axis, and the HPA axis 
provides a major negative feedback mechanism for the immune system (Rhen 
and Cidlowski, 2005), this chapter describes investigations performed to 
characterise the relationship between cytokines and the function of the HPA 
axis.  In the Introduction, I outlined evidence that morning cortisol was 
elevated in alcohol-dependent patients (ADPs) during intoxication, and even 
more during withdrawal.  
 
Stimulation tests using pharmacological challenges, have also provided 
evidence for HPA axis dysfunction in ADPs.  Most commonly, a diminished 
response to stimulation has been reported.  Physiological challenges, such as 
the Cortisol Awakening Response (CAR), the rise in cortisol occurring in the 
first 30 minutes of waking, have shown a similarly blunted response in early 
abstinence.  The advantages of the CAR is that it represents a response to a 
physiological stimulus rather than pharmacological stimuli at supra-
physiological levels, and can be collected by patients in their home or in their 
room, if in-patients, so interferes minimally with their ward routine. 
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Pro-inflammatory cytokines such as IL-1, TNF-α and IL-6 stimulate the HPA 
axis, resulting in an acute elevation in cortisol.  When cortisol is elevated 
acutely, pro-inflammatory cytokines such as IL-6, and Th-1 cytokines such as 
IL-12 are suppressed, while anti-inflammatory cytokines such as IL-10 are 
not.  Under chronic conditions of elevated cortisol, glucocorticoid resistance 
may develop and this relationship may be altered.  In Chapter 2, I reported 
elevations in both the pro-inflammatory cytokine IL-6 and the anti-
inflammatory cytokine IL-10 in early detoxification relative to late 
detoxification.  The aim of this investigation was to characterise the 
relationship between morning cortisol, and Cortisol Awakening Response – as 
a measure of HPA axis responsiveness to challenge, with cytokine levels and 
changes during alcohol detoxification. 
 
3.2  Hypotheses 
Based on previous evidence and my data regarding cytokines during 
detoxification, I hypothesised that: 
1. Serum cortisol would be elevated during early detoxification relative to late 
detoxification. 
2. There would be a relationship between serum cortisol and the cytokines 
IL-6, IL-12, and IL-10. 
3. Cortisol Awakening Response would show a relationship to IL-6 and IL-10. 
The relationship between HPA axis and cytokines depends on whether the 
inflammatory stimulation of the HPA axis predominates, or whether the 
immunosuppressive drive of the HPA axis is over-riding.  For this reason, I 
was unable to be more specific about the expected nature of the relationship.  
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If the balance in the HPA-cytokine relationship was in favour of cytokines I 
expected there to be a positive correlation between IL-6 and cortisol with no 
relationship with IL-10 and IL-12.  If cortisol predominated, I expected an 
inverse correlation with IL-6 and IL-12, and a positive correlation with IL-10. 
  
3.3  Methods 
3.3.1  Sample collection 
Participants were asked to collect Cortisol Awakening Response (CAR) 
samples three times during the study – early, middle and late detoxification.  
They were given four sample collection kits with written instructions to obtain 
samples using specially prepared cotton wool swabs (Sarstedt, North 
Carolina) at four time points: immediately upon waking, and 15, 30 and 45 
minutes later.  They were instructed not to smoke or brush their teeth during 
collection and not to eat or drink 10 minutes before sample collection.  
Samples were stored in the ward sample fridge until the arrival of the research 
team, then centrifuged and the saliva stored at -20°C until analysis.  The 
research team confirmed verbally with the patient that they had collected the 
samples as directed.   
 
Serum for morning cortisol and cortisol binding globulin was collected as part 
of the sample for cytokine analysis, between 8am and 10am.  Storage and 
processing were as described in Chapter 2.   
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3.3.2  Sample analysis 
Saliva samples were analysed by Michael Newson and myself, using 
commercially available ELISA kits (DRG, Germany).  The detectable range 
was 0.537ng/ml – 80ng/ml.  The intra-assay and inter-assay reproducibility 
were between 1.47% – 4.52% and 5.82% – 7.47% respectively.  Increase in 
cortisol was calculated by subtracting the initial salivary cortisol value from the 
highest value among the other four values.  I chose this approach, rather than 
calculating an area under the curve, or using the 30 minute value specifically, 
which are the two most commonly reported methods for analysing the CAR, 
for two reasons.  First, it allowed for slight inaccuracies in timing of sample 
collection (Griefahn and Robens, 2011).  Second, in some patients, sample 
volumes from specific time points were too small to be analysed so the 
complete set of four was not available.  Serum samples were analysed for 
cortisol using commercial chemiluminescent microparticle immunoassay kits 
in the local hospital laboratory.  The lower limit of detection was 1ug/dl and 
the assay had a coefficient of variation of <10%.  The normal reference range 
for cortisol used by the hospital laboratory was 160-550nM.   
 
3.3.3  Statistical analysis 
The Free Cortisol Index, a proxy measure of unbound – and therefore 
biologically available – cortisol, was calculated by dividing cortisol 
concentration by Cortisol Binding Globulin concentration (le Roux et al., 
2002).  It is particularly of use in conditions where CBG changes, such as the 
decrease seen in acute sepsis.  The distribution of cortisol, Cortisol Binding 
Globulin and Free Cortisol Index was inspected graphically to ascertain 
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whether they derived from a parametric distribution.  Data points (in this case, 
one value) that exceeded three standard deviations were excluded from the 
analysis.  Mixed models were applied in SPSS 20.0 (IBM) to ascertain the 
effect of time point on cortisol and Free Cortisol Index.  Parametric 
correlations for each time point were undertaken to examine the relationship 
between cytokines (log-transformed) and cortisol, as the HPA axis is 
stimulated by pro-inflammatory cytokines and in turn, provides negative 
feedback to the innate immune system, suppressing their production (see 
Figure 1.1 on page 37 for a schematic diagram of these relationships).  These 
were not corrected for multiple comparisons owing the risk of Type II error, but 
confidence intervals (bootstrapped using SPSS 20.0, IBM) have been 
supplied as suggested by Field (Field, 2012).   
 
3.4  Results 
The demographic characteristics of the sample were as reported in Chapter 2.  
Those samples that had been collected incorrectly, for example during the 
night, over a twenty-four hour period, or using a different body fluid, were not 
processed further.  Those samples where inadequate saliva had been 
produced for the first collection point were excluded from analysis.  Few 
patients were able to complete Cortisol Awakening Response sample 
collection, despite written instructions and prompting from ward staff.  Eleven 
completed all three collections, while four more completed early and late 
collections, four early and middle collections, and four middle and late 
collections.  Those who completed samples did not differ significantly from the 
main group in terms of mean CIWA-Ar score, mean depression or craving 
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rating, serum cortisol or Free Cortisol Index, or IL-6, IL-10, IL-12, CCL-2, 
CCL-11 or CXCL-8 concentrations at any time point, or on performance on 
any cognitive test (p >0.05).  Serum specimens were available from 51 
patients. 
 
3.4.1  Profile of serum cortisol 
There was a significant effect of time point on total serum cortisol (F (2, 46) = 
5.249; p = 0.009), shown in Figure 3.1, though no significant effect of time 
point on the Free Cortisol Index (F (2, 40) = 1.393; p = 0.260).  The mean 
cortisol concentration for each time point fell within the clinical laboratory 
normal range of between 160nM and 550nM (early: 374.9 ± 147.21nM; mid-
detoxification: 328.3 ± 133.93nM; late: 309.3 ± 96.48nM).  However there was 
a minority of patients whose cortisol exceeded the normal range.  This 
proportion was 15% in early detoxification, 4% in mid detoxification and 0% in 
late detoxification (see Figure 3.2).  Of note, a smaller proportion of patients 
had morning cortisol levels below normal range: 2% of participants had a 
lower than normal morning cortisol during early detoxification, 9% during mid 
detoxification and 5% during late detoxification.  The relative proportions of 
normal, abnormally high and abnormally low serum cortisol, were significantly 
different between time points (chi-square (24.52, 4) p <0.0001).   
 
There was no statistically significant difference between cortisol 
concentrations in those patients who had withdrawal scores above the 
treatment threshold (>10) and those with withdrawal scores below the 
treatment threshold (early, middle and late: p>0.20); neither was there a 
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correlation between withdrawal severity and cortisol (early, middle and late: 
p>0.40).  Cortisol Binding Globulin concentrations did not change during 
detoxification (p>0.05): early: 54.6 ± 9.32; middle: 53.2 ± 9.37; late: 53.2 ± 
9.23 mg/l.  Free Cortisol Index also did not change significantly during 
detoxification (p>0.05): early: 6.8 ± 2.52nmol/mg; middle: 6.2 ± 2.68nmol/mg; 
late: 6.3 ± 2.88nmol/mg.    
Figure 3.1: Time course of serum cortisol during alcohol detoxification 
 
Legend: ** refers to results of Bonferroni corrected pair-wise comparisons showing a 
significant difference between early and late detoxification cortisol (p = 0.007).   
Figure 3.2: Proportion of samples that fell within and outside the normal 
range 
 
Legend: The proportion of samples that fell within the normal range increased significantly 
during detoxification (p <0.001). 
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3.4.2  The cortisol awakening response 
Samples from each time point was considered separately as they were 
slightly different samples and the proportion of missing values was too great 
to make imputation or use of mixed methods feasible alternatives.  The 
Cortisol Awakening Response showed a mean increase in cortisol of 31% of 
the initial value (range -31% – 178%) during early detoxification, 42% (range -
17% – 161%) during mid and 31% (range - 39% – 80%) during late 
detoxification. However a normal or abnormal morning serum cortisol did not 
predict whether a patient’s Cortisol Awakening Response was in the normal 
range. 
 
3.4.3  Relationship between cortisol and cytokines 
There were no relationships between serum cortisol and the cytokines IL-6, 
IL-10 and IL-12.  There was a statistically significant moderate positive 
correlation between IL-6 and the Free Cortisol Index at the middle time point 
only, shown in Figure 3.3a (r = 0.328; 95% C.I.: 0.089 – 0.534; p = 0.03).  
There was also a statistically significant moderate positive correlation 
between the increase in cortisol during the Cortisol Awakening Response and 
IL-6 at the middle time point, shown in Figure 3.3b (r = 0.462; 95% C.I.: 0.129 
– 0.685; p = 0.03).  Neither the Free Cortisol Index nor the mean Cortisol 
Awakening Response increase were correlated with IL-10 or IL-12, at any 
time point.   
 
Figure 3.3a: Relationship between Free Cortisol Index and IL-6 during 
mid-detoxification 
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Figure 3.3b: Relationship between Cortisol Awakening Response and IL-
6 during mid-detoxification 
 
 
 
3.5  Discussion 
I found that morning serum cortisol decreased significantly during alcohol 
detoxification, though there was no significant change in the Free Cortisol 
Index.  There was a substantial minority of patients with abnormally high and 
abnormally low morning cortisol levels, and this proportion declined too during 
detoxification.   In those patients who were able to provide appropriate 
samples for the Cortisol Awakening Response, the mean response was within 
the normal population range.  I was unable to compare proportions of patients 
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with normal or abnormal Cortisol Awakening Response over the course of 
detoxification because of the high numbers of missing values.  Both the Free 
Cortisol Index and Cortisol Awakening Response were positively correlated 
with IL-6 during mid-detoxification.  No other relationships between HPA 
measures and cytokines were found.  
 
My study has replicated previous reports of a decrease in cortisol during 
detoxification (Adinoff et al., 1991) (Kruger et al., 2006) (Keedwell et al., 2001) 
in a larger cohort of UK alcohol-dependent patients treated with 
benzodiazepines.  In addition, I have found that some participants had both 
abnormally high and abnormally low cortisol measures, but that these were 
likely to normalise over time.  Of note is that while all means fell within the 
clinical normal range as defined by the local hospital laboratory, the mean 
value in late detoxification was above 300nM, which corresponds to a level 
considered high in the psychiatric literature, for example, in depression 
(Christensen et al., 1989).   
 
Even though the first measurement of cortisol in this study occurred after 
participants had received medication for withdrawal symptoms, early 
detoxification cortisol was elevated relative to late detoxification.  This, 
together with the lack of relationship between cortisol and withdrawal severity, 
supplies additional support for the theory that benzodiazepines do not modify 
the HPA axis response to detoxification, despite their effect on withdrawal 
symptoms (Keedwell et al., 2001).  This is in contrast to gamma-
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hydroxybutyrate, which was associated with a decrease in cortisol relative to 
placebo when used to treat alcohol withdrawal (Nava et al., 2007). 
 
Although there was a decrease in serum cortisol there was no change in the 
Free Cortisol Index.  This implies that the changes seen in serum cortisol do 
not change significantly the amount of biologically available cortisol.  However 
given that there were no changes in Cortisol Binding Globulin during 
detoxification, it is possible that the variability of Free Cortisol Index 
contributed to lack of association.  Thus a study with a larger sample is 
required to appropriately investigate their inter-relationships. 
 
The mean Cortisol Awakening Response was within normal limits (30% – 
75%) at all time points.  This is in contrast to reports of hypo-responsiveness 
to psychological or pharmacological challenge in other alcohol-dependent 
populations (Sinha et al., 2011) (Lovallo et al., 2000) (Errico et al., 2002) 
(Junghanns et al., 2005) (Fox et al., 2012) (Merry and Marks, 1972) (Coiro 
and Vescovi, 1999) (Adinoff et al., 2005) (Bailly et al., 1989).  The single 
previous study of the Cortisol Awakening Response (Junghanns et al., 2007) 
which reported a blunted awakening response in ADPs in early abstinence, 
did not define this in terms of the normal range; rather they were compared to 
an alcohol-dependent group with a mean abstinence duration of several 
months.  Stressful events are known to affect the Cortisol Awakening 
Response and are associated with a greater increase (Wust et al., 2000a) so 
it could be that the acute physiological stress of withdrawal and psychological 
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stress of admission to hospital influenced our findings; in other studies 
detoxification had been completed prior to testing.   
 
There was a significant positive correlation between IL-6 and both the Free 
Cortisol Index, and the increase in cortisol during the Cortisol Awakening 
Response during mid-detoxification.  This is consistent with previous pre-
clinical reports that IL-6 stimulates the HPA axis (Bethin et al., 2000).  It 
suggests that while the HPA axis in ADPs has been reported to show blunted 
responses to physiological stressors e.g. CRH or waking, it may still be 
responsive to an inflammatory stress such as IL-6.  Importantly, this 
relationship is seen only transiently during alcohol detoxification, which 
suggests that at early and late time points, other factors are more important in 
determining cortisol concentrations and the Cortisol Awakening Response. 
 
3.5.1  Limitations 
Despite the large number of samples, only IL-6 was consistently detectable in 
my samples out of all the pro-inflammatory cytokines reported to stimulate the 
HPA axis.  It may be that other HPA axis markers and cytokines are more 
sensitive to changes in endocrine-immune relationships: for example, TNF-α 
and ACTH were negatively correlated following the dexamethasone-CRH 
stimulation test when no relationships between cortisol and cytokines were 
found (Schuld et al., 2003).  Studies using more sensitive techniques to detect 
TNF-α and measurement of ACTH would be of interest to investigate 
relationships further.  The major limitation of the Cortisol Awakening 
Response is the difficulty in obtaining samples – only 36% of our participants 
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were able to provide at least two adequate sample sets despite verbal and 
written instructions and prompting by ward staff.  In a healthy epidemiological 
cohort the proportion of adequate Cortisol Awakening Response samples 
returned was around 45%, suggesting that this is a problem inherent to the 
method (Carnegie et al., 2014).  The Cortisol Awakening Response is 
susceptible to timing errors, which is likely to have affected our results despite 
all the measures taken to ensure timely collection.  It is also reported that 25% 
of healthy people do not show a Cortisol Awakening Response (Wust et al., 
2000b) (Fries et al., 2009), so a proportion of participants may ordinarily show 
no response.  Further investigation of the Cortisol Awakening Response in 
later abstinence may prove informative in this regard.  Lastly, I did not have a 
control group.  Given that cortisol levels in ADPs have been reported to be 
higher than control groups sampled in the same study, but still within clinical 
laboratory limits, a control group may have provided additional information.  
 
In summary, I found that mean morning cortisol levels were within a clinical 
laboratory normal range throughout detoxification, but one that is considered 
high in the psychiatric literature.  Morning serum cortisol during early 
detoxification was raised relative to late detoxification, which replicates 
previous findings.  However neither Cortisol Binding Globulin nor the Free 
Cortisol Index changed.  Similarly, the mean cortisol awakening response was 
within the normal range at each time point in detoxification.  I found a 
significant, though moderate, association between IL-6 and both morning 
serum cortisol and increase in cortisol during the Cortisol Awakening 
Response, both at the mid-detoxification point.  This suggests that the HPA 
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axis is sensitive to inflammatory stimulation during mid-detoxification.  That 
this association was not present at other points in detoxification suggests that 
other factors are important in variations in both cortisol and cytokines.  Further 
investigations using validated suppression and stimulation tests, where 
researchers have more control over the samples collected, including 
measurement of ACTH and more sensitive methods for measuring pro-
inflammatory cytokines with a greater effect on HPA axis function, such as 
TNF-α, could be pursued to characterise the relationship between the HPA 
and the immune system during alcohol withdrawal in greater detail.  
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CHAPTER 4 
IN VITRO AFFINITY OF BENZODIAZEPINES FOR THE TRANSLOCATOR 
PROTEIN (18KDA) 
 
This chapter describes in vitro experiments conducted in preparation for the 
imaging study to investigate whether clinical doses of benzodiazepines could 
compete with the radioligand for binding to the TSPO.  Given that my imaging 
study was to take place as early in abstinence from alcohol as practically 
possible, participants might be taking prescribed benzodiazepines.  Even if 
prescription had ceased, long-lived active metabolites may still have been 
present.  The TSPO was originally known as the Peripheral Benzodiazepine 
Receptor (see (Papadopoulos et al., 2006)).  Diazepam, one of the most 
commonly prescribed benzodiazepines, has been reported to have an affinity 
for the TSPO of either 27.43 ± 8.92nM (Rao and Butterworth, 1997) or 432nM 
(Doble, 1983) in in vitro assays conducted on human brain tissue at 4°C.  
Concerns about an interaction of benzodiazepines with the TSPO have led to 
the withdrawal of benzodiazepine treatment from participants prior to 
scanning with a TSPO radioligand (Doorduin et al., 2009).   
 
It was therefore important to investigate whether these potential doses of 
diazepam or chlordiazepoxide, benzodiazepines commonly used for alcohol 
detoxification, could compete with the PET tracer for TSPO binding.  The 
affinities of midazolam and lorazepam for the PET tracer for TSPO were also 
investigated.  The former is of interest in TSPO-PET research as it is a short-
acting benzodiazepine potentially useful as a sedative in easily distressed 
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participant populations; and the latter because it is commonly prescribed in 
psychiatric populations that are increasingly investigated using TSPO-PET 
(e.g. (Doorduin et al., 2009)).   
 
Previous estimates of benzodiazepine affinity for the TSPO in human brain 
have been conducted at a low temperature and in Tris-HCl buffer, which does 
not reflect ionic or temperature conditions found in vivo (Rao and Butterworth, 
1997) (Doble, 1983).  Furthermore, the binding site for the novel TSPO PET 
ligand, [11C]PBR28, may differ from that of the earlier ligands [3H]PK11195 
and the benzodiazepine [3H]Ro5-4864 (4-chlorodiazepam), since PBR28 has 
been shown to block only ~80-90% of [3H]PK11195 specific binding (Owen et 
al., 2010).  This may result from PK11195 and PBR28 having overlapping 
binding sites, as is thought to be the case for PK11195 and Ro5-4864 (Scarf 
and Kassiou, 2011).  Thus earlier studies which used [3H]PK11195 and 
[3H]Ro5-4864 (Rao and Butterworth, 1997) (Doble et al., 1987) may not fully 
reflect the interaction between benzodiazepines and [11C]PBR28.  
 
4.1  Aims and hypotheses 
I aimed to characterise the affinity of diazepam, chlordiazepoxide and their 
common metabolites desmethyldiazepam and demoxepam, and oxazepam 
for the PK11195 binding site on the TSPO, in human brain tissue under 
conditions designed to approximate the in vivo cerebral environment.  The 
TSPO affinities of PK11195 and diazepam were investigated to see if they 
were affected by changes in ionic concentrations reflecting the extracellular 
and intracellular environment.  The affinity of midazolam and diazepam for the 
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PBR28 site on the TSPO was measured to establish whether there was a 
significant difference in benzodiazepine affinity for the PK11195 site and the 
PBR28 site.   
 
Of secondary interest was whether the rs6971 polymorphism in the gene 
encoding the TSPO, which dramatically alters binding affinity of most TSPO 
radioligands producing ‘High Affinity Binders’ (HABs) and ‘Low Affinity 
Binders’ (LABs) (Owen et al. 2010), (Owen et al. 2011) (discussed in Chapter 
1, Section 1.6.3), also influences the binding affinity of benzodiazepines. 
 
I hypothesised that: 
1. The affinity of benzodiazepines for the TSPO would be low, such that they 
would not affect TSPO ligand binding at clinical doses. 
2. The affinity of benzodiazepines for the TSPO would not be affected by 
ionic conditions. 
3. There would be no significant difference in affinity for the PK11195 binding 
site and the PBR28 binding site, as PBR28 is able to block 80% of all 
PK11195 binding. 
4. That binder status (HAB or MAB) would have an effect on the affinity of 
benzodiazepines to the TSPO. 
 
4.2  Methods 
4.2.1  Samples 
Post-mortem human brain tissue from donors without an ante-mortem 
neurological diagnosis, previously characterised as High Affinity Binders 
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(HABs) (n=4) or Mixed Affinity Binders (MABs) (n=4) were obtained from the 
Multiple Sclerosis Brain Bank and stored at -80 oC until use (see Table 4.1 for 
details).  Brain sample procedures all met the requirements of the Human 
Tissue Act (2004).   
 
Table 4.1: Demographic details of brain samples 
Donor 
number 
Binding 
status 
Age at death Sex Cause of death 
1 HAB 82 M Not recorded 
2 HAB 92 M Congestive cardiac failure, old age 
3 HAB 84 F Congestive cardiac failure, ischaemic heart 
disease, atrial fibrillation 
4 HAB 69 F Lung cancer 
5 LAB 90 M Old age 
6 LAB 78 F Acute myeloid leukaemia 
7 LAB 68 M Cor pulmonale, cryptogenic fibrosing 
alveolitis, cardiac failure 
8 LAB 84 M Bladder cancer, pneumonia 
 
4.2.2  Competition assays 
I performed all procedures in this experiment independently.  Brain tissue was 
homogenised as described previously (Owen et al., 2010).  Tissue 
membranes were resuspended in assay buffer (50mM Tris-Base, 140mM 
NaCl, 1.5mM MgCl2, 5mM, KCl, 1.5mM CaCl2, pH7.4, 37°C) at a protein 
concentration of ~500 µg/ml and incubated with racemic [3H]PK11195 (5nM) 
and benzodiazepine compounds at a range of concentrations (diazepam, 
chlordiazepoxide, lorazepam, desmethyldiazepam, oxazepam: 10nM - 1mM; 
midazolam: 3nM – 100µM) for 60 minutes (37°C).  Each point was determined 
in triplicate or quadruplicate.   
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Specific binding was defined using unlabelled racemic PK11195 (10µM).  
Assays were terminated via filtration through GF/B filters followed by three 
washes with ice-cold wash buffer (50mM Tris-HCl, pH 7.4, 4oC), prior to 
transfer to vials.  Scintillation fluid (3ml) was added to each vial and bound 
radioactivity determined using a Beta liquid scintillation counter.  Midazolam 
and diazepam competition assays were repeated with [3H]PBR28 (5nM) with 
unlabelled PBR28 (10µM) to define specific binding.  Only HAB tissue (n=4) 
was used in these studies since [11C]PBR28 does not provide a measurable 
signal in PET studies involving LABs.   
 
The effect of ionic composition of the assay buffer was investigated by 
comparing the IC50 of PK11195 when the assay was performed in intra-
cellular buffer (50mM Tris-Base, 10mM NaCl, 140mM KCl, 0.5mM MgCl2, pH 
7.0, 37°C) with the IC50 when it was performed in extra-cellular buffer (50mM 
Tris-Base, 140mM NaCl, 1.5mM MgCl2, 5mM, KCl, 1.5mM CaCl2, pH7.4, 
37°C) in HABs (n=2) and LABs (n=2).  This was repeated using diazepam.   
 
Experiments were also undertaken to ascertain whether the affinity of 
diazepam and PK11195 changed according to assay temperature, by 
conducting parallel experiments using the method above at 37°C and 4°C in 
assay buffer (50 mM Tris-Base, 140 mM NaCl, 1.5 mM MgCl2, 5 mM, KCl, 1.5 
mM CaCl2, pH 7.4), using tissue from 3 HABs, with 1 hour of incubation at 
37°C and 2 hours of incubation at 4°C (to account for a slower time to 
equilibrium at lower temperatures and render the results comparable with 
published in vitro studies at 4°C).   
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4.2.3  Statistical analysis 
Competition data were analysed using non-linear regression curve-fitting 
software (GraphPad Prism 6.0).  Affinities were calculated using the Cheng-
Prusoff equation (Cheng and Prusoff, 1973) with Kds for PK11195 (29 nM) and 
PBR28 (3.4 nM) previously determined by Owen and coworkers (2010).  Two-
tailed Student’s t-tests, also performed in GraphPad Prism 4.0 were used to 
ascertain whether there was a difference in affinity for the PK11195 site and 
PBR28 site.   
 
4.3  Results 
Binding affinities of benzodiazepines for the [3H]PK11195 binding site on the 
TSPO are given in Table 4.2.  The highest affinity was obtained with 
diazepam (Ki = 719nM).  Chlordiazepoxide and midazolam showed much 
lower affinity (Ki > 2µM). The affinities of PK11195 and diazepam for the 
TSPO were not affected by changes in ionic conditions (see Table 4.3), 
implying that previous estimations of affinity of ligands for the TSPO using an 
extracellular buffer can be applied to in vivo conditions in which the ligand 
binds intracellularly.  Contrary to my hypothesis, there was no effect of 
temperature on affinity of diazepam (Ki at 37°C = 992 ± 557; Ki at 4°C = 1008 
± 148; p = 0.959) or PK11195 (Ki at 37°C = 15.2 ± 6.0; Ki at 4°C = 14.9 ± 5.1; 
p = 0.877) for the TSPO.   
 
The affinities for lorazepam, desmethyldiazepam, demoxepam, and 
oxazepam were too low to be estimated accurately (> 50µM).  All compounds 
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for which accurate estimates of affinity were possible, displayed a ~3.5-10 fold 
higher affinity in the HABs compared to the LABs (Table 4.2 and Figure 1) 
which was consistent with my hypothesis.   The affinities (Ki) of diazepam and 
midazolam for the PBR28 binding site on the TSPO were 943 ± 58nM and 
2,240 ± 136nM, respectively.  These did not differ significantly from the affinity 
at the PK11195 site (Diazepam p = 0.202; Midazolam p = 0.956). 
Figure 4.1: Competition curves showing TSPO affinity of diazepam and 
midazolam (PK11195 site)  
 
Legend:  Graph of data obtained from competition assays performed using human brain at 
pH 7.4; 37 °C using [3H]PK11195 (5 nM).  Curves represent the fraction of specific TSPO 
binding blocked by increasing concentrations of diazepam and midazolam.  Diazepam points 
are squares and midazolam triangles. Closed symbols denote data points in the assay 
performed using HAB tissue (n=4) and open symbols denote data points from the LAB assay 
(n=4). The solid curves represent HAB data and the dashed curves LABs data. 
 
Table 4.2: Affinity of commonly-prescribed benzodiazepines for the 
PK11195 site on the TSPO   
Compound Ki HABs (nM) ± SEM Ki MABs (nM) ±SEM Fold 
difference  
Diazepam  719 ± 169  2,141 ± 307 3.4 
Midazolam 2,270 ± 620 >50,000 >10 
Chlordiazepoxide  5,700 ± 1,270 >50,000 >10 
Lorazepam >50,000 >50,000 N/A 
Desmethyldiazepam >50,000 >50,000 N/A 
Demoxepam  >50, 000 >50, 000 N/A 
Oxazepam >50,000 >50,000 N/A 
Legend: SEM = Standard error of the mean; N/A = Not applicable 
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Table 4.3: Effect of ionic conditions on affinity of diazepam and PK11195 
for the TSPO 
Specimen 
no. 
Diazepam PK11195 
 Intracellular 
IC50 
(95% CI) 
Extracellular 
IC50 
(95% CI) 
Intracellular IC50 
(95% CI) 
Extracellular IC50 
(95% CI) 
HAB1 1527 
(991.3-2353) 
1867 
(1277-2730) 
11.1 
(6.1-20.2) 
10.2 
(7.3-14.2) 
HAB2 1547 
(1018-3619) 
1317 
(796.9-2176) 
13.3 
(9.1-19.4) 
10.5 
(6.5-16.8) 
LAB1 3318 
(2203-4999) 
4395 
(2968-6508) 
7.1 
(5.2-9.7) 
9.0 
(5.3-15.6) 
LAB2 2389 
(1577-3619) 
2847 
(1923-3217) 
8.9 
(6.2-12.7) 
10.6 
(6.9-16.3) 
 
4.4  Discussion 
To determine whether benzodiazepine treatment leads to significant 
occupancy of the TSPO, the binding affinities need to be considered in 
conjunction with the brain free concentrations of these compounds.  
Diazepam, which has the highest TSPO affinity, is highly protein-bound with a 
free fraction of 2-3% following a single dose, and the free plasma 
concentration has been shown to be equal to cerebrospinal fluid concentration 
in man (Kanto, 1975), (Kanto et al., 1975), implying an equilibration of the free 
concentrations across the blood-brain barrier.  A single oral dose of 10mg 
diazepam produces a peak total plasma concentration of 720nM (Dundee et 
al., 1979), and hence a peak free concentration of 21nM in plasma and brain.  
Such concentrations would be expected to produce ~1% occupancy of the 
TSPO, based on the affinity estimated in this study.   
 
A cross-sectional study of diazepam concentrations in chronically treated 
patients suggested an increase in the free fraction with chronic treatment (3-
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4%; (Kanto et al., 1974)), and induction of metabolism producing lower steady 
state plasma concentrations than may be expected: 147 to 1482nM (Kanto et 
al., 1974), implying a free concentration between 6 and 60nM.  However, 
another study in chronically treated population reported a steady state 
concentration of 2580 nM – 3547nM in those taking 30mg/day dose 
(Rutherford et al., 1978) implying a free concentration of up to 106nM.  Out-
patients were included in both studies with compliance assessed by self-
report, so may reflect inaccurate reporting.  However, (Rutherford et al., 1978) 
also included in-patients, whose intake was monitored by nursing staff, so 
these results may be more accurate.  Thus, at maximum recommended doses 
of diazepam TSPO occupancy is estimated to be 9%. 
 
Unlike diazepam, TSPO occupancy by midazolam and chlordiazepoxide, the 
two other benzodiazepines with measurable affinity, would be expected to be 
negligible if clinical pharmacokinetic data are used to calculate likely 
competition at the TSPO at clinically relevant doses.  A single dose of 30mg 
chlordiazepoxide (Ki ~ 5700nM in HABs) orally produces a maximum 
concentration of 2mg/l (equivalent to 6.67uM (Boxenbaum et al., 1977)).  
Repeated dosing has been shown to produce a lower steady-state of around 
1.5mg/l (Boxenbaum et al., 1977).  However, 93% of chlordiazepoxide was 
found to be protein bound, suggesting that the free fraction is around 7% 
(equivalent to 473nM (Boxenbaum et al., 1977)).  When this value was 
interpolated in the curve generated using our in vitro data, there was no block 
of specific binding expected to be observed.  Similarly, midazolam (Ki ~ 
2270nM in HABs), which is usually given acutely for anxiolysis, at a dose of 5 
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mg produces a maximum concentration of 559ng/l (equivalent to 170nM 
(Schwagmeier et al., 1998)).  Like other benzodiazepines, midazolam is highly 
protein bound, leaving a free fraction of 3.9%, equivalent to a peak free 
concentration of 0.59nM (Vinik et al., 1983), which is also a concentration 
demonstrated not to produce any block when interpolated into our data. 
 
The implications for my imaging study were that, provided that participants 
taking diazepam were scanned following the end of their medication regime, 
prescribed benzodiazepines were unlikely to compete with the radioligand at 
the TSPO.  Patients taking chlordiazepoxide could be scanned during active 
treatment, and residual metabolites were unlikely to be a problem.  More 
broadly, the implications for TSPO-PET research depended on study design.  
In studies where intra-subject comparisons are made, for example in a 
blocking study or pre- and post-treatment scans, chronic doses of 
benzodiazepines are unlikely to affect the findings providing the 
benzodiazepine dose is maintained between assessments.  However, 
between-group comparisons where there are differences in benzodiazepine 
doses between the groups, a 9% difference in TSPO availability may be a 
consequence of doses of diazepam exceeding 30mg per day. However, 
sedation of patients likely to become distressed by the scan with standard 
doses of midazolam is unlikely to affect TSPO availability.  
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CHAPTER 5 
INVESTIGATION OF MICROGLIAL ACTIVATION IN ALCOHOL DEPENDENCE: A 
[11C]PBR28 PET-CT STUDY !
5.1  Introduction !
This chapter describes findings from a group comparison study investigating 
the presence of microglial activation in alcohol-dependent men in early 
abstinence.  As discussed in Chapter 1, Section 6, microglia are the resident 
macrophages of the central nervous system.  They have an array of highly 
branched ramifications that are acutely sensitive to the extracellular 
environment.  This morphology enables them to respond quickly to pathogen 
invasion and become activated, which involves retraction of ramifications and 
assumption of a more amoeboid appearance, often with proliferation and 
migration to the site of injury.   
 
It has been recognised that microglia which appear activated in morphology 
may in fact express a range of different cell surface molecules and secrete a 
range of mediators.  So-called ‘M1’ activation is particularly of interest as this 
phenotype is inflammatory, associated with production of inflammatory 
cytokines and prostaglandins, and putatively associated with increased 
neuronal death.  In vitro studies have demonstrated that alcohol can activate 
both microglia and astroglia via Toll-Like Receptor 4.  The relevance of this 
receptor is that it is a receptor for bacterial products such as 
lipopolysaccharide, which is associated with an M1 inflammatory response.   
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Activated microglia have been emphasised in clinical research into 
neuroinflammation, as it is possible to detect them using Positron Emission 
Tomography (PET).  This is because expression of a mitochondrial protein 
known as the Translocator Protein 18kDa (TSPO), which has low background 
levels of expression in the brain parenchyma, is increased in activated 
microglia.  Increased TSPO expression has been demonstrated pre-clinically 
using [3H]PK11195 autoradiography in alcohol withdrawal (Obernier et al., 
2002), (Marshall et al. 2013).   
 
Only one post mortem study has been published which investigated microglial 
activation in alcohol dependence.  He and Crews (2008) studied samples 
from the cingulate cortex of five alcohol dependent patients and from the 
ventral tegmental area, midbrain, and amygdala of eight alcohol dependent 
patients.   Three cases died from cirrhosis.  In other cases the listed cause of 
mortality was less specific and could not be related with certainty to advanced 
end organ damage as a result of alcohol.  The mean age of the subjects – 60 
- was higher than in my imaging study described below.  Antibodies for the 
microglial proteins ionised calcium binding adaptor 1 (Iba1) and glucose 
transporter 5 (GluT5) were used to identify microglia via 
immunohistochemistry.  Microglial morphology was also inspected.  There 
was an increase relative to controls of both Iba1 and GluT5 immunoreactivity 
in the cingulate cortex, and of GluT5 but not Iba1 in the ventral tegmental area 
and midbrain of samples from alcohol dependent subjects, consistent with 
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increased microglial numbers.   There were no differences in the amygdala.  
Numbers of activated microglia identified according morphology were not 
different between groups. 
 
There is firmer evidence of microglial activation in clinical samples of patients 
with alcohol-related complications.  TSPO-PET using [11C]PK11195 has also 
been used to show increased TSPO in small patient cohorts with hepatic 
encephalopathy (Cagnin et al., 2006) in the context of alcohol dependence.  A 
single case report of increased [11C]PBR28 binding in a heavy drinker was 
reported in a conference abstract during my study, but the clinical details of 
the case including whether actively drinking or in early abstinence, and 
importantly TSPO binder genotype, were not specified (Hannestad et al., 
2012).  Given clinical evidence relating microglial activation to prognosis in 
acute and chronic neurodegenerative processes, and pre-clinical evidence 
suggesting its presence in alcohol dependence, further investigation of 
microglial activation in an alcohol-dependent clinical population is warranted.  
  
5.2  Aims and hypotheses 
The aim of this study was to investigate whether microglial activation is 
detectable by TSPO-PET in recently detoxified alcohol-dependent men, and 
whether there was a relationship between microglial activation and cognitive 
function.  I hypothesised that: 
1. TSPO expression would be increased in the brains of alcohol-dependent 
patients, particularly in those areas associated with microglial activation or 
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increased microglial numbers in pre-clinical or post-mortem samples 
(Obernier et al., 2002), (Riikonen et al. 2002), (He and Crews, 2008): 
cerebellum, hippocampus, midbrain, thalamus and cingulate cortex.  
2. There would be a relationship between TSPO expression and 
performance on tests of verbal and spatial memory, and frontal lobe tests, 
which are all affected by alcohol (Davies et al., 2005).   
Further exploratory analyses were performed to ascertain the relationship 
between TSPO expression and other clinical symptoms: depression, anxiety 
and craving.   
 
5.3  Methods 
5.3.1  Participants and recruitment 
Alcohol-dependent patients (ADPs) were recruited through local statutory and 
non-statutory addiction services.  Inclusion criteria comprised: meeting DSM-
IV criteria for alcohol dependence; involvement in alcohol treatment services; 
and being within one month of detoxification.  Some flexibility was allowed for 
availability of scanning slots and the participants.  Exclusion criteria included 
major physical or psychiatric illness (though history of depression and anxiety 
were permitted); dependence on other substances of abuse, excluding 
nicotine (though use was allowed); alanine transaminase (ALT) exceeding five 
times the upper limit of normal; abnormal clotting parameters; and 
consumption of steroids or non-steroidal anti-inflammatory medication within 
two weeks of the scan.  Although a blood alcohol concentration of 0.0mg/dl on 
the day of the scan was stipulated, a positive drug screen was not an 
exclusion criterion, as patients close to detoxification were likely to test 
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positive to benzodiazepines, the mainstay of treatment during detoxification, 
or other drugs used prior to detoxification, for example, cannabis, which can 
remain in urine for up to a month after use.   
 
Healthy control participants were shared between this and a concurrent 
[11C]PBR28 PET study.  Additional healthy control participants were recruited 
via local volunteer databases.  Exclusion criteria included history of physical 
or psychiatric illness (though history of depression or anxiety was allowed); 
harmful alcohol consumption; use of illicit substances; and consumption of 
steroid or non-steroidal anti-inflammatory medication within two weeks of the 
scan.  Additional general exclusion criteria for both groups included: Low 
Affinity Binder (LAB) TSPO genotype; exposure to radiation such that the total 
dose would exceed 10mSv within three years; ulnar artery insufficiency; and 
blood donation within two months.   
 
Women were excluded from the study in alcohol dependence because of 
concerns regarding radiation risk to the foetus in the case of undiagnosed 
pregnancy.  However, in order to minimise radiation exposure, data from 
healthy control participants were shared with another study in healthy 
volunteers (Owen, Guo, et al, in preparation, n = 9) that included women.  All 
participants gave informed consent about data sharing and both studies 
received approval from local NHS Research Ethics Committees and the 
Administration of Radioactive Substances Committee (ARSAC). 
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It was difficult to decide on a sample size as pre-clinical autoradiography data 
did not quantify the increase in TSPO seen in alcohol withdrawal, which 
meant that there was uncertainty regarding the magnitude of increase in 
signal anticipated. Furthermore, the study was to be done using novel TSPO-
PET tracers that had not been used in the imaging centre previously.  
Therefore, Dr Qi Guo calculated a tentative sample size based upon 
mathematical simulation informed by in vitro binding data (see Guo et al. 
2012).  It was calculated that in order for the study to have 80% power to 
detect a 50% difference in signal between groups with a 95% probability, that 
8 High Affinity Binders and 8 Mixed Affinity Binders in each group would need 
to be recruited. 
5.3.2  Clinical evaluation 
Participants were evaluated for alcohol dependence using DSM-IV criteria, 
and total lifetime alcohol consumption assessed by the modified Skinner’s 
questionnaire (Skinner and Sheu, 1982).  The Mini-International 
Neuropsychiatric Interview, 6th edition (MINI-6) (Sheehan et al., 1998) was 
administered by a doctor with at least three years’ experience in psychiatry, to 
assess psychiatric co-morbidity and substance use.  A full medical history was 
taken, and a physical examination was performed.  Screening blood tests 
were performed, including urea and electrolytes, liver function tests, clotting 
function, and full blood count.  In addition, blood was taken and analysed for 
TSPO genotype.  Participants were breathalysed, and a urine drug screen 
performed. 
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5.3.3  Questionnaires 
Participants completed the Spielberger Trait Anxiety Score (STAI) 
(Spielberger, 1983).  Physiological dependence in alcohol-dependent 
participants was quantified using the Severity of Alcohol Dependence 
Questionnaire (SAD-Q) on the day of screening.  A score of greater than 31 
indicates severe dependence, 16 – 30 moderate dependence, and below 16 
mild dependence (Stockwell et al., 1983).  The Clinical Assessment of 
Withdrawal from Alcohol (CIWA-Ar) was completed by the attending doctor in 
the alcohol study, to establish that participants were not in need of treatment 
of withdrawal symptoms (score <10) (Sullivan et al., 1989).  All participants in 
both studies completed the Spielberger State Anxiety Score (SSAI), Beck 
Depression Inventory (BDI), and the Fatigue Severity Scale (FSS).  A score 
on the STAI or SSAI of above 40 is considered high (Spielberger, 1983).  A 
score above 9 on the BDI is considered indicative of mild depression, 19 
moderate depression and 30 severe depression (Beck et al., 1961).  The FSS 
was developed to quantify fatigue in chronic inflammatory disorders such as 
multiple sclerosis (MS), and has been validated in MS, systemic lupus 
erythematosis, hepatitis, and chronic fatigue syndrome.  A score of 4 or above 
is consistent with significant fatigue (Krupp et al., 1989).   
 
Those enrolled in the study investigating alcohol dependence also completed 
the Alcohol Urge Questionnaire (AUQ) (Bohn et al., 1995), Obsessive 
Compulsive Drinking Scale (OCDS), but those controls derived from the other 
study, did not.  The AUQ is an eight item, eight question Likert-style 
questionnaire, which measures acute craving (range: 8 – 64).  It is 
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predominantly used in clinical populations to assess progress, and correlates 
with the SAD-Q and OCDS (Bohn et al., 1995).  The OCDS is derived from 
obsessive compulsive disorder symptom scores and measures intrusive 
thoughts and compulsions around alcohol over a period of weeks (range: 0 – 
56).  Like the AUQ, there is no normal range; rather a higher score indicates 
greater preoccupation with alcohol and has been reported to relate to lapses 
and relapse (Anton et al., 1996). 
 
5.3.4  Cognitive tests 
Cognitive tests were completed on the day of scanning in the case of the 
alcohol dependence study, and on the day of screening in the other study.  
They were derived from a battery sensitive to the effects of alcohol 
dependence on cognition developed previously by the research group (Davies 
et al., 2005).  Frontal lobe function assessments including digit span, and Trail 
Making Task A and B (Reitan, 1958), tests of spatial memory – Rey-Osterrieth 
Figure (ROCF) (Osterrieth, 1944), and verbal memory – and Weschler 
Memory Scale paragraph version (WMS) (Weschler, 1987) were 
administered. 
 
5.3.5  Blood tests 
Participants in the alcohol study had blood taken immediately before the scan 
for serum and plasma.  High sensitivity CRP (0.3 – 500mg/dl) was analysed 
by clinical biochemistry services at the Hammersmith Hospital.  Plasma 
samples, where available (n = 6), were sent to the Toxicology Laboratory at 
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Charing Cross Hospital for analysis of diazepam, chlordiazepoxide and their 
common metabolite desmethyldiazepam levels, using high-performance liquid 
chromatography with a detection threshold of 4µg/ml. 
 
5.3.6  Scanning procedures: Positron Emission Tomography 
Participants were scanned at the Imanova Centre for Imaging Science, 
London.  Each participant received a [11C]PBR28 PET scan in a Siemens 
Biograph 6 PET-CT with Truepoint gantry (resolution 4.6mm centre Full Width 
Half Maximum field of view).  A low dose Computed Tomography 
transmission scan was administered initially to facilitate attenuation and 
scatter correction.  Then, a dynamic 3-D PET image was acquired over 90 
minutes.  A bolus of [11C]PBR28 (controls: mean 330.4MBq (range: 312.4 – 
347.3); ADPs: mean 328.9MBq (range: 302.7 – 346.5) was injected over 
twenty seconds at the beginning of the scan.  Arterial blood samples were 
collected from the radial artery to generate the plasma input function.  A 
continuous sampling system (ABSS Allogg, Mariefred, Sweden) was used to 
measure whole blood activity for the first fifteen minutes.  Discrete blood 
samples were drawn for measurement of whole blood and plasma counts, at 
five-minute intervals for the first 30 minutes, then at ten-minute intervals for 
the remainder of the scan.  Arterial blood samples taken at 5, 10, 20, 30, 50, 
70 and 90 minutes were analysed using High Performance Liquid 
Chromatography (HPLC) to determine the activity attributable to parent 
plasma fraction.!
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5.3.7  Scanning procedures: MRI 
Participants received a high-resolution T1 MRI scan in a Siemens Verio 3T 
scanner (Siemens Healthcare, Erlangen, Germany).  All structural MRI 
images were inspected by a clinical neuroradiologist, for unexpected findings 
of clinical significance, or features that might confound PET analysis.  
  
5.3.8  Imaging analysis 
PET images were reconstructed via filtered back projection with attenuation 
and scatter correction by PET technicians working at Imanova Limited.  
Dynamic images were separated into twenty-six frames (8 x 15s, 3 x 1 min, 5 
x 2 min, 5 x 5 min, 5 x 10 min).  A metabolite-corrected plasma input function 
was generated by Dr Qi Guo, who performed all pre-processing prior to 
statistical analysis, using a method described previously (Owen et al., 2014).  
Briefly, the total plasma time activity curve (TAC) was calculated by 
multiplying the whole blood curve by plasma-over-blood ratio, and the parent 
fraction data were fitted to a sigmoid model: 
 
! = 1− !!!! + 10! ! + ! / 1+ !  
 
where t is time and a, b and c are fitted parameters.  The fitted parent fraction 
profile was multiplied by the total plasma curve and then smoothed post-peak 
using a tri-exponential fit to derive the required parent plasma input function.  
A time delay correction was applied to each scan to account for delays 
between blood sample measurement and tomographic measurement of tissue. 
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PET data were corrected for motion via frame-by-frame co-registration to 
each participant’s T1 MRI, using SPM5 (Wellcome Trust Centre for 
Neuroimaging, http://www.fil.ion.ucl.ac.uk/spm).  Anatomical regions of 
interest (ROIs) – hippocampus, midbrain, cerebellum, thalamus and cingulate 
cortex – were delineated by the application of an in-house anatomical atlas, 
which was warped to the participant’s structural MRI scan.  ROIs were applied 
to the PET data to derive regional TACs.   
 
Published data suggest that a two tissue compartmental model provides the 
optimal model fit for [11C]PBR28 PET data (Fujita et al., 2008).  A two tissue 
compartmental model using a metabolite corrected input function, with blood 
volume fixed at 5%, was therefore applied to dynamic PET data, using Matlab 
R2008b (Mathworks, Natick, MA, USA).  Volume of distribution (VT) was 
estimated according to the following equation: 
!! = !!/!!(1+ !!!!) 
where VT is the regional volume of distribution, K1 and k2 are rate constants 
for the movement of [11C]PBR28 from plasma to brain parenchyma and 
parenchyma to plasma respectively, and k3 and k4 are rate constants for the 
movement of [11C]PBR28 from free in the tissue to bound to the specific target, 
and from bound to free, respectively. 
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5.3.9  Hippocampal volume analysis and partial volume correction 
Hippocampal atrophy is commonly described in imaging studies of alcohol 
dependence (Sullivan et al., 1995), (Sullivan et al., 1996), (Agartz et al., 1999), 
(Laakso et al., 2000).  The volume of the hippocampus was therefore  
calculated during pre-processing of the structural MRI using SPM5.  After 
warping the Montreal Neurological Institute template to the participant’s T1 
image, the transformation parameters were applied to the in-house atlas so 
that the atlas and the participants T1 was aligned.  The volume was 
calculated as resolution per voxel (2x2x2mm) x number of voxels in the 
hippocampal region in T1 degined by the warped atlas x the probability map 
of grey matter generated using SPM5.  Hippocampal volume was then 
compared between HCs and ADPs using a two-tailed t-test.  I established that 
there was evidence of hippocampal atrophy in the alcohol dependent group 
(HCs mean = 7853 + 1004.9; ADPs mean = 7132 + 823; p = 0.026).  Partial 
volume correction was therefore undertaken, as described below. 
    
The relatively poor spatial resolution of the PET scanner (4.6mm) and 
procedures during image reconstruction mean that a PET image consists of 
overlapping 3D Gaussian distributions from each point radiation source.  This 
blurring is known as the ‘partial volume effect’ (PVE).  The partial volume 
effect can be expressed as a linear relationship between the measured 
intensity, g, at a given voxel, r, and the a distribution of uptake, f: ! ! = !"# ∗ ! ! + !!(!) 
where psf is the non-variant point spread function of the scanner,  is 
additive noise, * refers to the convolution of psf and f, and r is a 3-D vector.  
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PVEs may cause underestimation of signal in areas of high binding located 
next to areas of low binding e.g. cerebrospinal fluid, and are greater in small 
regions and atrophic brain.  Partial volume correction using LoReAN, a hybrid 
voxel-region-based algorithm (Coello et al., 2013), was undertaken by Dr 
Guo.  The point spread function (psf) of the scanner was established using a 
cylindrical phantom with a known dose of Carbon-11. 
 
5.3.10  Parametric analysis 
Exploratory voxel-based analysis was undertaken by Dr Guo to establish 
whether other brain regions than those identified a priori were affected in the 
patient group.  A Logan plot graphical method (Logan et al., 1990) using the 
plasma input function, 5% fixed blood volume, and a linear start time at 35 
minutes was applied to each voxel to generate a parametric VT map for each 
participant. 
 
5.3.11  Statistical analysis 
I performed the statistical analysis aside from the parametric analysis.  
Median substitution used for missing values in questionnaires and cognitive 
tests.  Demographic and questionnaire data was graphed to assess 
distribution.  Differences between groups were assessed using unpaired 2-
tailed t tests applied to parametric data, and Mann-Whitney tests to non-
parametric data.  Analyses of Covariance (ANCOVA), implemented in SPSS 
20.0 were performed to examine the effect of patient group on [11C]PBR28 VT 
across regions of interest identified a priori.  Genotype was included as a fixed 
factor in the analysis as it is known to influence VT.  Age was included as a 
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covariate as TSPO expression is reported to vary with age (Kumar et al., 
2012).  Parametric images were compared using an ANCOVA with age and 
genotype as covariates, with correction for multiple comparisons implemented 
in Randomise (FSL, Oxford, 2004).  Two-tailed correlations, accounting for 
age and genotype, were performed between hippocampal VT and 
performance on the Weschler Memory Scale, Rey-Osterrieth Complex Figure, 
and frontal VT and performance on Trail Making Tasks.   
5.4  Results 
5.4.1  Demographic characteristics of the sample 
Twenty-one ADPs and ten healthy controls were recruited for the study as 
shown in Figure 5.1.  Two healthy participants were ineligible because of 
binder status or co-morbidity at screening.  A number of participants dropped 
out in both groups between screening and the scan because of other 
commitments or withdrawal of consent.  Four ADPs were later unfit to scan 
because of a fractured jaw, intolerance of arterial line insertion and an 
unexpected finding of pontine myelinolysis on MRI scan.  Three ADPs had 
unusable scan data because of movement or small cerebrovascular lesions 
detected by the neuroradiologist that were not apparent on neurological 
examination.  The final sample included 9 alcohol-dependent patients and 20 
healthy controls. 
 
Demographic characteristics of the final sample are shown in Table 5.1. There 
were no significant differences in age (p=0.590) but there was a trend towards 
controls having spent more time in education (p = 0.09).  Compared with 
healthy controls (HCs), ADPs unsurprisingly drank significantly more in the 
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month prior to detoxification (p = 0.000) and in their lifetime (p = 0.004), and 
had a longer lifetime duration of drinking (p = 0.036).  The mean duration of 
abstinence at the time of the scan for the ADP group was 24 days (range 13 
to 38 days).  The median number of previous detoxifications was 1 (range 0 – 
7).  The mean Severity of Alcohol Dependence Questionnaire score in the 
ADP group was 29 ± 9, corresponding to moderate to severe dependence on 
alcohol.  
 
Fewer control participants were smokers than the ADP group (controls: 4 
current smokers, 3 ex-smokers; ADPs: 8 current smokers).  Similarly, no 
control participants abused substances or tested positive for drugs of abuse, 
whereas three ADP participants abused cannabis and two cocaine, and 
tested positive for these at the time of scanning.  Four control participants and 
four ADP participants had a past history of depression requiring medication.  
There was no other psychiatric co-morbidity.  Neither group suffered from 
clinically apparent medical co-morbidity.  
 
One control participant was taking amlodipine.  Two ADPs were taking both 
acamprosate and disulfiram to prevent relapse, and one had been prescribed 
acamprosate during detoxification.  Three other ADPs were taking 
antidepressants.  All were taking thiamine and vitamin B complex tablets.  
Seven patients were treated with chlordiazepoxide to manage their withdrawal 
symptoms during detoxification prior to the study.  One received diazepam, 
and one underwent an unmedicated detoxification.  No ADP participants were 
still being prescribed benzodiazepines at the time of scanning, but three had a 
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positive urine screen for benzodiazepines.  The mean duration since last 
benzodiazepine dose was 14 days (range 6 – 29 days). 
Figure 5.1: Recruitment Flowchart 
 
 
Table 5.1: Demographic characteristics of the sample 
 Alcohol-dependent Control p 
n 9 19  
Age  45 ± 13 45 ± 7 ns 
Male:Female 9:0 14:5 ns 
TSPO genotype (HAB: MAB) 3:6 10:10 ns 
Years of drinking 26 (18 – 34) 15 (0 -24) 0.036* 
Lifetime dose (kg) 83.29 (14.57 – 273.96) 10.91 (0 – 39.92) 0.004* 
Cigarette smoking (n) 8 5 0.004** 
Illicit drug use 4 0 0.006** 
Past history of depression 4 2 ns 
Legend: Parametrically distributed data are presented as mean ± standard deviation.  Non 
parametrically distributed data are presented as median (range).  Proportions are presented 
as ratios.  Differences between groups are calculated using 2-tailed t-tests for 
parametric data, the Kolmogorov-Smirnov test for non parametric data, and Fisher’s 
exact test for proportions.  * p < 0.05; ** p < 0.01. 
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5.4.2  Clinical questionnaires and cognitive function 
Performance on clinical questionnaires and cognitive tests is tabulated in 
Table 5.2.  Alcohol-dependent patients scored higher on the Obsessive 
Compulsive Drinking Scale but not the Alcohol Urge Questionnaire.  They 
also scored higher on measures of depression and anxiety: the Beck 
Depression Inventory, Spielberger State Anxiety Inventory and Spielberger 
Trait Anxiety Inventory.  Their scores on the Fatigue Severity Scale, a scale 
used in chronic inflammatory conditions, were also significantly increased 
relative to healthy controls. 
 
Alcohol-dependent patients performed more poorly than healthy control 
participants on both immediate and delayed verbal recall.  Delayed spatial 
memory, but not immediate spatial memory, was significantly worse in the 
ADP group.  There were no differences in frontal lobe tasks.  
 
Table 5.2: Psychological questionnaires and cognitive tests 
Clinical questionnaires Alcohol-dependent Control p 
Obsessive Compulsive Drinking 
Scale 
12.4 ± 8.0 3.9 ± 2.4 0.003** 
Alcohol Urge Questionnaire 16 ± 9.5 12 ± 6.6 0.326 
Beck Depression Inventory 11 ± 6 4 ± 4 0.002** 
Spielberger Trait Anxiety Inventory 44 ± 6 35 ± 11 0.015* 
Spielberger State Anxiety Inventory 33 ± 10 29 ± 9 0.013* 
Fatigue Severity Scale 4 ± 0.7 2 ± 1.2 0.004** 
Cognitive Tests    
Weschler Memory Scale Immediate 8 ± 2.9 11 ± 2.8 0.027* 
Weschler Memory Scale Delayed 6 ± 2.5 9 ± 3.6 0.013* 
Rey-Osterrieth Complex Figure 
Immediate 
14 ± 11.2 20 ± 8.4 0.147 
Rey-Osterrieth Complex Figure 14 ± 9 21 ± 7.9 0.048* 
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Delayed 
Trails A (time to complete) 30.3 ± 9.30 29.32 ± 16.9 0.861 
Trails B (time to complete) 62.8 ± 36.48 57.7 ± 30.25 0.700 
Digit span 16.0 ± 3.12 17.6 ± 4.52 0.340 
Legend: * p <0.05; ** p < 0.01 
 
5.4.3  Peripheral blood measures  
All screening blood parameters were within normal limits in both groups, apart 
from mean cell volume (MCV), gamma glutamyl transferase (GGT) and 
alanine transaminase (ALT) in the alcohol-dependent group (see Table 5.2), 
that is, consistent with recent alcohol intake.  Bilirubin, albumin and clotting 
values were normal, demonstrating that hepatic synthetic and metabolic 
functions were preserved in the patient group.  Mean high sensitivity C-
reactive protein (hsCRP) was within normal range in both groups and there 
was no significant difference between groups.  No diazepam or 
chlordiazepoxide was detectable in any pharmacokinetic samples, but 
desmethyldiazepam was detectable in three samples (370 ± 148nM).   
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Table 5.3: Blood parameters 
 Alcohol-dependent Control p 
Haemoglobin 14.8 ± 1.2 14.6 ± 1.2 0.731 
Mean cell volume 96.1 ± 6.1 84.9 ±13.6 0.007** 
White cell count 9.3 ± 2.0 6.5 ±1.3 0.002** 
Bilirubin 8 ± 5 12 ±8 0.161 
Alanine Transaminase 56 ± 20 26 ± 8 0.110 
Alkaline Phosphatase 71 ±50 68 ± 19 0.702 
Gamma glutamyl transferase 134 (range 15 to 466) 30 ± 20 0.064 
Albumin 40 ± 3 44 ± 3 0.004** 
Adjusted Partial Thromboplastin Time 26.6 ± 2.3 28 ± 2 0.086 
Legend: * p <0.05; ** p < 0.01 
 
5.4.4  [11C]PBR28 Volume of distribution: ROI analysis 
TSPO expression was significantly decreased by about 20% in the 
hippocampus in alcohol-dependent patients relative to healthy controls (F (1, 
24) 5.694; p = 0.025; effect of patient group -1.196 (95% C.I.: -0.162 to -
2.231)), corrected for the effects of genotype and age.  Time activity curves 
for the hippocampus are shown in Figure 5.2, with HABs and MABs shown 
separately.  Mean VTs in the hippocampus for all genotypes and groups are 
shown in Figure 5.3.  Differences in other regions of interest – midbrain, 
thalamus, cerebellum and anterior cingulate cortex – did not reach statistical 
significance, although a trend towards lower VT was detected in the midbrain 
(F (1, 24) = 3.879; p = 0.061), as illustrated in Figure 5.4.  As anticipated, age 
and genotype were significantly associated with variation in [11C]PBR28 VT in 
all regions tested (for example, in the hippocampus: genotype F (1, 24) = 
8.190; p = 0.009; age: F (1, 24) = 5.370; p = 0.029).  In the hippocampus, the 
effect of genotype was 1.459 (95% C.I.: 0.407 – 2.512) (F = 8.190; p = 0.009).  
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There was no patient group x genotype interaction (p>0.05).  VT was not 
associated with duration of abstinence in alcohol-dependent group, controlling 
for age and genotype in any region. 
 
Figure 5.2: Time activity curves in the hippocampus 
 
Legend: This figure shows mean time activity curves with error bars representing standard 
deviation, from the hippocampus in healthy controls, shown in black, and ADPs, shown in red.  
 
Figure 5.3: [11C]PBR28 VT is lower in the hippocampi of ADPs than in 
controls (mean + sd) 
 
Legend:  Blue circles reflect healthy control values and red squares alcohol dependent 
values.  There is a larger standard deviation in the healthy control sample especially in 
the HAB subset.  This reflects the greater age range in the health control group, as age 
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was positively associated with [11C]PBR28 VT in all ROIs studied (see Table 5.1 for 
relative age ranges and page 137 for effect of age on VT). 
  
Figure 5.4: Lower VT in ROIs apart from the hippocampus did not reach 
significance (mean + SD) 
 
 
5.4.5  [11C]PBR28 Volume of distribution: parametric analysis 
Parametric analysis, controlling for the effects of age and genotype, did not 
yield any clusters meeting the multiple comparison threshold.  At a less 
stringent threshold of p = 0.13, several clusters were identified: the left 
hippocampus, left insula, left caudate, and thalamus and cerebellar cortex, 
bilaterally exhibited lower VT in the alcohol-dependent group.  These are 
shown in Figure 5.5. 
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Figure 5.5: Results of parametric voxel-based analysis 
 
 
5.4.6  Relationship between hippocampal [11C]PBR28 VT and memory 
Correlations, controlling for the effects of age and genotype, were found 
between hippocampal VT and scores on the delayed Weschler Memory Scale 
(WMS), a measure of verbal memory, and delayed Rey-Osterrieth Complex 
Figure (ROCF) test, a measure of spatial memory, when the patient group 
and the healthy group were combined (WMS: Pearson’s r = 0.720, p = 0.000; 
ROCF: Pearson’s r = 0.004), as shown in Figure 5.6 and 5.7.  When the 
patient and control groups were separated, the association between verbal 
memory and hippocampal VT remained in the healthy control group 
(Pearson’s r = 0.738; p = 0.001), but not the alcohol-dependent group 
(Pearson’s r = 0.331; p = 0.468).  A trend toward an association remained 
between spatial memory and hippocampal VT in the healthy group (Pearson’s 
r = 0.445; p = 0.073), but not in the alcohol-dependent group (Pearson’s r = 
0.058; p = 0.902).  There were no associations between hippocampal VT and 
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performance on digit span or the Trail Making Task, nor any associations 
between frontal cortex VT and performance on digit span or the Trail Making 
Task. 
 
Figure 5.6: Correlation between hippocampal VT and verbal memory 
 
 
Figure 5.7: Correlation between VT and spatial memory 
!
5.5  Discussion 
This is the first study to report changes in [11C]PBR28 VT in a cohort of 
otherwise healthy, alcohol-dependent patients within the first few weeks of 
abstinence.  Contrary to my hypothesis, the main finding is that TSPO VT is 
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significantly decreased in the hippocampus in alcohol-dependent patients, 
relative to healthy control participants.  There was also a trend towards a 
decrease in the midbrain.  In the study population taken as a whole there was 
a direct relationship between both verbal and spatial memory and 
hippocampal [11C]PBR28 VT.  In the healthy control group, the correlation 
between verbal memory and hippocampal VT remained significant and a trend 
towards a correlation between spatial memory and hippocampal VT remained.  
These correlations were not present in the alcohol-dependent group.  
Published findings regarding the effect of genotype and age on VT (Kumar et 
al., 2012) were replicated. 
 
The finding of a regional, hippocampal decrease in alcohol-dependent 
patients shortly after detoxification may be of clinical significance, as lower 
binding was associated with poorer memory.  Visuo-spatial and verbal 
learning and memory deficits associated with the hippocampus are well-
recognised in pre-clinical models of alcohol dependence, as well as in clinical 
populations (e.g. (Matthews and Morrow, 2000) (Fama et al., 2009) (Davies et 
al., 2005)).  Alcohol-related hippocampal atrophy has also been described in 
structural imaging studies (Sullivan et al., 1995), (Sullivan et al., 1996), 
(Agartz et al., 1999), (Laakso et al., 2000).  There is debate about the 
underlying pathology causing the atrophy.  Loss of neurons has been 
inconsistently reported, and loss of glia and microglia (Korbo, 1999), 
dendrites, or synapses, or the cessation of neurogenesis, have been 
proposed (reviewed in (Harper, 1998)).  The finding of this study, that is, a 
decrease in [11C]PBR28 VT following partial volume correction in the setting of 
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hippocampal atrophy suggests is consistent with Korbo’s histological study 
showing loss of glia and microglia in this brain region post-mortem (Korbo, 
1991). 
 
Structural MRI studies have failed to demonstrate an association between 
hippocampal volume and hippocampal memory function (Sullivan et al., 
1995), (Ratti et al., 1999).  Smaller hippocampal white matter volume, 
however, has been related to withdrawal seizures (Sullivan et al., 1996).  
Three patients had a history of seizures; however I did not investigate a 
relationship to seizures owing to sample size.  A single PET study found that 
the density of the alpha-5-receptor subtype of the GABA receptor was 
associated with improved memory function (Lingford-Hughes et al., 2012a).  
This, taken together with my finding, suggests that PET may be of more use 
than structural imaging, to characterise alcohol-related changes of relevance 
to cognitive function. 
 
Based on pre-clinical data, I had hypothesised that higher TSPO binding, 
reflecting microglial activation, would be present in alcohol dependence rather 
than lower levels compared with healthy controls.  However it may be that the 
changes occurring after prolonged alcohol intake are different from those 
occurring after brief, binge exposure, which might account for the lower level 
in practice.  Pre-clinical binge paradigm data published during my study found 
that hippocampal microglial activation during withdrawal was associated with 
an increase in TSPO (Marshall et al. 2013). However, this was associated 
! 143 
with an increase in the anti-inflammatory IL-10, and no changes in pro-
inflammatory cytokines such as TNF-α or IL-6 concentrations.  It has been 
suggested that this microglial response supports neurogenesis, suppressed 
during chronic drinking, in early abstinence (Nixon et al., 2008).  Microglia in 
this context may therefore be neurotropic rather than neurotoxic. 
 
In post-mortem human brain samples representing more chronic alcohol 
intake, loss of microglia and glia in the hippocampus has been reported 
(Korbo, 1999).  Thus it is possible that microglial loss in the hippocampus 
either exacerbates damage, or delays the return of neurogenesis.  
Alternatively, it has been reported that TSPO is also expressed by 
hippocampal neural stem cells (Varga et al., 2009).  Pre-clinical findings 
regarding the effect of alcohol on neurogenesis have yet to be replicated in 
human post-mortem samples and human neurogenesis in adulthood is 
reported to be rare (Sutherland et al., 2013), so it is less likely that lower 
TSPO binding reflects loss of neural progenitors in the hippocampus.   
 
A difference between pre-clinical and clinical data is the delay between the 
initiation of detoxification and the scan, raising the possibility that short-lived 
microglial activation may be missed.  Nixon and colleagues describe 
increased microglial activation as measured by [3H]PK11195 autoradiography 
on the first day and the seventh day of withdrawal but not at one month post 
withdrawal (Marshall et al. 2013).  Other animal models describe shorter-lived 
activation of microglia as measured by immunohistochemistry (Zhao et al., 
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2013).  However, microglial activation following alcohol binge dosing has been 
reported to persist at twenty-one days of abstinence (Obernier et al., 2002), 
which suggests that microglial activation, if present, may have been 
detectable at this duration of abstinence.  In my study there was no 
relationship between duration of abstinence and VT, corrected for age and 
genotype. 
 
The delay between the beginning of alcohol detoxification and scanning was 
unavoidable for several practical reasons.  Patients presenting to local alcohol 
services for detoxification, were either detoxified as out-patients within days of 
presenting, or were admitted to an in-patient unit.  Those who were detoxified 
as out-patients were usually recruited after their first detoxification 
appointment and screened within the next day or so.  Those who were 
admitted for in-patient detoxification were either recruited on a local ward, or 
were recruited and screened prior to detoxification if they were going to a 
third-sector detoxification unit in Portsmouth.  If the latter was the case, the 
earliest they could be scanned was on discharge from the unit, usually around 
two weeks after detoxification.  TSPO genotyping took a minimum of seventy-
two hours.  Scan days needed to be booked a month in advance. 
 
An additional and important concern was the potential impact of 
benzodiazepines on [11C]PBR28 binding.  As described in Chapter 4, this was 
unlikely to be the cause for concern after the first two days of detoxification, 
and only if patients were treated with diazepam (Kalk et al. 2013 2013).  Only 
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one of the patients received diazepam and pharmacokinetic data from my 
study found detectable levels only of the metabolite, desmethyldiazepam, 
which does not bind the TSPO.  TSPO may be affected by medication, such 
as the anaesthetic agent propofol (Hines et al., 2012).  Further, anti-relapse 
medication has been reported to have anti-inflammatory effects (Franchi et 
al., 2010).  However if this were the case, a general effect on binding, rather 
than regional differences, would have been anticipated.  I was also unable to 
compare the effects of smoking, which is reported to affect hippocampal 
damage in the context of alcohol dependence (Gazdzinski et al., 2008), as all 
but one patients smoked, compared to a minority of controls who did.  
 
Although this finding was contrary to my hypothesis, it is not one without 
precedent.  When TSPO PET was undertaken using [11C]PK11195 little 
specific signal was detected in healthy brain.  This is not the case with 
[11C]PBR28, which means that it is, in theory, more sensitive to decreases 
from healthy expression levels, as well as increases.  Recent pre-clinical and 
clinical data support this.  Individual age-matched depressed patients showed 
a decrease in global cerebral [11C]PBR28 VT relative to their matched 
controls, though there was no difference in mean VT  between groups 
(Hannestad et al., 2013).  A longitudinal study in primates of the microglial 
response to lipopolysaccharide showed that in one subject the binding 
decreased by 40% relative to baseline, suggesting that microglial activation 
and/or TSPO expression is more dynamic than previously appreciated.  
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The study is affected by limitations mainly around the patient sample: a small 
sample size, with varied prescribed medications, a few weeks from cessation 
of alcohol intake.  To an extent these limitations reflect the logistics of 
recruitment and PET scanning patients at high risk of disengagement from 
services as well as from research, in a setting where patients are not on-site 
and delivery of care occurs through a combination of statutory and voluntary 
organisations. 
 
5.6  Conclusion 
This study found a statistically significant decrease of 20% in [11C]PBR28 VT 
in the hippocampus of alcohol-dependent patients in early abstinence.  
Hippocampal VT was inversely correlated with performance on a delayed 
memory task, which suggests that this may be of clinical relevance.  
Previously reported relationships between genotype and age, and VT were 
replicated.  Importantly, no increase in binding was found in the alcohol-
dependent participants, raising questions about the function of microglia in 
this context and how this may translate into a treatment target.  Certainly the 
pre-clinical literature initially suggested that anti-inflammatory treatment may 
be useful (Pascual et al., 2007). It remains to be established whether 
microglial activation occurs during drinking or more acutely during the first 
forty-eight hours of detoxification.   
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CHAPTER 6 
BRAIN GLUTAMATE AND GLUTAMINE AND THEIR RELATIONSHIP TO 
MICROGLIAL ACTIVATION AND COGNITIVE FUNCTION !
6.1  Introduction 
In Chapter 5, microglial activation was investigated using [11C]PBR28 PET, 
and significantly lower TSPO binding was found in the hippocampus and 
midbrain in alcohol-dependent (ADP) men compared with control participants.  
This chapter describes an experiment undertaken to investigate the 
relationship between microglial activation detected by TSPO PET and brain 
glutamate concentrations measured with Magnetic Resonance Spectroscopy 
(MRS).  This is of interest because increased brain extracellular glutamate 
concentrations (Dahchour and De Witte, 2003) and increased glutamatergic 
transmission contribute to the pathogenesis of the symptoms and 
complications associated with alcohol withdrawal.    
 
As described in the Chapter 1, Section 7, glutamate is involved in 
neurotransmission as well as metabolic pathways in the brain.  Chronic 
alcohol intake results in upregulation of NMDA receptors and an increase in 
NMDA receptor sensitivity to glutamate.  Sudden withdrawal of alcohol is 
associated with an increase in extra-cellular glutamate, which in the presence 
of upregulated, sensitive NMDA receptors, can lead to glutamatergic 
excitoxicity (Mayer et al., 2002).  Clinically, increased glutamate transmission 
is important in the pathogenesis of alcohol withdrawal, as pre-clinical studies 
(Stepanyan et al., 2008) and clinical studies support the use of NMDA 
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antagonists to manage withdrawal symptoms (Krupitsky et al., 2007).  A pre-
clinical alcohol model demonstrated concurrent glutamate excess and 
microglial activation in the hippocampus, so the two may be related (Ward et 
al., 2009).  Pre-clinical research in other acute brain insults suggests that 
microglia may be protective against glutamatergic excitoxicity  (Vinet et al., 
2012) (Palazuelos et al., 2009) (Lambertsen et al., 2009).  I therefore 
undertook an MRS study of frontal and occipital cortex glutamate 
concentrations in conjunction with the [11C]PBR28 PET study as I 
hypothesised that both [11C]PBR28 VT and glutamate would be increased in 
the alcohol dependent group, and that there may be a correlation between the 
two. 
 
Brain glutamate can be measured in clinical populations using Magnetic 
Resonance Spectroscopy (MRS), though this measures both intra-
cellular/metabolic and synaptic glutamate.  MRS uses a succession of 
radiofrequency pulses in a strong magnetic field in order to disrupt the axes of 
hydrogen nuclei.  It exploits the effects of the immediate molecular 
environment on the frequency with which the nuclei move from the flipped 
axis to the pre-existing axis, a process which generates electric currents.  
These are detected by the scanner and used to generate a spectrum of 
peaks, which correspond to the concentration of different molecules in the 
voxel studied.  Clinical studies using MRS during alcohol withdrawal and early 
abstinence (see Table 1.3), have found that brain glutamate concentrations 
([Glu]) are raised during the early phase of alcohol withdrawal (Yeo et al., 
2013) (Hermann et al., 2012).  During early abstinence, both increased and 
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decreased [Glu] have been described and may be modulated by brain region 
studied or clinical factors such as smoking (Mason et al., 2005) and relapse 
prevention treatment (Umhau et al., 2010).   
 
6.2  Aims and hypotheses 
Based on previous evidence available when I designed the PET and MRS 
studies, I hypothesised the following: 
1. Brain glutamate, glutamine, and [Glx] (glutamate and glutamine 
concentrations combined) concentrations would be raised in alcohol-
dependent patients (ADPs) from controls. 
2. Glutamate, glutamine, or [Glx] would be positively correlated with 
[11C]PBR28 binding. 
3. Glutamate, glutamine, or [Glx] would be negatively correlated with 
cognitive test performance. 
  
6.3  Methods 
6.3.1  Recruitment and sample  
Recruitment and demographic characteristics were as for the [11C]PBR28 
PET study in alcohol dependence described in Chapter 3, as the MRS scan 
was performed in the same group comparison study.   
 
6.3.2  Magnetic Resonance Spectroscopy 
Participants were scanned with a 32-channel head coil and a Siemens Verio 3 
Tesla MRI scanner on the same day as the PET scan.  The Magnetisation 
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Prepared Rapid Gradient (MPRAGE) (Repetition Time (TR)/Echo Time (TE) = 
2300/2.98ms; 9° flip angle; resolution 1mm3) was used to acquire a 3-D 
sagittal T1-weighted image.  The T1 images were also used for segmentation 
of the voxel into grey matter, white matter and cerebrospinal fluid using SPM8 
(Ashburner and Friston, 2005). 
 
A 20mm x 20mm x 20mm voxel was placed over the anterior cingulate cortex 
(ACC), defined as anterior to the genu of the corpus callosum and superior to 
the anterior commissure to posterior commissure line, centred on the median 
line (shown in Figure 6.1a).  The ACC was chosen, as it was an area where 
more numerous microglia were found post-mortem in alcohol-dependent 
patients (He and Crews, 2008).  Unlike deeper brain structures such as the 
hippocampus or nucleus accumbens, it is possible to obtain analysable 
spectra from the ACC in a 3 Telsa magnetic field.   
 
A 30mm x 30mm x 30mm voxel was placed over the occipital cortex (OCC) 
parallel to the cerebellar tentorium, and as posterior as possible within the 
limits of the brain, again centred on the median line (see Figure 6.1b).  The 
occipital cortex was chosen since this is an area with optimal signal to noise 
ratio, due to its location close to the radiofrequency coils and good static 
magnetic field homogeneity.  As a result, robust, diurnally-stable 
measurements can be produced (Evans et al., 2010).  It is also the only 
region that can accommodate the 30mm x 30mm x 30mm voxel necessary to 
capture GABA.  3-D shimming was performed to correct for inhomogeneities 
in the magnetic field.   
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Figure 6.1a Voxel placement in the Anterior Cingulate Cortex 
 
Figure 6.1b Voxel placement in the Occipital Cortex 
 
Both water-unsuppressed and water-suppressed sequences were captured 
from the ACC and OCC.  In the ACC, a Point Resolved Spectroscopy 
(PRESS) sequence was applied (96 averages; TR/TE: 3000/30ms; 90° flip 
angle; 2000Hz bandwidth) to measure a range of metabolite concentrations 
including glutamate ([Glu]), glutamine ([Gln]), gamma-hydroxy-butyric acid 
([GABA]), creatine ([Cre], a measure of cellular metabolism), N-acetyl 
aspartate ([NAA], a marker of neuronal integrity), choline ([Cho], a marker of 
membrane turnover), and myoinositol ([mI], a glial marker) (see Figure 6.2).  
PRESS is a technique whereby magnetic gradients are applied along three 
orthogonal axes in the during each radiofrequency pulse to provide spatial 
localisation of the signal.  A typical spectrum derived from a single subject 
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during my study, showing the characteristic spectra of brain metabolites, is 
shown in Figure 6.2. 
 
Figure 6.2: PRESS sequence spectrum 
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Legend: Spectra are presented with increasing frequency from right to left by convention.  
The black spectrum is the raw data and the red line the model fit generated by LCModel.  The 
main spectra of the metabolites are labelled with the following abbreviations: Cho = choline; 
Cr = creatine; Gln = glutamine; Glu = glutamate; mI = myoinositol; NAA = N-acetyl aspartate.  
 
In the OCC, a Mescher-Garwood PRESS (MEGA-PRESS) sequence was 
applied in order to detect GABA as well as [Glx], and [NAA] (240 averages; 
TR/TE: 1500/68ms; 90° flip angle; edit pulse frequency -1.9ppm; edit pulse 
bandwidth 45Hz; edit centre frequency: 4.70ppm).  MEGA-PRESS is a 
method that uses a pulse at a specific frequency to differentiate the GABA 
peak from others at a similar frequency, although some contaminations with 
similar structures such as homocarnosine and certain macromolecules remain 
(Mescher et al., 1998).  As a consequence, the GABA signal resolved by this 
edited spectrum is referred to as [GABA+].  A typical spectrum derived from 
MEGA-PRESS in a single subject is displayed in Figure 6.3. 
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6.3.3  Image processing  
Image analysis was conducted using LCModel Version 6.3-1H (Provencher, 
1993) using a standard basis set of metabolites acquired on a Siemens 
scanner of the same brand and field strength (3T).  LCModel makes use of full 
spectra generated from in vitro metabolite solutions to inform analysis of the in 
vivo spectrum as a linear combination of separate spectra.  Provided the 
same sequence is used, Basis sets, that is spectra acquired from a phantom 
containing a specified concentration of a metabolite, from a similar scanner 
can be used (Provencher, 1993).  ‘Water scaling’, that is, adjustment of the 
area under the curve of each metabolite to area under the curve for water in 
each participant, was undertaken.  However as water-scaled metabolite 
concentrations differ from mM by a factor of ~20% they are reported as 
‘institutional units’ rather than mM (Provencher, 2014).   
 
Figure 6.3: MEGA-PRESS sequence spectrum 
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Legend: Spectra are presented with increasing frequency from right to left by convention.  
The black spectrum is the raw data and the red line the model fit generated by LCModel.  The 
main spectra of the metabolites are labelled with the following abbreviations: GABA = Gamma 
amino butyric acid; Glu = glutamate; Glx = a joint measure of glutamate and glutamine which 
is calculated if their peaks cannot be resolved adequately. 
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In the MRS literature it is commonplace to use either water scaling or a ratio 
of other metabolites as a way of normalising the measurement to account for 
differences in voxel composition.  The validity of creatine as a reference rests 
on the assumption that creatine concentrations are constant across brain 
regions and are unaffected by brain pathology (Maddock and Buonocore, 
2012).  The ratio is uninformative if creatine differs between groups.  My 
primary analysis therefore used water scaling and an adjustment for 
percentage of cerebrospinal fluid in the voxel.  To allow comparison with 
previous findings, an analysis of metabolite:creatine ratios was conducted 
from the PRESS data.  The concentrations supplied by MEGA-PRESS output 
in LCModel did not provide creatine concentrations, so no creatine ratios are 
reported for the occipital cortex metabolites.  
 
Those concentrations where the standard deviation produced by LCModel 
exceeded Cramer-Rao standard error lower bounds of 25%, were excluded 
from analysis.  For this reason, some metabolites could not be analysed: 
[GABA+] in the ACC, and glutathione in the OCC, as their standard error 
bounds for the majority of analyses exceeded 25%.  Those analyses with non-
random residuals or a ‘wild baseline’ (Provencher, 2014) were not included in 
statistical analysis (for ACC: 2 ADPs, 1 HC; for OCC: 2 ADPs, 1 HC). 
 
6.3.4  Statistical analysis 
All statistical procedures were performed using SPSS 20.0.  A priori 
hypotheses regarding group differences were tested using independent-
sample t-tests, with Bonferroni correction for multiple comparisons.  For other 
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metabolites, exploratory analysis with no correction for multiple comparisons 
was undertaken.  Pearson’s correlations, corrected for genotype, were 
conducted to characterise relationships between [11C]PBR28 VT in the anterior 
cingulate cortex and [Glu] and [Glx] in the MRS cingulate voxel.  Pearson’s 
correlations were also undertaken to interrogate the relationship between 
glutamate and [Glx] with cognitive test performance.  A more sophisticated 
statistical method such as MANOVA, which would take into account the 
correlation between performances on different cognitive tests, was not used 
here since the sample size was too small. 
 
6.4  Results 
The mean metabolite concentrations are presented in Table 6.2.  Anterior 
cingulate cortex (ACC) [Gln] was significantly lower in Alcohol-dependent 
Patients (ADPs) than controls (p = 0.016).  There were no significant 
differences in ACC glutamate.  Although both ACC and occipital [Glx] were 
also significantly lower in ADPs (ACC: p = 0.03; occipital: p = 0.044), these 
differences disappeared after correction for multiple comparisons.  
Exploratory analysis revealed that ADPs had significantly lower choline 
([Cho]) and creatine concentrations ([Cr]) in the ACC, without differences in 
ACC N-acetylaspartate ([NAA]), or myoinositol concentrations ([mI]), and with 
no differences in occipital y-hydroxy-butyric acid concentrations ([GABA+]) 
and [NAA].   
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Table 6.2: Comparison of metabolites between ADPs and HCs (mean + 
SD) in Institutional Units 
Metabolite ADPs HCs p 
Anterior cingulate cortex    
[Glu] 7.23 ± 1.277 7.47 ± 0.919 0.661 
[Glx] 7.82 ± 3.239 10.74 ± 1.676 0.033* 
[Gln] 1.93 ± 0.388 2.97 ± 0.987 0.016* 
[Cr] 5.98 ± 0.578 6.88 ± 0.814 0.017* 
[NAA] 6.32 ± 1.271 7.08 ± 0.714 0.147 
[Cho] 1.39 ± 0.218 1.88 ± 0.181 0.000** 
[mI] 4.87 ± 1.277 5.15 ± 0.615 0.540 
ACC metabolite:Cr ratios    
[Glu]:[Cr] 1.20 ± 0.114 1.12 ± 0.244 0.402 
[Glx]:[Cr] 1.50 ± 0.127 1.61 ± 0.434 0.528 
[NAA]:[Cr] 1.06 ± 0.183 1.06 ± 0.210 0.970 
[Cho]:[Cr] 0.23 ± 0.027 0.28 ± 0.041 0.023* 
[mI]:[Cr] 0.81 ± 0.128 0.75 ± 0.086 0.336 
Occipital cortex    
[Glx] 5.27 ± 1.245 6.61 ± 1.260 0.044* 
[GABA+] 2.19 ± 0.350 2.44 ± 0.795 0.423 
[NAA] 9.43 ± 1.420 9.68 ± 2.091 0.778 
Legend: ADPs = alcohol-dependent patients; [Cho] = choline concentration; [Cr] = creatine 
concentrations; DLPFC = dorsolateral prefrontal cortex; [GABA+] = Gamma amino butyric 
acid concentration; [Gln] = glutamine concentration;  [Glu] = glutamate concentration; HCs = 
healthy controls; [mI] = myoinositol concentration; [NAA] = N-acetyl aspartate  
 
ACC [Cr] was lower in the alcohol-dependent patient group.  As explained 
above, this renders other metabolites corrected for [Cr] concentrations, 
uninformative.  These were calculated only to allow comparison with other 
studies in the same population that only used the [Glu]:[Cr] ratio.  There were 
no significant differences in [Glu]:[Cr] or [Glx]:[Cr] between groups.  The 
decrease in choline seen when absolute concentrations were considered 
remained significant. 
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There were no significant correlations between ACC [Glu] or [Glx] and ACC 
[11C]PBR28 VT, or between occipital [Glx] and occipital [11C]PBR28 VT.  There 
were no significant correlations between ACC [Glu] or [Gln], or occipital [Glx] 
and cognitive performance on any test. 
 
6.5  Discussion 
There was significantly lower [Gln] in ACC of alcohol-dependent patients in 
early abstinence compared with healthy controls.  [Glx] was also lower in both 
the ACC and occipital cortex, although not significantly so after correcting for 
multiple comparisons.  These findings contradicted my hypothesis, as I 
expected to find higher [Glu] and [Glx] in ADPs.  There was significantly lower 
[Cho] which remained after Bonferroni correction, and significantly lower [Cr], 
which did not.  There was a significantly decreased [Cho]:[Cr] ratio in the ACC 
(though this disappeared after Bonferroni correction) but no other significant 
differences in metabolite:creatine ratios between groups.  I found no 
association between MRS measures of [Glu], [Gln] or [Glx] and [11C]PBR28 
VT.  The absence of significant correlations in the ACC between [Glu], [Gln] or 
[Glx] and [11C]PBR28 VT was perhaps unsurprising given the small sample 
numbers and the need to take genotype into account.  In addition, the PET 
study found no differences between ADPs and controls, which suggested an 
absence of microglial activation in this region.  Finally, in contrast to a 
previous study which found an inverse association between the glutamate 
creatine ratio and short term memory, I found no association between 
performance on cognitive tests and ACC [Glu] or [Glx], [Glu]:[Cr] or [Glx]:[Cr], 
or occipital [Glx]. 
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The finding of a significant decrease in [Gln] in the ACC and the suggestion 
that there may be decreased [Glx] in the ACC and occipital cortex, are novel 
findings in alcohol dependence.  Glutamine has been suggested to be a proxy 
for synaptic glutamate, as it is formed from glutamate absorbed by astrocytes 
(Yuksel and Ongur, 2010).  However, changes in widely distributed 
metabolites may not represent changes in neurotransmission (Myers et al., 
2014).  Decreased [Glu] and [Gln] may also represent diversion of glutamate 
towards other metabolic pathways.  For example, glutamate is the precursor 
of glutathione, an antioxidant reported to be depleted in alcohol dependence 
(Peter, 2013).  Decreased [Glu] or [Gln] could therefore represent diversion of 
glutamate to replenish glutathione stocks in early abstinence.  Although 
glutamate is also a precursor of GABA, additional synthesis of GABA is 
unlikely, as occipital concentrations in my sample did not differ between ADPs 
and controls.  Of interest is that the findings are opposite to those in hepatic 
encephalopathy, a common complication of alcohol dependence, where [Glx] 
is reported to be increased (van der Graaf, 2010).   
 
As observed in the introduction, findings with respect to [Glu], [Gln] and [Glx] 
in alcohol dependence are variable according to population and brain region 
studied.  Even in other studies considering only the anterior cingulate cortex 
with a similar duration of abstinence to my study, increases (Lee et al., 2007), 
decreases (Mon et al., 2012), or no differences (Bauer et al., 2013) in [Glu], 
and no differences in [Glx] (Bauer et al., 2013) have been reported.  A single 
previous study considering occipital [Glx] found no differences (Mason et al., 
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2005).  In Lee and colleagues’ study, a different way of quantifying glutamate, 
using creatine as a reference compound, was used (Lee et al., 2007).  This 
could account for differences between their finding and mine, as they also 
found a significant decrease in creatine in their alcohol-dependent 
participants; the implication is that this decrease, rather than raised glutamate, 
is likely to explain the increase in glutamate:creatine ratio.   
 
Other findings such as the decrease in choline are consistent with previous 
reports in early abstinence (Ende et al., 2005) (Lee et al., 2007) (Mon et al., 
2012).  The MRS choline signal is a composite of choline and choline-
containing compounds, such as phosphocholine, a component of cell 
membranes.  Choline is an essential nutrient, with many roles in the brain 
including membrane component synthesis (Kennedy, 1956).  It has been 
found to promote glutathione synthesis (Adibhatla and Hatcher, 2005), 
increase glial glutamate uptake (Hurtado et al., 2008) and promote 
hippocampal neurogenesis (Diederich et al., 2012) following acute brain 
insults such as stroke.  It has been demonstrated to reduce ischaemic volume 
in pre-clinical models of stroke (Hurtado et al., 2013); however clinical trials of 
choline have failed to demonstrate neuroprotection, perhaps because of poor 
bioavailability (Davalos et al., 2012). 
 
MRS studies of choline in relation to alcohol consumption have highlighted the 
importance of the point at which measures are taken in alcohol misuse and 
dependence.  Choline has been reported to rise in association with drinking in 
both pre-clinical and clinical studies (Zahr et al., 2010) (Meyerhoff et al., 
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2004), yet in early abstinence, choline has consistently been reported to be 
lower in ADPs than in healthy controls.  It has been proposed that choline 
rises as a compensatory measure during heavy drinking but that chronic 
drinking causes decompensation (Ende et al., 2006).  In other clinical 
contexts, choline has been proposed as a possible MRS marker of 
inflammation because of an association with demyelination (De Stefano and 
Filippi, 2007).  The finding here of decreased choline in the same sample as 
decreased hippocampal [11C]PBR28 binding raises the possibility that 
decreased choline is related to the suppression of neurogenesis.  This could 
be investigated in a larger sample of patients with a single TSPO genotype. 
  
6.5.1.  Limitations 
A limitation of this study in the light of the PET study findings was that I was 
unable to image the hippocampus using MRS, as this requires higher 
magnetic field strength than that available to me to generate interpretable 
spectra.  Nonetheless, analysis of ACC and occipital voxels allows 
comparison with other studies in early abstinence.  Another limitation was that 
the MRS sample size was much smaller than the main imaging study, as only 
controls that I recruited for the alcohol study had MRS measures taken.  The 
sample size was further diminished by poor spectra from several participants, 
either because of movement or because of the proximity of the ACC voxel to 
the frontal sinus.  This substantially limited my ability to investigate 
correlations with clinical variables or [11C]PBR28 VT.  Additionally, the logistics 
of scanning precluded measurement of glutamate during the very first days of 
detoxification, when other studies have found increased concentrations (Yeo 
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et al., 2013) (Bauer et al., 2013) (Hermann et al., 2012).  Finally, MRS 
measures both synaptic and metabolic pools of glutamate, making it difficult to 
distinguish the two (Stagg et al., 2011) (Myers et al., 2014). 
 
In summary, the findings of decreased [Cho], [Glu] and [Glx] in cerebral 
voxels of alcohol-dependent patients are consistent with depletion owing to 
increased glutathione metabolism.  There was no relationship between 
glutamate, glutamine or [Glx] and [11C]PBR28 VT though this may relate to the 
very small sample size and the additional variability related to genotype.  !
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CHAPTER 7 
DISCUSSION AND FUTURE DIRECTIONS 
 
The main findings of my thesis are as follows: 
• The pro-inflammatory cytokine IL-6 is associated with more severe 
withdrawal symptoms and with depression throughout detoxification. 
• The pro-inflammatory chemokine is associated with better performance 
on cognitive tests at the end of detoxification. 
• IL6 is positively associated with morning serum cortisol concentrations 
and with the magnitude of the Cortisol Awakening Response during 
detoxification. 
• [11C]PBR28 VT is decreased in the hippocampi of alcohol dependent 
patients in early abstinence relative to controls. 
• There is a positive association between hippocampal [11C]PBR28 VT 
and performance on a test of verbal memory. 
• Prescribed benzodiazepines, other than diazepam at very high doses, 
are unlikely to interfere with interpretation of [11C]PBR28 scanning 
data. 
• There is no significant association between brain glutamate 
concentrations as measured by MRS and [11C]PBR28 VT. 
The aim of my thesis was to characterise peripheral and central nervous 
system markers of inflammation during alcohol withdrawal and early 
abstinence in alcohol dependence.  A secondary aim was to describe their 
relationship to clinical measures, particularly cognitive function, in order to 
generate hypotheses regarding their clinical relevance.  Thirdly, I investigated 
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their relationships to neurochemical and neuroendocrine derangements 
previously described in withdrawal and early abstinence.   
 
In order to address these aims, I conducted a series of experiments using a 
range of approaches including peripheral cytokine and cortisol assay, Positron 
Emission Tomography (PET), and Magnetic Resonance Spectroscopy (MRS), 
as well as the administration of psychological questionnaires and cognitive 
tests, in two populations of alcohol-dependent men.  In this chapter, I will 
outline the implications of my findings and possible avenues of further study.  
 
First, I have described, for the first time, the profile of twenty-five cytokines 
and chemokines during alcohol detoxification.  I have established that 
macrophage associated cytokines and chemokines IL-6 (pro-inflammatory), 
IL-10 (anti-inflammatory), and CCL-2 (pro-inflammatory) are raised during 
early detoxification relative to later in detoxification, and that IL-6 in particular 
is associated with the severity of withdrawal symptoms and depressive 
symptoms throughout withdrawal.   
 
The Th1-associated cytokine IL-12 and chemokine CXCL-10 increased during 
detoxification, with an increase in C-reactive protein, a common inflammatory 
marker.  IL-12 was not related to depressive symptoms, in contrast to its 
relationship with depressed populations.  
 
Further work could clarify the relative contributions of gut-derived 
lipopolysaccharide and sympathetic nervous system hyperactivity.  The 
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relationship between the sympathetic nervous system and cytokines during 
detoxification could be investigated by measuring the cytokine response to 
administration of an alpha-2-receptor agonist such as lofexidine or clonidine 
during detoxification.  The contribution of bacterial translocation from the gut 
and consequent hepatic inflammation could be assessed initially by 
investigating the relationship between circulating lipopolysaccharide and 
withdrawal severity.  If such a relationship exists, there would be rationale for 
testing the effect of early probiotic therapy during alcohol detoxification.  
Probiotic therapy has shown promise in prevention of hepatic encephalopathy 
(McGee et al., 2011) (Lunia et al., 2014), which, like alcohol dependence, 
involves small bowel bacterial overgrowth and bacterial translocation.  Finally, 
the cytokine profile during chronic intoxication would also be of interest.  A 
recent study showed that a single bout of binge drinking was associated with 
a significant increase in peripheral LPS (Bala et al., 2014).   
 
The relationship of peripheral cytokines and chemokines to cognitive function 
was complex.  There was no association between IL-6, or CXCL-8, and 
cognitive function.  Contrary to my hypothesis, CCL-2 was associated with 
better cognitive function in a range of cognitive tests.  CCL-2 was chosen a 
priori as it is a cytokine associated with microglial function, related to poorer 
cognitive function in mild cognitive impairment and Alzheimer’s Disease, and 
had been found to be increased in brain tissue of alcohol-dependent patients 
post-mortem (He and Crews, 2008).  However evidence published since the 
inception of my study supports the hypothesis that CCL-2, in the presence of 
alcohol, may be protective.  Transgenic mice overexpressing CCL-2 do not 
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display suppression of Long Term Potentiation following acute alcohol 
administration (Bray et al., 2013) and show additional up-regulation of 
synaptic proteins, but not those associated with cell death, following chronic 
alcohol administration (Gruol et al., 2014).  
 
Second, I investigated whether there was evidence of microglial activation in 
early abstinence using [11C]PBR28 PET.  The findings in the PET study were 
also not as hypothesised.  For the first time, I have characterised TSPO 
binding in healthy alcohol-dependent men in early abstinence.  I found that 
[11C]PBR28 VT was decreased in the hippocampus, which was contrary to my 
hypothesis.  There were no areas of increased VT in the brains of the patient 
group.  This was not consistent with microglial activation in alcohol 
dependence, in that microglial activation has been detected in other 
conditions as increased binding of TSPO-PET tracers (reviewed in (Politis et 
al., 2012)).  Further, there was a positive correlation between performance on 
verbal memory and hippocampal VT, which invites two possible explanations, 
as both microglia and hippocampal neural progenitors have been reported to 
express TSPO.  If  [11C]PBR28 VT  in the hippocampus is a predominantly 
microglial signal, it suggests that microglia may serve a protective, rather than 
destructive, function in the hippocampus in the healthy brain and in alcohol 
withdrawal.  This is supported by recent pre-clinical literature showing that 
microglia are activated to an anti-inflammatory phenotype during alcohol 
withdrawal (Marshall et al. 2013) and may support resumption of 
neurogenesis (Nixon et al., 2008).   
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My in vitro study showed that the findings of the PET study would not have 
been affected by conducting scans during the first twenty-four to forty-eight 
hours of detoxification, provided patients were treated with chlordiazepoxide 
not diazepam (Kalk et al. 2013 2013).  Pre-clinical evidence suggested that 
this would have been the most likely period during which microglial activation 
peaked (Nixon et al., 2008).  It was not logistically possible to scan the 
moderately to severely dependent population available for recruitment during 
this early period, however, as they either required in-patient detoxification 
which took place remotely or, if treated as out-patients, were reluctant to be 
scanned during the early, most difficult phase of their withdrawal.  Such a 
scanning study could be undertaken in a mildly physiologically dependent 
population who would be willing to tolerate scanning in early detoxification, 
and would be of interest to investigate whether short-lived microglial activation 
occurs during these phases of alcohol dependence.   
 
It may also be that hippocampal microglial activation and damage are early 
events in alcohol dependence, as supported by reports of hippocampal 
cognitive deficits and atrophy in both rodent and human binge-drinking 
adolescents (Medina et al., 2007) (De Bellis et al., 2000) (Nagel et al., 2005).  
A recent study demonstrated an increase in LPS following a single alcohol 
binge (Bala et al., 2014).  Given the report of microglial activation in response 
to peripheral LPS in non-human primates (Hannestad et al., 2012), it would be 
of interest to investigate whether such activation occurs in the setting of an 
alcohol binge, and whether there is a relationship between the degree of 
activation and cognitive function. 
! 167 
 
The findings described in this thesis demonstrated peripheral inflammation 
during alcohol detoxification, but did not demonstrate neuroinflammation in 
early abstinence.  The relationships between inflammatory processes in the 
periphery and microglial function in the brain, require further investigation.  
Both the positive relationship between CCL-2 concentrations and cognitive 
function in the cytokine study and the positive correlation between 
[11C]PBR28 VT  and verbal memory, are more consistent with a protective role 
for at least certain aspects of the immune function.   However, the findings 
have significantly added to the understanding of interacting processes 
occurring during withdrawal and early abstinence, and may provide an avenue 
of enquiry into the phenomenon of extended withdrawal, and into depression 
in alcohol dependence.  It has long been recognised that after the acute 
alcohol withdrawal symptoms subside, symptoms of insomnia, anxiety and 
depression persist for the several weeks defined as early abstinence 
(Schuckit and Hesselbrock, 1994) (Brown et al., 1995).  Even during 
prolonged abstinence, abnormalities in stress responsiveness remain and 
contribute to relapse (reviewed in (Heilig et al., 2010)).  This, together with 
relative insensitivity to reward, following induction of substance dependence, 
is known as ‘allostasis’ (Koob and Le Moal, 2001).  It would be interesting to 
investigate, therefore, the relationship between cytokines and relapse 
following detoxification, and whether this is mediated by relationships between 
cytokines and withdrawal and mood symptoms described in Chapter 2. 
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Past literature has emphasised HPA axis dysfunction (Koob and Le Moal, 
2001) (Heilig et al., 2010) in the pathogenesis of allostasis.  My thesis has 
extended pre-clinical work showing interactions between peripheral 
inflammatory stimulus and the HPA axis (Whitman et al., 2013) (Breese et al., 
2008) by describing for the first time the relationship between peripheral 
cytokines and HPA axis function during alcohol detoxification in man.  This 
was the third experiment listed in my introduction (page 15).  I found a positive 
correlation between IL-6 and both serum cortisl and Cortisol Awakening 
Response, suggesting that the peripheral inflammatory drive exacerbates the 
stress response during detoxification.  The relationship between HPA axis 
function and cytokines in this context could be extended using validated 
endocrine challenge and suppression studies during early abstinence.  
Measurement of additional hormones, such as ACTH, and cytokines, such as 
TNF-α, may be more sensitive to the endocrine-immune relationship (Schuld 
et al., 2003) and would provide information about interactions at various 
anatomical locations.  
 
The findings from the study described in Chapters 2 and 3 are also of 
relevance to co-morbidity in alcohol dependence.  The relationship of IL-6 to 
Visual Analogue Scale Depression, adjusted for withdrawal severity, found 
throughout detoxification was described for the first time in my study.  Raised 
IL-6 has been consistently reported in depression and is may predict 
response to antidepressants (Yoshimura et al., 2009) (Yoshimura et al., 
2013).  Another study has found an inverse correlation between anti-
inflammatory IL-10 and depression in alcohol-dependent patients (Leclercq et 
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al., 2012).  I also replicated the finding that morning serum cortisol decreased 
during detoxification.  Of interest is that the levels seen in my study were 
similar to morning cortisol seen in depressed cohorts, even at the later time 
points.  The decrease in [Glx] found in the MRS study – the fourth experiment 
listed on page 15 of the Introduction - is also similar to findings in depressed 
subjects (for a review, see (Luykx et al., 2012)).  Disappointing findings in 
early stage clinical trials of anti-inflammatory treatments in depression (e.g. 
(Inamdar et al., 2014)) have been attributed to heterogeneity in the depressed 
population – that is, the depressed patients in the trial had normal cytokine 
levels.  It has been proposed that identification of sub-groups with an 
inflammatory response should be targeted for treatment.  The evidence from 
my study suggests that alcohol-dependent patients with co-morbid depression 
would be such a sub-group.  Further studies characterising the cytokine 
profile in patients with alcohol dependence and co-morbid depression would 
potentially provide a novel treatment rationale in this co-morbidity.   
 
In summary, the findings presented in this thesis have characterised the role 
of peripheral inflammation and neuroinflammation during alcohol detoxification 
and early abstinence and placed them in the context of known neurochemical 
and neuroendocrine derangements related to detoxification.  Their 
relationship to cognitive function in alcohol dependence is complex and 
warrants further investigation, in binge drinking cohorts.  However, my 
findings suggest that cytokines may contribute to clinical symptoms in 
detoxification and early abstinence and may be important in the pathogenesis 
of allostasis in alcohol dependence, and in co-morbid mood disorders.  This 
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provides a promising avenue of enquiry to develop more effective 
interventions targeting relapse prevention and depression. 
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